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Abstract 
The reaction of alkylating reagents with DNA yields a variety of potential mutagenic 
and carcinogenic lesions. One such group, the 06-alkyl-2'-deoxyguanosines (O6 
alkyl dGs) are known to induce guanine to adenine transitions, which may lead to the 
activation of oncogenes. Antibodies with predefined specificities can be employed in 
the detection and quantification of such lesions. 
Four 06-alkyl dG analogues (methyl, ethyl, n-propyl and hydroxyethyl) have been 
synthesised. Each was made into a suitable antigen by, i) conjugation to BSA and/or 
C"43 and ii) incorporation into an oligonucleotide. An 06-4(carboxybenzyl) dG 
derivative has also been synthesised and conjugated to BSA and C'43. All conjugates 
and oligonucleotides have been characterised. 
Each 06-alkyl dG antigen has been used for inimunisation. Hybridoma technology 
was employed to give monoclonal antibody producing cell lines. Screening assays 
were developed for the detection of a cell line producing a monoclonal antibody 
specific for 06-alkyl dG. Three monoclonal antibodies have been produced. The 
relative affinities of each antibody for each 06-alkyl dG have been determined. The 
highest affinity antibodies have been immobilised on sepharose. Immunoaffinity 
columns have been constructed and employed in the extraction of 06-alkyl dG from a 
pool of nucleosides. 
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Chapter 1. Introduction 
1.1 DNA 
Deoxyribonucleic acid (DNA) is the chromosomal material that contains the genetic 
information within the cells of living systems. It consists of billions of 
deoxyribonucleotides of four different types which are joined together in a sequence 
which is characteristic of each organism. Each deoxyribonucleotide consists of a 
D-deoxyribofuranose and one of four nitrogenous bases, adenine (A), thymine (T), 
guanine (G) or cytosine (C). A phosphate diester group joins the 3' and 5' positions 
of the sugars to create a continuous strand which forms the backbone of the molecule 
(fig. 1.1a). The bases pair by hydrogen bonding, which holds the two strands of the 
molecule together. Base-pairs consist of a purine and a pyrimidine and in the most 
common tautomeric form A pairs with T (two hydrogen bonds), and G with C (three 
hydrogen bonds), to form the bridges joining the two strands (Watson and Crick, 
1953) (fig. 1.1b). 




N CN 0-P =0 I 	 • .J NH2 	(b) CH3 71 0-111
0 . 	1' 	 H N- H - - - 
NH2 	
< 7N - - - 
X4 3 2- /N N 





- C - p = 0 	N 	
N N 0 - 	 - -  
Nf_ - 
I 
0 0 _1;•o 	
N 	N 	N H• - 
o 	QH3 II 	 H 





Figure 1.1(a) Part of the polynucleotide strand of DNA showing the sugar 
numbering system 
(b) Normal base pairing in DNA showing the base numbering system 
For organisms to produce viable progeny the chromosomal material must remain 
almost identical over generations. Whpn one considers that the 23 pairs of 
chromosomes in human cells contain 3 x 109 base pairs, it is apparent that 
transmission of this information from parent to offspring requires a highly 
specialised mechanism. The Watson and Crick (W/C) hypothesis for the semi-
conservative replication of DNA allows an understanding of the accurate 
transmission of hereditary information. The parent DNA molecule unwind; then the 
two strands break apart one base at a time. New identical daughter DNA is 
constructed from deoxyribonucleotides available in the cell, using the parent strands 
as templates. As A can only pair with T, and C with G the new strands are 
complementary to the parent strands, giving replicas of the starting molecule. 
The information contained in DNA is used in the production of the proteins 
necessary for the survival of the organism. The genetic code is the starting point for 
two major events in cells, i) transcription: messenger ribonucleic acid (mRNA) 
synthesis and; ii) translation: protein synthesis. During transcription the enzyme 
DNA polymerase attaches to an area of double stranded DNA which opens up to 
expose one strand and this is used as a template for the synthesis of RNA (fig. 1.2). 
RNA is similar to DNA but has a ribose sugar, which contains a hydroxyl group in 
the 2' position, and uracil rather than thymine bases. The RNA is then trans1ated(4 
triplets df nucleotides which code for amino acids, the building blocks of proteins. 
The biosynthesis of these proteins utilises many complex enzyme systems which 
decipher and translate the genetic code. 
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Figure 1.2. Transcription, mRNA synthesis 
1.2 Damage to DNA 
The existence of genetic continuity within species may imply that DNA is a stable 
molecule and that replication and transcription are infallible mechanisms. However, 
DNA is continually undergoing changes referred to as mutations. Most mutations 
are disadvantageous as far as the individual in which they occur is concerned. 
Despite the occurrence of natural mutations, the probability of DNA damage is 
increased manyfold when an organism is exposed to certain biological, chemical or 
physical environmental factors. Many mutations are repaired by specialised 
enzymes, for example DNA polymerases which repair strand breaks and excise 
incorrectly inserted deoxyribonucleotides. When mistakes are not repaired disease 
and heritable disorders can result. 
1.2.1 Natural damage 
Chromosomal DNA is constantly undergoing natural changes, referred to as 
spontaneous mutations. These usually arise from the mispairing of bases during 
DNA synthesis, with 1 in 107 to 1011  misincorporations per base-pair replicated 
(Drake, 1969., 1991). In addition, hydrolytic reactions which occur in DNA under 
physiological conditions can cause deaminatibn, depurination and depyrimidation 
(Fersht and Knill-Jones, 1981). The accuracy of DNA synthesis relies on the ability 
of enzymes to discriminate against the insertion of an incorrect or damaged 
deoxyribonucleotide. Consequently, natural mutations in organisms are rare events. 
1.2.2 Chemical damage 
In most instances cancer 'is caused by mutation of DNA in cellular genes that control 
cell growth and cell mitosis. Only a small fraction of cells that mutate ever lead to 
cancer. Most defective cells have reduced survival capacity due to the loss of 
essential mechanisms and attack by the organism's immune system. Statistical 
evidence suggests that continued exposure of human beings to chemical agents 
including industrial chemicals, food additives, exhaust gases, dyes, flavourings, 
cigarette smoke and cosmetics, increases the incidence of specific types of cancer 
(Blackburn and Kellard 1986). 
Chemicals that interact with DNA and result in damage to the molecule are referred 
to as mutagens. Compounds causing mutations which alter normal cell function, 
possibly leading to carcinogenesis are commonly referred to as carcinogens. 
Primary carcinogens, typically electrophilic alkylating agents react directly with 
DNA, whereas secondary carcinogens must undergo some form of activation prior to 
their reaction with DNA. In addition, there are chemicals which are not themselves 
carcinogenic but their presence enhances the carcinogenicity of other compounds. 
DNA has an abundance of nucleophilic centres, subsequently electrophilic alkylation 
is a predominant modification. 
1.3. Alkylation of DNA 
During the last 30 years many studies have shown that alkylating agents interact with 
DNA to yield a variety of potential mutagenic and carcinogenic modifications 
(Loveless, 1969; Margison and Kleihues, 1975; Saffhill, et al 1985; Singer, 1986; 
Basu and Essigmann, 1990). Of the chemicals which are known carcinogens to 
humans, approximately one fifth are alkylating agents, the most common are shown 
in figure 1.3. (Singer 1975). 
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4 
Many of these compounds are found in the environment and it has been estimated 
that the daily human ingestion rate of dimethyl nitrosamine is 1-2p.g per person 
(Blackburn and Kellard, 1986). Nitrosamines are believed to be the most dangerous 
and widespread of all alkylating compounds. They are commonly found in tobacco 
products as a result of the nitrosation of natural tobacco during curing and 
fermenting, and are released into the environment via mainstream tobacco smoke 
(Tricker et al, 1991). In addition, nitrosamines can be produced in the stomach by 
nitrosation of secondary amines. Nitrates are present in food, and following 
ingestion and subsequent bacterial degradation nitrites and nitrous acid are 
commonly produced. In the environment of the normal stomach (pH3) amines are 
protonated and do not react with these nitrous compounds. However, treatment for 
stomach ulcers often involves elevating stomach pH, creating an environment in 
which amines are not protonated and therefore able to react with nitrites and nitrous 
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Figure 1.4. Production of nitrosamines by the reaction of nitrous acid and secondary 
amines in the stomach 
Alkylating compounds can be sub-divided into monofunctional and bifunctional 
agents. The former interact with only One of any of the nucleophilic centres in 
DNA. The' latter have the capacity to react with two sites in DNA and can 
consequently cross-link a base to another base or a protein. Sulphur mustard, 
nitrogen mustards, bis chloromethyl ether and epichiorohydrin are potential 
bifunctional alkylating compounds. Monofunctional alkylating agents can react at 
all of the oxygen and nitrogen atoms (except N9) of the four bases. Generally, the 
ring nitrogens of the bases are more nucleophilic than the oxygens, although the sites 
of reaction of the alkylating reagents usually depend on their mechanism of action. 
Pearson's "hard and soft acids, and bases concept" (1967) generally applies. This 
states that "soft" electrophiles react with extremely nucleophilic centres in an SN2 
type reaction, and "hard" electrophiles with less nucleophilic centres in an SN1 type 
reaction. The predominant sites of reaction of dimethyl sulphate (DMS) a "soft" 
electrophile, with DNA are at the nucleophilic N atoms of the bases. DMS reacts 
preferentially at the N7 of G, then the N1 of A, the N3 of C and the N3 of T, with 
almost no reaction at the oxygens (fig. 1.5). In comparison, the interaction of methyl 
nitrosourea (MNU) or nitrosamines, "hard" electrophiles, result mostly in the 
formation of alkylated phosphate triesters. The predominant alkylated base products 
are at the nitrogen s but there is a greatly increased extent of modification at the 
oxygens, preferentially 06 of G, followed by the 02 of T, the 04 of T and the 02 of 
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Figure 1.5. Principal targets in DNA bases for 'hard' and 'soft' electrophiles. 
The sites of alkylation in DNA may also be regulated by steric factors. In the 
normal right handed configuration (B form) DNA has a major groove and a minor 
groove, where the stacked bases form a hydrophobic core with the amino and keto 
groups pointing out into the grooves. The N3 of purine rings is fairly accessible in 
the minor groove, while the N7 of purines and 06 of G are easily accessible in the 
major groove. Occasionally, portions of the DNA molecule can adopt a left handed 
helical conformation referred to as Z-form (Rich et al, 1984) particularly at high salt 
concentrations (Arnott et at, 1980), or in DNA with continual alternating purine-
pyrimidine sequences (Hamada and Kakunaga, 1982). In this conformation normal 











phosphate backbones, which corresponds to the minor groove in normal B-DNA. 
This results in certain base atoms, particularly the 06,  N7 and C8 positions of G, 
being much less sterically hindered and thus more exposed to alkylating agents. 
Many alkylating reagents react directly with DNA. Dialkyl sulphates react primarily 
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Figure 1.6. Alkylation at the N7 position of guanine derivatives 
The nitrosoureas, niirosoguanidines and nitrosourethanes are spontaneously 
hydrolysed to produce alkyl diazonium hydroxides, which ultimately react with the 
06 position of G. Other compounds such as nitrosamines require enzyme catalysed 
chemical transformation to produce the primary carcinogen. This involves 
controlled oxidation by cytochrome P-450 enzymes. Dimethyl nitrosamine 
undergoes ct-hydroxylation by these enzymes to produce N-hydroxymethyl-N-
methyl-nitrosamine which spontaneously loses formaldehyde to generate methyl 
diazonium hydroxide, the primary carcinogen (fig 1.7). Alkyl diazonium hydroxides 
rearrange to give hydroxide ions and a positively charged alkyl species. In the 
presence of 0 the 06  reacts with the positive species to generate 06-alkylated G. 
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Figure 1.7 Alkylation at the 06 position of guanine derivatives 
1.3.1 06-alkylguanine: A pro-carcinogenic lesion 
The predominant modification following a reaction of an alkylating reagent with 
DNA is 7-alkyl G. This modification does not appear to be directly mutagenic 
(Ludlum 1970). In comparison, the less common modification 06-alkyl G has been 
shown to lead to point mutations in DNA following replication, (Loechier et al, 
1984; Yamagata et al, 1988). The molecular mechanism of this mutation is due to 
the enforced change in the tautomeric structure of the base causing it to mispair with 
T (Leonard et al, 1990) After' repLLcci.Ion this mispainng results in a G to A 
Ell 
transition which may result in the deletion or abnormal synthesis of a protein 
required for the survival of the cell. This transition has also been linked to the 
activation of the Ha-ras transforming oncogene (Sukumar et al, 1983). Activation of 
the ras gene family is associated with carcinogen-induced animal tumours. Studies 
have shown that a G to A transition specifically at the second base of the 12th codon 
of a Ha-ras oncogene results in its activation (Mitra et al, 1989). 
Comparison of the structures and W/C binding sites of G, 7-akyl G and 06alkyl G 
demonstrates the disruptiveness of the 06-alkyl derivative compared to the 7-alkyl 
derivative (fig. 1.8). 
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Figure 1.8 The binding sites of guanine, 7-alkylguanine and 06-alkylguanine 
The ability of 7-alkyl G to hydrogen bond to C in the usual way is not altered, since 
the W/C binding sites are unaffected by the addition of the alkyl group. However, 
alkylation at the 06 position of 0 alters the position of the double bond resulting in 
deprotonation of the Ni which then becomes a hydrogen bond acceptor, as it is in A, 
rather than a hydrogen bond donor as it should be in G. The resulting 06-alkyl G 
therefore has different hydrogen bonding capacity from non-alkylated G. This 
alteration allows 06-akyl G to pair with its normal base pairing partner, C; or to 
mispair with T. 
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Many researchers have addressed the problem of when and how C or T pair with O6 
alkyl G. This is complicated by the fact that the 06-alkyl group can adopt a syn or 
anti conformation (relative to the N' of the base) (fig 1.9a). In the former the alkyl 
group points into the helix, potentially disrupting the normal hydrogen bonding, 
while in the latter the alkyl group points into the major groove. X-ray diffraction 
(Parthasarathey and Fridey, 1986) and NMR studies of duplex oligonucleotides 
containing 06-methyl G (Patel et a!, 1986, and Kalnik et al, 1989), showed that the 
syn conformation was preferred. It was deduced that in this conformation the methyl 
group prevents T from base-pairing on the same plane as its partner, resulting in only 
a single hydrogen bond between the N2 of G and 04  of T (fig 1.9b). However, a G 
to A transition is unlikely to arise from the misincorporation of T opposite 06-alkyl 
G by this mechanism as a very unstable base pair is produced (Pederson et al, 1988). 
The original suggestion by Loveless (1969) that 06-alkyl G adopts the anti 
conformation allowing it to pair with C or T, was supported by a recent study in 
which an oligonucleotide containing 06-methyl dG (06-MeG) was examined by X-
ray diffraction (Leonard et al, 1990). One hydrogen bond between N' of G and N3  
of T, and a second from N2 of G and 02 of T, were found (fig 1.9c). In this 
conformation the 06-MeG : T mispair closely resembles a W/C base pair as the 
bases are on the same plane, and the helical parameters and torsion angles are similar 
to a native G: C pair. The 06-alkyl G: C base pair has also been examined in a 
duplex and found to be unstable at neutral pH, but at lower pH the duplex stabilises, 
possibly due to protonation of the N3 of C to form a W/C base pair (Leonard et a!, 
1990) (fig 1.9d). Thus, occasionally, 06-alkyl 0 may not cause a G to A transition. 
Molecular modelling and theoretical calculations suggest that there is only a small 
difference in energy (< 1 kcal/mol) between the syn and anti conformations of O6 
alkyl G when paired with T in a duplex and both are likely to exist (Loechier, 1991). 
This theoretical analysis postulates that anti 06-alkyl G forms one normal hydrogen 
bond between the N2 of 0 and 02 of T, and one branched hydrogen bond from the 
H3 of T to both the N1  and 06  positions of 06-alkyl G. Similarly syn 06-alkyl G 
forms the normal N2 of G, to 02  of T bond (2.07A) and also has bonding from H3  
of T, to N1  and 06  of 06-alkyl G, but this bond is elongated (2.98A). This is 
thought to occur due to the protrusion of the alkyl group into the hydrogen bonding 
region of the base pair causing the T to be in a different plane and thus farther from 
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1.3.2 Repair of 06-alky1guaniñe Lesions 
The action of alkylating agents has been observed in bacteria for many years. The 
existence of an adapted mechanism for the repair of 06alkyl G was first suggested 
when researchers (Jimenez-Sanchez and Cerda-Olmedo, 1975) exposed E. coli to 
minute levels of alkylating agents and found that the mutation frequency increased 
with time of exposure but finally reached a plateau. The repair enzyme 06-alkyl G 
DNA transferase (a suicide enzyme) has since been discovered (Olson and Lindahl, 
1980) and the gene has been localised on human chromosomes (Zunino et al, 1991). 
The enzyme (18 000 Mr)  operates by transferring the alkyl group from the 06  of G 
onto an internal cysteine residue (Pegg et al, 1983) (fig 1.10). Subsequent to this 
transfer the enzyme becomes inactive. The enzyme is highly specific for methyl 
groups and the transfer of a methyl group to a particular cysteine (cys 69) results in 
the activation of a transcriptional regulator leading to a 100 fold increase of the 
transferase activity per cell (Teo et al, 1986). This regulator is only weakly 
activated by the transfer of higher alkyl groups, for example 06-ethyl G (06EtG) is 
repaired 1000 times slower than 06-MeG and 06-isopropyl G is not repaired 
(Graves et al, 1989). Cells, therefore, have adapted a mechanism to undo the direct 
damage caused by alkylating agents, in particular, methylating agents. However, if 
the 06-alkyl G derivatives are not repaired bef6re1re pWchor occurs a mutation 
arises. 
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Figure 1.10. De-alkylation of 06-alkyl G by alkyl transferase 
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The most common general DNA repair mechanism in cells is excision repair. This 
mechanism removes the mis-inserted or damaged deoxyribonucleotide and replaces 
it with the correct deoxyribonucleotide. Firstly, an endonuclease creates a nick in 
the DNA strand at the site of the undesired residue. Subsequently, an exonuclease 
excises the part of the DNA strand containing the wrong deoxyribonucleotide. DNA 
polymerase allows the correct deoxyribonucleotide to be inserted into the gap in the 
strand. Finally, a ligase covalently links the strand to complete the repair. This 
mechanism has been reported to excise 06-alkyl G from a T : 06-alkyl G base pair 
in vivo (Samson et al, 1988) and in vitro (Voigt et al, 1989), although the 
mechanism is believed to function less efficiently with small alkyl lesions compared 
to bulky lesions (Sancar and Sancar, 1988). 
When 06-alkyl G forms hydrogen bonds with T, an unstable base-pair results, but 
the symmetry of the sugar-phosphate backbone in the DNA sequence remains 
unchanged (Leonard et al, 1990). As the structure is similar in overall shape to a 
W/C base-pair enzymes cannot detect and repair the mistake. The presence of the 
alkyl group can also act as a steric barrier preventing the interaction of enzymes. In 
addition, the repair enzymes appear to discriminate in favour of the mutagenic 
lesion. This is due to the fact that although 06-alkyl G can form a stable base-pair 
with C it is distorted and no longer resembles a W/C base-pair (Patel et al 1986; 
Leonard et al, 1990). Repair enzymes detect this as a mismatch, excise the correctly 
inserted C and allow the misinsertion of T. 
Many years of research have identified the chemical agents responsible for alkylation 
at the 06 position of G. In addition, the mechanism by which this creates a 
mutagenic lesion, which may ultimately lead to carcinogenesis, and the mechanisms 
of repair enzymes for this lesion have been widely investigated. Advances in the 
understanding of these mechanisms have led to the development of sensitive 
techniques to monitor and quantify the extent of damage and repair in the DNA 
molecule. 
1.4 Biomonitoring 
The knowledge that certain DNA modifications are implicated in carcinogenesis has 
encouraged researchers to develop .techniques to monitor the effects of exposure to 
environmental carcinogens. Original monitoring studies estimated exposure of 
organisms by measuring the levels of mutagenic substances in the ambient 
environmental media. Exact doses received by organisms, and individual 
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differences, for example in adsorption, metabolism and excretion, are impossible to 
measure by this system. Subsequently, the development of biological monitoring 
has allowed the precise determination of the internal dose of a mutagenic chemical 
or a related metabolite in the body. Additionally, it has become possible to measure 
the extent of reaction of the mutagen with DNA. 
The biomonitoring of carcinogen exposure in living humans presents various 
difficulties. Firstly, the tissues which are directly affected by the carcinogen (i.e. 
lungs, liver, stomach) are inaccessible, therefore surrogate tissues (i.e. white blood 
cells, peripheral blood lymphocytes, placental tissue) which may not have the same 
degree of DNA damage, are investigated. Secondly, there is large inter-individual 
variation, for example the P-450 isoenzymes have been recorded in humans with 
>1000 fold inter-individual variance, in terms of quantity, specificity and tissue 
distribution (Fujino et al, 1982). These enzymes activate many chemicals to produce 
carcinogenic metabolites and individuals with increased P-450 levels may be more 
susceptible to developing tumours than individuals with low level P-450 isoenzymes. 
Additionally, lowered rates of DNA repair have been recorded in certain individuals. 
For example 06-alkylDNA alkyltransferase is found at lower levels in patients with 
lung cancer compared to non cancer controls (Harris, 1989). This suggests that these 
subjects may have developed cancer due to their low repair enzyme levels. Thirdly, 
humans are exposed to low doses of complex mixtures of many chemicals, including 
carcinogens, in the environment. This may confound the interpretation of cancer 
risk assessment of any one compound. These 3 factors must be considered when 
developing a biomonitoring system. In short, for an assay tobe potentially useful it 
must; i) be sufficiently sensitive to allow detection of mutagenic derivatives at low 
levels; ii) require small samples of DNA; iii) be quantitatively related to exposure; 
and iv) be specific in identifying only the carcinogenic lesion of interest (Beach and 
Gupta, 1992). 
The majority of biomonitoring techniques involve the use of biomarkers which allow 
quantification of biochemical, physiological, cytological, immunological or 
molecular changes. A knowledge of the internal interactions of the mutagen with the 
target molecule is necessary before choosing the appropriate biomarker. It can then 
be applied to directly measure mutagens in body fluids or excreta or to measure the 
covalent binding of the mutagen/metabolite to DNA, RNA or proteins. The former 
method, although employed extensively in the past, is now considered to be limited 
due to the rapid removal of many chemicals from the body. In comparison the 
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products of the latter method (i.e. altered DNA, RNA or protein) can exist in cells 
for weeks to a lifetime depending upon chemical stability, efficiency of repair 
mechanisms and processes of cell turnover. Since DNA lesions are believed to 
represent an early but critical step in chemical carcinogenesis, their detection may 
serve as a dosimeter of environmental exposure. 
1.5 Detection of DNA lesions 
1.5.1 Classical techniques 
Over the years a number of direct and indirect assays to detect DNA lesions have 
been developed. There is no universal technique as many assays exhibit inherent 
advantages and disadvantages depending upon the system and compounds used. 
Generally, radio-chromatographic techniques (Baird, 1979) have been the most 
popular, although identification of modified bases in DNA by this method is limited. 
Specific activity of radiolabelled carcinogens, restriction to non-human use and 
limited sensitivity requiring the use of large quantities of DNA are the major 
disadvantages of this technique. Fluorescent techniques (Kreik et al, 1984) have also 
been explored with carcinogens which absorb in the UV visible spectrum (e.g. 
polyaromatic hydrocarbons and aflatoxin). DNA lesions can be directly measured 
by these techniques, but few human studies have been carried out. 
1.5.2 Immunochemical techniques 
Immunochemical detection methods which have been developed more recently rely 
on the principle that a specific antibody recognises a specific antigen. Antibodies 
produced in an immune response to a carcinogenic lesion (the antigen) are purified 
then employed to detect that lesion in native DNA samples. High specificity of 
antibodies in recognising minor alterations of molecular structure allows studies to 
be conducted on small samples with low damage levels in the DNA. This offers 
potential for studying human exposure to environmental carcinogens. 
1.5.2.1 An introduction to antibodies 
The interaction of an antibody with an antigen forms the basis of all 
immunochemical techniques. The nature of the antibody-antigen bonds, the strength 
of these bonds (affinity) and the stability of the complex (avidity), as well as 
specificity, are all important in determining the potential of an antibody for 
recognising an antigen. There are five classes of antibody. IgGs are the most 
abundant in serum after an immune response, and usually exhibit highest affinity. 
They are therefore the most common antibody employed in immunochemical 
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techniques. The IgGs have two heavy (H) peptide chains (55 000 daltons) and two 
light (L) peptide chains (25 000 daltons) which are joined by sulphur bridges to form 
a Y-like structure. The two arms of the Y; the Fab domains, each consist of an L 
and part of an H chain which contain a site that can bind to an antigen, while the 
base of the Y, the Fc domain, is concerned with immune regulation (fig. 1.11). The 
L and H chains can be divided into a constant region and a variable region, the latter 
containing approximately 110 amino acids in both chains. The variable regions of 
one H chain and one L chain combine to form one antigen binding site (IgGs 
therefore have two). Different combinations of amino acids in the variable regions 
provide the structural basis for the large repertoire of binding sites an antibody can 
exhibit to capture an antigen. The genetic basis for diversity of antibody binding 
sites is due to an intricate combination of recombination and mutation events 
(Hozumi and Tonegawa, 1976). 
4—Fab-* 
10 Fc 
antigen 	 I I 
binding sites heavy 
light chain  
- - sulphur bridges 
Figure 1.11. Structure of an IgG 
The variable region of each chain comprises 3 areas of hypervariabiity referred to as 
complementarity determining regions (CDRs). It is these areas which bind directly 
to a site on the antigen referred to as the epitope. Structurally related epitopes, in 
molecules other than the antigen, are often recognised by an antibody. This 
phenomenon of specificity forms the basis of cross reactivity. The binding of an 
antibody-antigen complex depends on noncovalent reversible forces, including 
hydrogen bonds, van der Waals forces, coulombic interactions and hydrophobic 
bonds. The overall interaction is a balance of attractive and repulsive forces, and a 
small change in either the antigen or the amino acid sequence of the antibody can 
alter the stability of the interaction. 
The basic thermodynamic principles of reversible biomolecular interaction apply to 
antibody-antigen binding. The strength of the binding (antibody affinity) is 
measured by the amount of antibody-antigen complexed at equilibrium. Compared 
to low-affinity antibodies, high-affinity antibodies bind larger amounts of antigen in 
a shorter period of time, and the dissociation rate of the complex is greater. 
Consequently, high affinity antibodies enhance performance in immunochemical 
techniques. The affinity constants measured for antibodies ranges from below 105  
mo1 1  to above 1012  mold (Harlow and Lane, 1988). The avidity of an antibody-
antigen complex refers to the overall stability, in terms of affinity, valency and 
geometric arrangement. Antibodies are multivalent (i.e. IgGs have 2 binding sites), 
and antigens can possess more than one epitope. It is therefore possible for two 
antibodies to bind one antigen, and for one antibody to bind two antigens. 
Multivalent interactions stabilise immune complexes and can allow low affinity 
antibodies to bind tightly to antigens. Immunochemical techniques which allow 
multivalent interactions can work well with low affinity antibodies, while techniques 
dependent on a monovalent interactions may fail to give results with these 
molecules. 
1.5.2.2 Antibodies to DNA 
The disease systemic lupus erythematosus (SLE) is characterised by the production 
of anti-DNA antibodies (reviewed by Avrameas and Trenynck, 1993). It is therefore 
known that the immune system has the capacity to produce antibodies to DNA. As 
early as the 1960's and 1970's researchers had begun to investigate the possibility of 
eliciting an immune response with natural complexes containing DNA. During this 
time antibodies were raised to ribonucleotides and ribonucleosides (Erlanger and 
Beiser, 1964), purines (Butler eta!, 1962), pyrimidines (Garro eta!, 1971), nucleic 
acids (Wallace eta!, 1971), and denatured DNA (Plescia eta!, 1964). The 
development of antibodies to carcinogen modified DNA occurred during the 1980's,. 
creating the potential for quantification of DNA lesions. Since this time researchers 
have aimed to raise antibodies to a variety of DNA modifications so that 
immunological probes for the detection of potentially dangerous mutations can be 
developed. Specific antibodies to a variety of modified bases in DNA have now 
been developed and characterised (Briscoe et a!, 1978; Muller and Rajewsky 1980; 
Saffhill et a!, 1982). 
There are several practical problems of inducing antibodies to carcinogen-DNA 
derivatives which are normally too small to elicit an immune response. This will be 
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discussed in further detail in chapter 2. The major shortcomings of immunological 
techniques are largely concerned with antibodies which cross react with more than 
one antigen. Generally antibody sensitivity is greatest for the original antigen, 
although many antibodies also recognise structurally related compounds (Santella, 
1988). More recently this cross-reactivity has been used to an advantage to allow the 
production of class-specific antibodies, eliminating the requirement of a single 
antibody for every possible DNA lesion. 
There are a number of different immunological techniques which can be applied in 
the identification of DNA lesions. Competitive radioimmunoassay (RIA); 
competitive or non-competitive enzyme linked immunosorbent assay (ELISA); and 
ultrasensitive radioimmunoassay (IJSERIA) are most commonly used. RIA involves 
mixing a tracer of radiolabelled antigen with an antibody and increasing 
concentrations of the unlabelled antigen requiring quantification (i.e. 06-alkyl G). 
This generates a standard curve of inhibition of the antibody binding to the 
radiolabelled tracer. Precipitation of the antibody-antigen complex allows 
determination of the amount of bound tracer. Low levels of bound tracer indicate 
the presence of high levels of 06-alkyl G, as this has competed with tracer for 
binding to the antibody. In ELISA the antigen is fixed to a plate and a standard 
curve of inhibition of antibody binding is constructed by adding a mixture of 
antibody and decreasing concentrations of the antigen requiring quantification (i.e. 
06-alkyl G). Binding of antibody to the plate is detected with a second antibody 
conjugated to an enzyme which produces a colour reaction on the addition of the 
appropriate substrate. Low levels of antibody binding to the antigen on the plate 
suggests that there are high levels of antigen in the mixture being investigated. 
USERIA is similar to ELISA except that the substrate is radiolabelled. These 
techniques can theoretically allow the detection of lesions at levels of 1 in 108  bases 
in 25-50kg of DNA (Santella, 1988), but more sensitive techniques have been 
developed (see below). 
1.5.3. 32P-Postlabelling techniques 
The 32P-postlabelling technique (Randerath K,et al, 198 1) can be used to detect 1 
lesion in 1010  bases in 1-10tg of DNA. Additionally, this technique is not lesion 
specific and can therefore detect multiple lesions in complex mixtures of DNA. The 
assay, which enzymatically incorporates radiolabel into the DNA constituents, 
consists of 5 biochemical reactions involving, i) digestion of the DNA containing 
the lesions into nucleotides, ii) enrichment of the lesions by eliminating normal 
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nucleotides, iii) attachment of a 32P label, iv) separation of the lesions by high 
resolution TLC and detection by autoradiography then, v) measurement of 
radioactivity to quantify lesions. 
Enrichment of the lesion is a crucial step in the assay. The principle is to eliminate 
normal nucleosides without eliminating or modifying the lesion, so that ultimately 
only the lesion becomes 32P labelled. There are several versions of the assay each 
varying in the enrichment step, for example the standard (Randerath K. et al 1981) 
and ATP deficient (Randerath E. et al, 1985) assays do not involve this step. This 
decreases sensitivity to the detection of 1 lesion in 107 to 108.  The two most 
commonly used enrichment techniques are butanol (Gupta, 1985) and nuclease 
P11S1 (Reddy, 1986 and 199 1) enrichment. The former involves an aqueous/organic 
solvent separation, where aromatic or hydrophobic lesions are partitioned into the 
organic solvent (butanol), while normal nucleotides remain in the aqueous phase. 
The P1/S1 technique utilises the P1 and/or S1 nuclease enzymes to hydrolyse normal 
3-nucleoside monophosphates to nucleosides, which cannot be 32P labelled due to 
the absence of the phosphate group. The structure of many lesions renders them 
resistant to hydrolysis by these enzymes and they therefore continue to possess a 
phosphate group and become selectively 32P labelled. 
The enrichment techniques differ greatly in lesion selectivity (Beach and Gupta, 
1992). For example dibenz[a,h]anthrancene diolepoxide DNA derivatives are 
recovered equally well by the butanol and nuclease procedures, while aceanthrylene 
derivatives are recovered at levels 2-fold higher in the nuclease P1, compared to the 
butanol procedure. Additionally, aromatic amine derivatives are almost non-
recoverable by butanol extraction, but a large number are isolated by the nuclease P1 
procedure. Unknown samples can be tested by 32P postlabelling, but absolute 
quantification of all lesions present may be impossible. Firstly, some may be 
eliminated by the enrichment procedure used, and secondly the efficiency of 32P 
labelling differs between lesions. In many cases it is therefore necessary to know the 
exact characteristics of the lesions of interest. 
DNA derivatives which result from alkylation have been detected by this technique, 
but the efficiency of detection has been poor as these derivatives cannot be extracted 
from normal DNA digest mixtures by the butanol or nuclease P1/S1 enrichment 
techniques. If the enrichment step is not carried out normal nucleotides will be 
present during the TLC separation step. TLC does not allow good separation 
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between alkylated and normal DNA constituents. The development of an efficient 
enrichment step for the extraction of alkylated nucleotides therefore appears to be an 
important requirement to allow the detection of quantities as small as 1 in 1010  of 
these derivatives. 
1.5.4 Immunoaffinity purification as an enrichment technique 
Immunoaffinity chromatography (JAC) is a separation method based on specific and 
reversible interactions between an antigen and an antibody immobilised on a solid 
support. Generally, the antibodies are chemically bound to beads which are then 
used to construct a column. The digested DNA containing the lesion to be quantified 
is applied to the top of the column. Immobilised antibody binds the lesion retaining 
it on the column, while the normal DNA is unretained. The pure lesion is eluted 
using an appropriate eluant. The coupling of antibodies to solid supports, -loading, 
Washing and elution strategies, and variability in column capacity, are discussed in 
detail in chapter 4. The major requirement for this enrichment technique is an 
antibody with a fairly high affinity for the lesion of interest. Recently, antibodies 
specific for 06-MeG were immobilised on sepharose and used in immunoaffinity 
mode to enrich 06-MeG (Cooper et a!, 1992). This derivative was subsequently 
quantified by 32P postlabelling and two dimensional TLC. The detection limit was 
determined to be 1 06-MeG in 108 normal deoxyguanosines, and 0.38, 0.39 and 
0.45 .tmol of 06-MeG per mol of dG were found in three human samples 
respectively. 
1.6 Aims 
The present study aimed to produce antigenic compounds containing the 
carcinogenic 06-alkyl dG lesions and subsequently produce a class specific antibody 
capable of recognising a range of 06-alkyl dG derivatives. It was hoped that the 
synthesis of a variety of 06-alkyl dG derivatives, their conjugation to proteins and 
their incorporation into oligonucleotides would lead to an immune response 
following immunisation. One antibody which recognises a class of compounds 
eliminates the need for a single antibody for each derivative, allowing an initial 
speedy identification of the amount of damage caused by a class of compounds. The 
project aimed to identify an 06-alkyl dG class specific antibody by developing 
appropriate ELISA experiments, and it was proposed that such an antibody would be 
taken to monoclonality. The ultimate purpose of the study was to construct 
immunoaffinity columns to allow the enrichment of 06-alkyl dO from normal DNA 
for the 32P postlabelling assay. 
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This approach requires the chemical synthesis of 06-alkyl G derivatives and their 
conjugation to a protein or incorporation into oligonucleotides, the details of which 
are discussed in chapter 2. Production and isolation of a class specific antibody 
requires extensive immunisation and screening strategies, which are described in 
chapter 3. Finally, chapter 4 outlines the problems in immobilising antibodies on 
solid supports and the application of immunoaffinity chromatography. 
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Chapter 2. The Synthesis and Characterisation of Antigens 
Containing 06-alkylguanine 
2.1. Introduction 
Alkylation of guanine in the 6-position by methylating and ethylating agents has 
received a great deal of attention during the last decade. The mutagenic properties 
of 06-MeG and 06-EtG have been demonstrated by, i) replicating synthetic DNA 
templates (Saffhill et al, 1985), ii) exposing cells to alkylating agents then 
sequencing the cellular DNA (Richardson, et al 1987) and iii) site directed 
mutagenisis (Chambers et al, 1985). The rate of methylation at the 06  position of G 
(in vivo and in vitro) is generally faster than that of ethylation (Singer 1975). The 
existence of repair mechanisms which have become specifically adapted to the repair 
of 06-MeG, results in relatively low numbers of this lesion in DNA. In comparison, 
06-EtG is repaired at a low level, therefore a fairly high number are present in DNA 
despite the lower reactivity of ethylating agents. 
The mutagenic activity of higher 06-alkyl G derivatives has received less attention, 
although di-n-butylnitrosamine has been shown to cause mutations (Spiegeihalder 
and Preussmann, 1983) and di-n-propylnitrosamine has been shown to induce liver 
tumours in rats (Druckrey, 1967). Nitroso compounds with larger alkyl chains have 
been found to produce a higher 06-alkyl 0 : 7-alkyl G ratio than methylating and 
ethylating agents (i.e. a ratio of 0.7 compared to 0.1) (Saffhill et al, 1985). The 
larger 06-alkyl G derivatives are often considered to be less mutagenic as they are 
more easily detected and repaired by enzymes (Basu and Essigmann, 1990). This 
should result in a reduction in mutagenicity as the size of the alkyl group increases. 
This was supported by a later study which reported mutation frequencies of 8-11% 
with 06-MeG and 06-EtG compared to 0.9% with 06-n-própyl and 06-n-butyl G 
(Chambers, 1991). In contrast, mutation frequencies of 2-3% were found with n-
propyl and n-butyl derivatives (Baumgart et al, 1993). An 06-n-octyl dG was also 
investigated and found to be equally as mutagenic as the smaller 06-alkyl G 
derivatives, suggesting that larger alkyl groups are not less mutagenic. Large O6 
alkyl Os are thought to be repaired by excision repair mechanisms rather than by 
alkyl transferases (Mackay et al, 1992). This may explain the discrepancies in the 
findings of these researchers. In addition, the sequences surrounding the lesion are 
believed to influence the efficiency of repair (Liem et a!, 1993). 
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In addition to alkylating compounds, h'droxyalkylating agents have been 
investigated and found to react at the 06  position of G, (Kohda et a!, 1987). In 
comparison with ethylating agents a hydroxyethylating agent was shown to induce 
cancer in mice at a similar incidence, and with a shorter latency period (Swenson et 
a!, 1979). Hydroxyethylating agents are widespread in the environment from 
industrial pollution and as metabolites of nitrosamines (von Hofe et a!, 1986). In 
addition, ethene and ethylene oxide, which are used extensively in the chemical 
industry, have been shown to produce hydroxyethylated DNA derivatives 
(Segerback, 1983). 
2.1.1 Requirements of an 06-alkyl G antigen 
The production and selection of a class specific antibody for the detection of these 
potential carcinogenic lesions requires immunisation and screening with a variety of 
06-alkyl 0 derivatives. The two limiting steps in the production of a. suitable O6 
alkyl G antigen are, i) the availability of 06-alkyl G and ii) its conversion into a 
compound capable of eliciting an immune response. Generally, 06-alkyl G 
derivatives are not commercially available and have to be produced chemically in 
the laboratory or extracted from cells treated with ailcylating compounds. In 
addition, substances with molecular weight less than 1000 do not normally elicit an 
immune response. Therefore antibodies to single bases, deoxynucleosides or 
deoxynucleotides are induced by immunisation with complexes made up of the low 
molecular weight substance conjugated to proteins or incorporated into synthetic 
immunogenic molecules. Bases, nucleosides and nucleotides can be conjugated to 
proteins. Antibodies raised to deoxynucleoside or deoxynucleotide conjugates are 
likely to have higher recognitiOn for native DNA than antibodies to free bases 
(Erlanger and Beiser, 1964). 
In the present study we therefore used 06-alkyl-2'-deoxyguanosines (06-alkyl dG) 
and related derivatives. The specific alkyl groups investigated were methyl, ethyl 
and n-propyl. The difference in structure between these three groups is small (fig 
2.1) so an antibody to any one derivative may have the potential to cross react with 
another. In addition, 06-hydroxyethyl dG (06-hydroxyEt dG) was investigated. 
This derivative differs from 06-ethyl dG (06-EtdG) by the addition of a single 
hydroxyl group, but has an overall similar shape (fig 2.1). An antibody with 
specificity relying on shape may cross react with the 06alkyl dG derivatives and 
06-hydroxyEtdG. An 06-(4-carboxybenzyl) dG derivative (06-CBdG) was also 
used. This group produces an 0-CH2 bond at the 06  position of dG (fig 2.1). 
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Immunisation with this compound may produce antibodies which recognise the 06 
position of dG linked to a CH2 group plus any small group. 
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Figure 2.1. 06-alkyl dG and related derivatives 
These 06  modified dG derivatives were converted into antigens by conjugation to 
proteins. In addition, some of the derivatives were incorporated into 
oligonucleotides to investigate a novel approach for producing antibodies to 
modified deoxynucleosides. 
2.1.1.1.Synthesis of 06-alkyl dG 
General strategies for the chemical synthesis of modified bases have been outlined. 
Initially 06-alkyl G was synthesised by attaching a thiol group to the 06  position, 
then displacing it with chlorine. The 06-chloro G derivative was converted to 06- 
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alkyl G after reaction with an excess of sodium alkoxide in the corresponding 
alcohol (Balsinger and Montgomery, 1960). This procedure is not applicable to the 
synthesis of 06alkyl dG. The most commonly used procedure for the synthesis of 
the modified nucleoside is that of Farmer et al (1973) in which an ethereal solution 
of diazoalkane is reacted with the nucleoside. The predominant product is 7-alkyl 
dG (42%), followed by 06-alkyl dG (24%), and a variety of additional 
modifications including N'-alkyl and N2,06-dialkyl dG. Low yields due to non-
selectivity of the site of alkylation of diazoalkanes makes this an undesirable method 
for large scale synthesis of 06-alkyl dGs. 
Biological procedures for the production of 06-alkyl dGs have been employed 
(Schendel and Robins, 1978; Hochleitner et al, 1991). Cells grown in the presence 
of alkylating agents are killed by adding ice-cold medium. The membranes are 
lysed and DNA and RNA obtained byphenol-chloroform extraction. After 
digestion by RNase enzymes, the desired modified products are selected by 
chromatography. These purification procedures are lengthy as many modified 
derivatives are produced. 
A practical route for the synthesis of 06-alkyl dGs, which avoids direct use of 
alkylating reagents, was outlined by Gaffney and Jones (1982). 
Triisopropylbenzenesulphonyl chloride, is attached to the 06  position then displaced 
by a nitrogen nucleophile (trimethylamine), which is displaced by alkoxide ions (fig. 
2.2). A similar route was followed by Li and Swann (1989) but the protecting 
groups were adapted to allow the synthesis of 06-alkyl dG for incorporation into 
oligonucleotides. We therefore followed this procedure for the synthesis of the 06 






X—OW N H 
0 





X 	 x- 
x 
1. ROH 





TPS= triisopropylbenzenesulphonyl; DMAP= dimethylaminopyridine; R= alkyl group; X= an 
appropriate protecting group 
Figure 2.2. Modification of the 06 position of dG (Gaffney and Jones, 1982) 
2.1.2 Conjugation of modified nucleosides to protein carriers 
The immunochemistry of low molecular weight compounds began in 1917 when 
Landsteiner established that the original specificity of an antibody towards a protein 
was changed by introducing a small group referred to as a hapten. The antibodies 
recognised the small groups, although they were not themselves immunogenic. 
Complexing DNA with methylated protein has allowed the production of anti-DNA 
antibodies (Butler et al, 1962; Tanenbaum and Beiser, 1963; Erlanger and Beiser, 
1964; Poirier et a!, 1980). The complex results because the methyl groups convert 
the carboxylic acid groups of the protein to methyl esters. At acidic pH the 
positively charged amino groups of the protein couple with the negatively charged 
phosphate backbone of DNA. Free nucleosides and nucleotides require covalent 
coupling to proteins. Serum albumins, immunoglobulins, ovalbumin and 
haemocyanin are the most commonly used proteins. Linking procedures have taken 
TPS-C1 
DMAP 




advantage of carboxyl groups of aspartic and glutamic acid, amino groups of lysine, 
the imidazole function of histidine, the phenolic function of tyrosine and suiphydryl 
groups of cysteine residues in proteins. The most commonly applied techniques are 
summarised in table 2.1. 
Table 2.1. Methods For The Conjugation of Nucleotides and Nucleosides to 
Proteins 
Method Reference 
Periodate oxidation of the ribose moiety 
of ribonucleosides or 5' nucleotides Erlanger and Beiser 1964 
followed 
by linkage to amino groups of proteins  
Succinylation of a hydroxy group 
followed by linkage of the free succinyl Steiner et a! 1969/1972 
carboxyl group to amino groups of a 
protein using a water soluble diimide  
Use of water soluble carbodiimides to Halloran and Parker 1964, 
conjugate nucleotides to proteins via a 1966 
phosphoramide linkage  
Oxidation of the 5'OH group of 
nucleosides to a carboxyl group followed Sela et a! 1964 
by use of a carbodiimide to link the 
COOH to an amino group on the protein  
The formation of diazotisable derivatives Garbar et a! 1968 
of an azoprotein  
Linkage via the C6 atom of a punne to Beiser et a!, 1968 
produce a purin-6-oyl protein conjugate 	I 
The most widely applied technique for ribosides is that of Erlanger and Beiser, in 
which the 2' and 3' C atoms of the cis diol moiety of ribose are oxidised resulting in 
ring opening and the production of two aldehyde functions. Free amino groups on 
proteins react spontaneously with these groups, and after treatment with sodium 
borohydride a morpholine ring system is formed. This procedure cannot be applied 
to deoxyribonucleosides which do not possess adjacent hydroxyl groups and 
therefore cannot undergo the periodate reaction. The most common coupling 
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procedure for deoxynucleosides is succinylation of the deoxyribose hydroxyl group 
followed by coupling of the resulting carboxylic acid group to an amino group on a 
protein using a carbodiimide (Steiner et a!, 1969). Carbodiimides are ideal for use 
with modified DNA as they function in very mild conditions therefore chemical 
alteration of the modified DNA is avoided. Carbodiimides are also employed to link 
deoxynucleosides to proteins via the 5' hydroxyl group after oxidation to a carboxyl 
group (Sela et al, 1964), and to link deoxyribonucleotides via the phosphate group to 
form a phosphoramide linkage (Halloran and Parker, 1966). The remaining methods 
described in Table 2.1 are not commonly used with modified nucleosides and 
nucleotides because of possibile destruction or alteration of the overall structure of 
the base. 
In this study 06-MedG, 06-EtdG, 06-n-PrdG and 06-hydroxyEt dG were 
conjugated to bovine serum albumin (BSA) and chicken gamma globulin (CG) by 
succinylating the 3' hydroxyl groups of the nucleosides followed by linkage to amine 
groups of proteins using a carbodiimide (Steiner, 1969). The carboxyl group of 06 
(4-carboxybenzyl) dG was also activated by a carbodiimide and conjugated to amine 
groups of BSA and CQ. 
2.1.3. Oligonucleotide synthesis 
There are two solid phase oligonucleotide synthesis methods in general use, i) the 
phosphotriester method (Letsinger and Mahadevan, 1965) and ii) the more 
commonly used phosphoramiclite method (Beaucage and Caruthers, 1981). The 
development of the phosphoramidite method has recently been reviewed by 
Beaucage and Iyer (1992) and the practical synthesis and purification of 
oligonucleotides by this method has been described by Brown and Brown (1991). 
In short, solid phase synthesis involves the assembly of an oligonucleotide on an 
inert solid support. A cycle of events in which the required reagents are delivered to 
the growing molecule is repeated for the addition of each new nucleotide. The 
entire reaction and work up (filtering off excess reagents and by-products, then 
washing before the next step) takes place in one reaction vessel. At the end of the 
synthesis the oligonucleotide is cleaved from the solid support and purified. The 
required reagents and nucleotides (which must be appropriately protected) are 
commercially available, adding to the ease of synthesis. 
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In the past synthetic oligonucleotides were not considered immunogenic unless 
coupled to a protein carrier. Most immunisations carried out with oligonucleotides-
protein conjugates used short (10-20 nucleotides), low molecular weight molecules. 
Advancements in automated solid phase DNA synthesis means that oligonucloetides 
of up to 150 residues can be easily synthesised. In addition, the development of 
procedures for modifying the phosphate backbone of DNA allows the synthesis of 
enzymatically stable compounds. 06-MedG, 06-EtdG, 06-n-PrdG and 06. 
hydroxyEt dG were therefore incorporated into oligonucleotides to investigate the 
possibility of producing antibodies to 06  modified dG by immunising with these 
compounds. 
An 06-alkyl dG moiety suitable for incorporation into an oligonucleotide must 
possess the following characteristics: 
a 4',4"-dimethoxytrityl temporary protecting group on the 5' hydroxyl position. 
This group prevents self polymerisation of the nucleotide, and its removal by 
trichioroacetic acid during oligonucleotide synthesis allows the efficiency of the 
synthesis to be monitored. 
a 2-cyanoethyl diisopropyl phosphoramidite linking group on the 3' hydroxyl - 
this is an essential group containing the phosphate (which is protected) necessary for 
oligonucleotide synthesis. 
a suitable protecting group on the amino group of the base. This must remain 
stable during the course of the synthesis, yet be labile for removal after the 
synthesis. 
During the synthesis of oligbnucleotides containing 06-alkyl dG there are a 
significant number of side-products (Borowy-Borowski and Chambers, 1987). 
Many result from exposure of the oligonucleotide to the harsh conditions necessary 
for the removal of the protecting group from the base, e.g. benzoyl and isobut,f1 
deprotection of the base has been reported to take 72 hr in ammonia at 650C.  The 
predominant impurity is a 2,6-diaminopunne (DAP), which can result during the 
ammonia deprotection. Nucleophilic attack by the ammonia at the 06  position 
results in displacement of the 06-alkyl group by an amino group. The presence of a 
DAP in oligonucloetides has been shown to -increase stability of duplexes as it can 
form three hydrogen bonds (Howard et al, 1966; Scheit & Rackwitz, 1982). In 
addition, this molecule has similarities with with both adenine and guanine. 
Therefore, a DAP in an oligonucleotide has the potential to mispair with other 
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nucleosides (Krieg, 1963). For this study DAP is an undesirable side product, since 
it will reduce the number of 06-alkyl dG residues in the oligonucleotide. 
There are two possible solutions to this problem, i) to deprotect with an alternative 
reagent or, ii) to use a more labile N2 protecting group which can be removed under 
less harsh conditions. The removal of an isobutyrl protecting group with methoxide 
ions has been reported (Gaffney and Jones, 1982). This procedure is lengthy (72hr) 
and is not applicable to 06  modified dG derivatives other than 06-MedG, as 
methoxide ions can exchange with the larger 06-alkyl groups. A phenylacetyl 
group has been used to protect the base. Removal of this group after 50 min in 
ammonia at room temperature has been reported (Li and Swann, 1989). At the end 
of normal oligonucleotide synthesis the product is dissolved in a concentrated. 
aqueous ammonia solution, which also removes the cyanoethyl protection on the 
phosphates. Phenylacetyl protection was chosen for the present study as it requires 
straightforward, mild deprotection procedures. 
2.2. Results and discussion 
The conversion of 2'-dG to an Oó-alkyl dG derivative suitable for i) conjugation to a 
protein, and ii) incorporation into an oligonucleotide, involved a number of 
reactions. The general procedure followed (Li and Swann, 1989) required slight 
variations depending on i) whether the final product was to be conjugated to a 
protein or incorporated into an oligonucleotide and ii) the nature of the alkyl group 
being attached. 
2.2.1. Selective alkylation of the 06  position of dG 
Mesitylene suiphonyl chloride was used to suiphonate the 06 position of dG to form 
the 06-sulphonated derivative [a].  The suiphonyl group was displaced by N-
methylpyrrolidine to form derivative [b].  This extremely nucleophilic group easily 
displaces the suiphonyl group in addition to being readily displaced itself by 
alkoxide ions allowing the 06-alkyl derivative [c] to be formed (fig. 2.3). The 
entire three step reaction was carried Out in 90-240mm. (depending upon the alkyl 
group being added) in a one flask procedure. A strong 	was required to 
produce the alkoxide ions which react at the 06  position of dG. As most 
nucleophiles react at the 06  position as well as converting the alcohol to alkoxide 
ions, 1,8-diazabicyclo[4.5.0.]undec-7-ene (DBU), a 	 was used. 
The bicyclic structure of this compound prevents its reaction at the 06  position, 
probably due to steric hindrance. 
Methanol, ethanol and n-propanol were sucessfully converted to the alkoxide 
derivatives which subsequently reacted at the 06  position. The reaction time for 
longer alkyl chains was slower and the yields lower (table 2.2). The lower yields 
were in part due to difficulties in purifying the higher 06-alkyl dGs by flash 
chromatography. 
Table 2.2. Efficiency of the alkylation reaction 
Alkyl Group Reaction Time Yield% 
methyl 40mm 77 
ethyl 2hr 65 
n-propyl 4hr 55 
hydroxyethyl 4hr 33 
4-carboxybnzyl 2hr 28 
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MS= mesitylenesuiphonyl; DBU= 1,8-diazabicyclo[4.5.0]undec-7-ene; TEA= triethylamine: 
DMAP= dimethylaminopyridine; R= alkyl; X= an appropriate protecting group 
Figure 2.3. Modification of the .06 position of dG (Li and Swann, 1989) 
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Ethylene glycol was used to add a hydroxyethyl group to dG. Acetic anhydride was 
reacted with an excess of ethylene glycol to produce monoacetyl ethylene glycol. 
This avoided the activation of both hydroxyl groups of ethylene glycol- by DBU. 
This protected compound was sucessfully activated and added to the 06 position of 










X = an appropriate protecting group 
Figure 2.4. Production of 06-hydroxyEtdG 
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06-CBdG was synthesised by reacting methyl-4-(hydroxymethyl)benzoate (MHMB) 
with DBU then with protected dG (fig 2.5). Only the hydroxymethyl function of 
this compound was activated by DBU. The ester methyl group, which acts as a 
protecting group during the 06  substitution reaction was later removed to produce 
O6 CBdG 
/')K 
HO 	 OCH3 + 	









x_o_) N N— X 
X = an appropriate protecting group 
Figure 2.5. Production of 06-CBdG 
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2.2.2 Synthesis of 06-MedG, 06-EtdG 06-n-PrdG and 06-CBdG for 
conjugation to a protein carrier (scheme 1) 
The hydroxyl groups of the sugar and the 2-amino group of the guanine base were 
protected with acetyl groups by refluxing dG with acetic anhydride, to form 
3',5',N2-(triacetyl)-2'-dG [1]. The protected nucleoside was then modified at the 06 
position with methanol, ethanol, n-propanol and NUMB, as previously discussed, to 
give [2,3,4 and 51 respectively. The protecting groups were removed by the addition 
of 2.5M NaOH to give compounds [6,7,8 and 9].  The acetyl groups protecting the 3' 
and 5' hydroxyl positions were removed within 5 min at room temperature. The 
removal of the acetyl groups protecting the NH2 position of the heterocyclic base 
required 24-48 hr. 
The 06-(4-carboxybenzyl) derivative [9] was now in a suitable form for conjugation 
to a protein. The 06-methyl, ethyl and n-propyl derivatives required the addition of 
a succinyl linker which was attached to the 3' hydroxyl group using succinic 
anhydride and DMAP as a catalyst. Succinic anhydride also reacts at the 5' hydroxyl 
group of the deoxyribose sugar and therefore this position was protected with a 
dimethoxytrityl (DMTr) group. DMTr chloride reacted primarily with the 5' 
primary hydroxyl group and minimal tritylation occured at the 3' secondary 
hydroxyl position. In addition to reacting at the 5'-OH, DMTr chloride also reacted 
with the NH2 position of the base, and gave compounds [10,11,12], but this was not 
disadvantageous as in addition to providing a suitable protecting group DMTr 
provided a method to monitor the extent of nucleoside-protein conjugation. It was 
necessary to maintain alkaline conditions throughout the synthesis and purification 
of DMTr compounds, as neutral-acidic environments result in cleavage of the DMTr 
group. After the addition of the DMTr groups and a succinyl linker, 06-methyl, 
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Scheme 1. Synthesis of 06-alkyl dG for conjugation to a protein carrier 
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2.2.3. Synthesis of 06-hydroxyEtdG for conjugation to a protein carrier 
(scheme 2) 
06-hydroxyEt dG was synthesised using protecting groups suited to oligonucleotide 
synthesis and these will be discussed later. After modification of the 06 position as 
previously discussed, all protecting groups were removed to obtain 06-hydroxyEt 
dG [16]. Again it was necessary to add a succinyl linker before protein conjugation 
was possible. The reactive positions of 06-hydroxyethyl dG (5' OH, 2-amino and 
hydroxyethyl OH) were therefore protected with DMTr groups and the succinyl 
linker added, as previously described for the 06-alkyl dG derivatives, to give 
compounds [17] and [18] respectively. 
NN 
L 


























Scheme 2. Synthesis of 06-hydroxyEt dG for conjugation to a protein 
2.2.4. Protein Conjugation (scheme 3) 
The succinylated 06-MedG, 06-EtdG, 06-n-PrdG and 06-hydroxyEt dG 
derivatives and 06-CBdG, were treated with 1-ethyl-3-(3-
dimethylamino)carbodiimide (EDC) to activate the carboxylic acid group of the 
succinyl linker and the carboxybenzyl group of 06-CBdG. The carbodiimide 
reacted with the carboxyl group to produce an 0-acyl isourea. This reacted readily 
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with amine groups on the lysine residues of the protein producing a protein-
nucleoside conjugate and a urea salt. Each 06  modified dG derivative was' 
conjugated to BSA to produce [19,20,21,22,23]. BSA contains a proportionately 
high number of lysine residues (59) and dissolves readily in water. Conjugation to 
this protein was expected to yield highly substituted soluble conjugates. 
Conjugation to two proteins was necessary for antibody screening, therefore each 06 
modified dG derivative was also linked to CyG. 
+ - N=C=N— --- -N— Cl- 
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Scheme 3. Protein conjugation. 
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It was necessary to find a suitable solvent in which to conduct the conjugation 
reactions. In general, proteins are soluble in water but relatively insoluble in organic 
solvents. 06-CBdG dissolved readily in water and was conjugated to both proteins 
without problems. 06-MedG, 06-EtdG, 06-n-PrdG and 06-hydroxyEt dG were 
insoluble in water and it was hoped that the use of a water miscible solvent would 
allow sufficient contact between the protein and the nucleoside for conjugation to 
occur. The solubility of BSA, CyG and each 06  modified dG derivative was tested 
in a variety of 50:50 organic solvent/water systems. It was thought that the removal 
of the DMTr groups may make the modified nucleosides more water soluble, 
therefore a small sample of each was detritylated and also tested for solubility. 
The solubilities of each 06  modified dG derivative were similar. BSA was the more 
soluble protein (table 2.3). The proteins dissolved most efficiently in 50% aqueous 
pyridine. The tritylated 06  modified dG derivatives dissolved readily in most 
solvent system investigated. Detritylation made the 06  modified derivatives more 
water soluble, but they became less soluble in organic solvents (apart from DMF). 
Table 2.3. Test of the solubility of BSA, CG and tritylated and de-tritylated 06 
modified dG derivatives 





tritylated 06  
modified dG 
 derivative 
detritylated  06 
modified dG 
derivative 
acetonitrile * * 0 0 
DCM ** * **** 0 
1,4dioxane ** * **** 0 
DMF *** ** *** **** 
DMSO *** ** 0 0 
pyridine **** *** **** 0 
0= insoluble, *= slightly soluble, to ****readily  soluble 
Conjugations were therefore carried out with tritylated nucleosides in a 50:50 
solution of pyridine and water. Typically 5-10mgs of protein were dissolved in 
0.4mls of water, and 0. 1 m of pyridine was added. This introduced the protein 
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gradually to the solvent environment. Likewise, 10mgs of tritylated 06 modified 
dG was dissolved in 0.4mls of pyridine and 0.1 ml of water was added. Water 
soluble carbodiimide (EDC) was added to this solution. The presence of the small 
amount of water allowed the carbodiimide to dissolve. Mixing of the samples often 
resulted in precipitation of the nucleosides and/or the proteins. For example, the 
first few drops of nucleoside solution added to the protein solution were in a very 
high concentration of water and therefore precipitated. The precipitates rarely 
redissolved on the addition of more solvent. Repeated experiments showed that 
rapid addition of one solution to the other resulted in the components remaining in 
solution. 
The conjugated products were not soluble in 100% water. This was attributed to the 
hydrophobicity of 06  modified dG and its effect on the protein conjugate. 
Purification by gel filtration to remove the unconjugated nucleoside and excess 
carbodiimide was carried out in 50:50 ethanol/water. A small amount of each 
conjugate was kept aside to allow the extent of nucleoside-protein conjugation to be 
calculated. The remainder was detritylated using acetic acid and the products were 
purified by gel filtration. 
2.2.5. Characterisation of conjugates 
Substitution of 10 haptens per protein molecule have been reported to give a 
superior immune response subsequent to immunisation (Landsteiner,1945). A more 
recent investigation by Stollar (1980) which examined the work carried out to that 
date suggested that 8-25 haptens per protein led to the production of suitable 
antibodies. Despite these findings some researchers have produced excellent 
antibodies with as few as 5 haptens per protein (Klaus and Cross, 1974), although 
efficiency of antibody production is probably hapten dependent. 
The extent of nucleoside substitution is usually determined from the ultraviolet (UV) 
absorbance spectrum. The protein contribution to the A260  and  A280  of the 
conjugate is determined from the known spectrum of unmodified protein for a 
known protein concentration. Proteins have a weak absorbance around 260n.m. (fig 
2.6a) whereas most nucleosides have a maximumat this point. The difference 
between the total A260  of the conjugate and the A260  of the protein is therefore 
largely contributable to the nucleoside. The concentration of nucleoside is then 
estimated by comparing the A260 to  A280  ratio of the conjugate with non-





Figure 2.6 UV scans of a) BSA, b) 06-alkyl dG and c) an 0-a&y1 dG-BSA conjugate 
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2.2.5.1. Calculating hapten substitution of 06-MedG, 06-EtdG 06-n-PrdG and 
06-hydroxyEtdG conjugates 
UV scans of succinylated 06-MedG, 06-EtdG, 06-n-PrdG and 06-hydroxyEtdG 
showed that these derivatives have a minimum absorbance at 260n.m. and maximum 
absorbance at 245 and 285n.m (fig. 2.6b). Therefore a direct comparison of 
A260:A280 is not an accurate index of the extent of hapten substitution. The degree 
of conjugation was therefore estimated by comparing the A245 where the modified 
nucleoside has maximal absorbance, with the A260 where the protein has minimal 
absorbance. For non-conjugated protein the A245:A260 was approximately 0.6:1 
(table 2.4). 
Table 2.4. Absorbance of 1mg of each conjugate 
Absorbance at: Ratio 
Protein 06modified A280 
dG  
A260 A245  A245:A260 
BSA - 0.28 0.20 0.13 0.65 
CyG - 0.34 0.23 0.14 0.61 
BSA 06-Me dG 38.7 28.2 47.4 1.68 
BSA 06-EtdG 39.3 26.9 39.5 1.47 
BSA 06-n-PrdG 39.2 29.7 42.3 1.42 
BSA 06-hydroxy 38.2 
EtdG  
33.5 41.3 1.23 
QyG 06-MIG 40.3 27.0 44.8 1.66 
CG 06-EtdG 37.2 27.2 45.6 1.68 
CyG 06-n-PrdG 36.8 30.6 38.2 1.25 
C'yG 06-hydroxy 38.8 
EtdG  
26.3 40.8 1.55 
The UV scans of the conjugates showed an increased absorbance at 245n.m. relative 
to protein (fig 2.6c). The A245:A260 ratios for all conjugations carried out were 
between 1.2 and 1.7 indicating that a significant degree of conjugation had occurred 
(table 2.4). These absorbance values could not be accurately translated into 
quantitative data because the absorbance measured at A260 was attributable to both 
the nucleoside and the protein. Consequently, at every wavelength the protein was 
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obscured by the nucleoside and therefore traditional protein conjugation calculations 
could not be conducted on 06-alkyl dG conjugates. 
Additional information on the extent of conjugation was obtained by measuring the 
orange colour produced during the removal of the DMTr groups from the 
conjugates. This colour was measured at 504n.m. and the number of DMTr 
molecules present, hence the number of nucleoside molecules present, was 
calculated using the extinction coefficient. DMTr analysis was carried out on 
aliquots of 06-EtdG-BSA and 06-n-PrdG-BSA conjugates which had been reserved 
for this experiment. 
Q-EtdG-BSA 	 O-n-PrdG-BSA 
A504 for 5.tg of conjugate = 62.4 	 A504 for 5i.g of conjugate = 71.7 
Using these values and the extinction coefficient for DMT at 504n.m (76j.tM/ml) the 
number of DMTr groups attached to 5jig of conjugate was calculated. 
c= Absorbance (at 504n.m) 
(E x d) 
-EtdG-BSA 
c = 1.68p.M/ml 
= 1.68 x 10 9moW5tg of BSA 
= 1.68 x 10 9rnol/7.7 x 10 11molBSA 
= 168 trityl groups per 7.7 BSAs 
E = extinction coefficient = 76j.tM/ml 
d = pathlength, = 0.5 
O-n-PrcjG-BSA 
c=1.89p.MJml 
= 1.89 x 10 9mo1/5j.tgofBSA 
= 1.89 x 10 9mo1f7.7 x 10-11molBSA 
=189 trayl groups per 7.7 BSAs 
Since there are 2 trityl molecules for each nucleoside the final results are: 
-EtdG-BSA 	 -n-PrdG-BSA 
84 nucleosides per 7.7 BSAs 
	
95 nucleosides per 7.7 BSAs 
approx. 11 nucleosides/BSA arrnrox. 12 nucleosides/BSA 
These amounts were within the average range of 8-25 haptens per protein, found in 
other studies. It was assumed that the extent of hapten substitution for all 06-alkyl 
and hydroxyEtdG conjugates in this study was similar to that of 06-EtdG-BSA and 
06-n-PrdG-BSA, as the shape of the UV scans and A245:A260 ratios were similar. 
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2.2.5.2. Calculating hapten substitution for 06-CBdG conjugates 
The extent of conjugation of 06-CBdG was estimated by UV scan analysis only, as 
no DMTr groups were added to this derivative. Maximum absorbance for 06-CBdG 
occured at 235n.m. and the aromatic ring wa detected by the presence of 3 
characteristic peaks betwen 245 and 265n.m (fig. 2.7a). UV scans of the conjugates 
(fig. 2.7b) closely resembled the modified nucleoside, therefore it was assumed that 
conjugation had occurred. The A245:A260 ratio was not considered as the 
nucleoside has high absorbance at 260n.m. (table 2.5) due to the benzene ring. 
Table 2.5. 06-(4-carboxybenzyl) dG conjugates 
Absorbance at: 
Conjugate A280 A260 A245  
06-CB dG-BSA 38.6 59.3 98.0 
06-CB dG-C3 37.7 70.5 106.7 
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Figure 2.7: UV scans of a) 06CBdG and b) 06CBdG-BSA Conjugate 
(a) 
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2.2.6 Synthesis of 06-MedG, 06-EtdG and 06-n-PrdG for incorporation into 
an oligonucleotide (scheme 4) 
Phenylacetic anhydride was chosen as an appropriate protecting group for the 2-
amino position of the heterocyclic base. The 3' and 5' sugar hydroxyl groups were 
firstly protected by mixing acetic anhydride with dG at room temperature for 48 
hours. Under these conditions the hydroxyl groups were selectively acetylated, to 
produce 3',5'-bis(0-acetyl)-2'-dG [24]. The 2-amino group of the base was then 
protected by refluxing [24] with phenylacetic anhydride forming 3',5'-bis(0-acetyl)-
N2-henylacetyl)-2'-dG [25]. The 06  position was modified as previously 
described by methanol, ethanol and n-propanol, giving compounds [26,27,28]. On 
addition of an aqueous 2.5M solution of NaOH the acetyl groups were displaced, 
giving 06-alkyl dG protected only at the base 2-amino position [29,30,3 1]. This 
reaction was neutralised with Dowex after exactly 5 min to avoid prolonged 
exposure of the nucleosides to extremely basic conditions, which would resultin 
partial removal of the N2-phenylacetyl protecting group. The 5'-OH was tritylated, 
giving compounds [32,33,34] and the 3'-OH, was selectively phosphitylated by 2-
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2.2.6.1. Synthesis of 06-hydroxyEt dG for incorporation into an oligonucleotide 
(scheme 5) 
The addition of ethylene glycol to the 06 position of dG was carried out as 
previously described using monoacetyl ethylene glycol. For oligonucleotide 
synthesis it was necessary for the 06hydroxyEt group to remain acetyl protected. It 
was therefore not possible to use acetyl protecting groups on the 3' and 5' sugar 
hydroxyl positions, as deprotection to remove the 3' and 5' sugar protecting groups 
would also result in some loss of the 06-monoacetyl group from the ethylene glycol 
moiety. The hydroxyl groups of dG were therefore protected with a 
tetraisopropyldisiloxane (TIPDS) group using Markiewicz reagent. This group was 
removed by the addition of tetrabutyl ammonium flouride (TBAF), leaving the 
guanine 2-amino and the 06-hydroxyEt protecting groups intact. 
The 3' and 5' OH groups of 3', 5'-bis(0-acetyl)-N2-(phenylacetyl)..dG [25] were 
deprotected to give N2-(phenylacetyl)-dG [38] and the TIPDS group added giving 
[39]. After. 6 modification giving [40] the TIPDS protection was selectively 
removed by the addition of TBAF to give compound [41]. 5' DMTr and 3' 
phosphoramidite groups were added to give [42] then the 06-hydroxyethyl dG 
oligonucleotide monomer [43]. 
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2.2.7. The synthesis of oligonucleotides containing 06-MedG, 06-EtdG, 06-n-
PrdG and 06-hydroxyEtdG 
To prevent enzymatic degradation of the oligonucleotides subsequent to 
immunisation, phosphorothioate (PS) linkages were incorporated. This was carried 
out using tetraethyl thiuram disulphide during oligonucleotide synthesis (Vu and 







tetraethyl thiuram assembling 



















racemic phosphorothioate 	I 
mixture 	 0- 
* = chiral phosphorus racemic mixtures 
Figure 2.8. Phosphorothioates 
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A racemic phosphorothioate mixture is produced and this is degraded very slowly by 
enzymes. PS linkages added to the 3' end of oligonucleotides have been shown to 
reduce degradation by the abundant 3' to 5' exonucleases (Putney eta!, 1981). 
Therefore the PS linkages were added to the Tend of the oligonucleotides 
synthesised in this study. 
Oligonucleotides incorporating 06-MedG, 06-EtdG and 06-n-PrdG were 
synthesised. Each consisted of 8 modified nucleosides and 46 thymidine (T) 
residues. The oligonucleotides were made up of only two different nucleosides to 
reduce the amount of screening required after immunisation. Sequences were 54 
nucleotides in length to ensure a high molecular weight (approximately 20 000) and 
included five PS linkages (fig 2.9 a-c). The exact number of PS linkages required to 
prevent degradation of the oligonucleotide in vivo before an immune response 
occuifëd was not known. Therefore an additional 49 nucleotide sequence consisting 
of 06-MedG and T and a backbone of PS linkages, was synthesised (fig 2.9d). In 
addition, a self complementary oligonucleotide containing eleven nucleotides and 
one 06-hydroxyEtdG was synthesised (fig 2.8e). For the purpose of the current 
study this sequence was to be used for screening only. 
PS linkages are indicated in boldface 
(a) 5' T5XT5XT5XT5XT5XT5XT5XTF5 3' X=06MedG 
(b) 5' T5YT5YT5YT5YT5YT5YT5YTF5 3' Y=06EtdG 
(c) 5'T5ZT5ZT5ZT5ZT5ZT5ZT5ZTF5 3' 	Z-06n-PrdG 
(d) 5' T5XT5XT5XT5XT5XT5XT5XT 3' 
e) S'CGC 06hydroxyEtdGAA TT GCG3' 
Figure 2.9. Oligonucleotides containing 06-MedG, 06-EtdG, 06-n-PrdG and 06 
hydroxyEt dG for immunisation and screening. 
Sequence (d) and the five 3' PS residues of sequences (a), (b) and (c) were 
synthesised using an adapted synthesis cycle suitable for phosphorothioates. 
Sequence (d) was cleaved from the solid support after synthesis. The latter 3 
sequences were left attached the solid support which was then used as a starting 
point for the synthesis of the remaining 49 non-PS residues. These, and sequence 
(e) were synthesised using the standard large scale (lp.mole) normal DNA coupling 
cycle. At the end of the synthesis the sequences were cleaved from the solid 
support. During oligonucleotide synthesis, after the addition of each nucleotide the 
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5' DMTr group was removed to allow the addition of another nucleotide. 
Monitoring of the colour produced by the removal of this group gave an indication 
of the extent of coupling of each nucleotide and the overall efficiency of synthesis 
(table 2.7). 
Table 2.7 Average coupling of each oligonucleotide 






After synthsis of the sequences it was necessary to remove the phenylacetyl 
protecting group from the 2-amino position of guanine. Li and Swann (1989) 
reported the removal of this group in concentrated aqueous ammonia after 50 min at 
room temperature. Sequence (a) was exposed to the above conditions then tested by 
HPLC which showed that minimal deprotection had occurred (see appendix for raw 
data). The sequence was then heated to 550C and tested by HPLC over a 
timecourse. Results showed that deprotection was almost complete at 24 hr (table 
2.8 and appendix). 
Table 2.8. Removal of the phenylacetyl protecting group 
State of Oligonucleotide 
Time (temperature) deprotected : protected 
(approximately) 
5O min (RT) 1:2 
4hr(550C) 3:2 
12hr(550C) 4:1 
24 hr (550C) 1 	 10: 1 
The remaining oligonucleotides were exposed to ammonia at 550C for 24 hr. 
Purification was carried out on a column of sephadex G25. For sequences (a-d) no 
HPLC purification was required as failure sequences contain only T and 06-alkyl 
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dG. If these failure sequences are sufficiently large to stimulate the immune system 
they will help in antibody production. If they are too small they are unlikely to 
cause adverse effects. Sequence (e) was purified by reversed phase HPLC. 
2.2.8 Analysis of oligonucleotides 
Analysis was carried out to ensure that each 06  modified dG derivative had been 
successfully incorporated into oligonucleotides and had not undergone conversion to 
diaminopurine (DAP) during ammonia deprotection. Each oligonucleotide was 
enzymatically digested into nucleoside components by snake venom 
phosphodiesterase which cleaves the phosphodiester linkage producing 5' 
monophosphate residues, and alkaline phosphatase which removes the phosphate 
group. The digested products were analysed by HPLC and compared with standard 
samples of dT, 06-alkyl dG and diaminopurine nucleoside. HPLC analysis was 
carried Out by ultraviolet spectroscopy at 280n.m. Injection of the digested products 
of sequence (b) and co-injection with dT and 06-ethyl dG confirmed that the first 
peak (retention time approx. 1 1mm) was attributable to dT residues and that the 
second peak (retention time approx 23mm) was attributable to 06-ethyl dG (fig. 
2.10a). Co-injection with DAP (fig 2;10b) and comparison of the HPLC trace in fig 
2. 1 O showed that minimal DAP was formed during the prolonged ammonia 
deprotection. The peak with a retention time of approximately 5min may have been 
due to the T5 phosphorothioate sequence which may not have been readily digested 
by the enzymes. 
Sequences (a) and (b) were also analysed by enzyme digestion and gave similar 
results to sequence (b). Sequence (d) was not analysed as an enzyme digest of this 
complete PS sequence would be unsucessful due to the presence of the 
enzymatically stable PS group throughout. However, the results from the first 3 
sequences suggested that the 06-MedG was intact in this sequence. 
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(b) 
Figure 2. 10. Enzyme digest analysis of 06 a1ky1 dG oligonucleoddes 
injection of enzyme ngest 
(a) ii 
L. VV 	20.00 	25.00 
time (mm) 
co-injection of enzyme digest with DAP 
T 
- - 	-',",,., 	L.UU 	20.00 	25.00 	30 
time (miii) 
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HPLC analysis of the digested products of the sequence containing 06-hydroxyEtdG 
sequence (e) showed that this derivative was no longer present (fig 2.11). It is 
thought that the conversion of 06-hydroxyEt dG to dG occurred during the 
ammonia deprotection following oligonucleotide synthesis, as the overall structure 
of the ethoxyacetyl group is similar to a base labile protecting group (fig. 2.12). The 
incorporation of 06-hydroxyEt dG into an oligonucleotides therefore requires 
alternative protection on the NH2 position of the base, so that ammonia deprotection 













L5.00 	20.00 	25.00 
time (mm) 
Figure 2.11. Enzyme digest analysis of 06-hydroxyEt dO oligonucleotides 
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Reagents were obtained from Fluka, unless otherwise stated. 1H and 13C NMR 
spectra were measured on a Bruker WP 200 spectrometer, mass spectra on a Kratos 
MS50 TC spectrometer and UV spectra on a Perkin-Elmer Lambda 15 
spectrophotometer. Controlled Pore Glass Supports, pore diameter 500A, particle 
size 125-177i, were obtained from Pierce. Sephadex G25 (Pharmacia NAP 10) was 
used for gel filtraton. Solvents were purified as follows: 





distilled over CaH2 
distilled over KOH 
distilled over Mg/I 
vacuum distilled 
distilled over Na 
benzophenone 
Merck silica gel 60 was used for flash chromatography and Merck silica gel 60 F245 
aluminium plates Were used for TLC in the following solvent systems: 
DCM/MeOH (9:1 v/v) (la) =(1)+ 1%TEA 
DCM/MeOH (8:2 v/v) (2a) =(2)+ 1%TEA 
DCM/MeOH (95:5 v/v) (3a) =(3)+ 1%TEA 
nBuOH/AcOH/H20 (3:1:1 v/v/v) 
DCM/MeOH/AcOH (10:2:1 v/v/v) (5a) =(5)+ 1%TEA 
CH3CN/EtOAc (5:5 v/v) (6a) =(6)+ 1%TEA 
Toluene/EtOAc (7:3 v/v) 	 (7a) =(7)+ 1%TEA 
Et20/Et0Ac(5v/v)  
rThe purity of all compunds synthesised was v fled by on spot on TLC. 
Synthesis of 06-alkyl-2 '-deoxyguanosine nucleosides for conjugation to 
protein carriers 
(see Scheme 1) 
3 ',S '-Bis(O-acetyl)-N2-(acetyl)-2 '-deoxyguanosine [1] 
3',5'-Bis(O-acetyl)-2'-deoxyguanosine (lOg, 28mmol) was dried by evaporation of 
anhydrous pyridine (3x30m1) then suspended in anhydrous pyridine (lOOml). Acetic 
anhydride (17.2m1, 0. l7mol, 6eqs) was added and the mixture refluxed for 3hr when 
TLC showed complete conversion to the triacetyl derivative. After cooling to RT the 
solution was poured into saturated aqueous KC1 (lOOml) and the product extracted 
with DCM (lOOml). The organic layer was dried with MgSO4 and evaporated to a 
small volume. The product was precipitated as a white powder by addition of MeOH. 
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(lOg, 91%) Rf 0.29 (solvent 1) Rf 0.15 (solvent 3) Rf 0.74 (solvent 5) [FAB] m/z 
Found 394.12845 Requires 394.12845 (M+H)+ H[d6DMSO]  2.06 (s, 3H, CH3CO) 
2.09 (s, 3H, CH3CO) 2.29 (s, 3H, CH3CO) 2.46-3.01 (m, 3H, H2',2") 4.31-4.65 (m, 
3H, H4',5',5") 5.36-5.38 (m, 1H, H3') 6.17-6.21 (m, 1H, Hi') 7.76 (s, 1H, H8) 9.89(s, 
1H, Hi') 
General Method based on the method of Li and Swann (1989) 
3 ',S '-Bis(O-acetyl) -N2 -(acetyl)-06-alkyl-2 '-deoxyguanosine [2,3,4] 
3',5'-Bis(O-acetyl)-N2-(acetyl)-2'-deoxyguanosine (1.5g, 3mmol) was dissolved in 
anhydrous DCM (40m1) with gentle heating. After cooling to RT anhydrous TEA 
(1.7m1, 15mmol, 5eq), 2-mesitylene suiphonyl chloride (1.4g, 6mmol, 2eq) and 
DMAP (100mg) were added. The reaction was stirred at RT for 30min when TLC 
showed complete convertion to the 06-sulphonated derivative. The solution was 
cooled to 0°C and N-methylpyrrolidine (3m1, 30mmol, lOeq) added. After 20min at 
0°C, TLC showed conversion to the N-methylpyrrolidine quaternary salt, Rf 0-0.1. 
After warming to RT the solution was stirred rapidly with the appropriate alcohol 
(21mmol, 7eq, methanol 0.84m1, ethanol 1.2m1 or n-propanol 1.56m1) and DBU 
(1.35m1, 9mmol, 3eq). TLC showed production of a high running compound after 
40mm, 2hr and 4hr for the methyl, ethyl and n-propyl derivatives respectively. Each 
reaction was quenched with aqueous KH2PO4 (lOOml, 1M, pH6.5) and the organic 
layer extracted and dried with MgSO4 then evaporated in vacuo. Each product was 
purified by flash chromatography (eluant: DCM/MeOH 95:5) and the appropriate 
fractions combined and evaporated in vacuo to a foam. 
methyl ethyl n-propyl 
Weight/Yield 1 .2g(77% 1.05g/65% 0.92g/55% 
Rf:(solvent 1) 0.69 0.71 0.75 
(solvent 3) 0.30 0.35 0.36 
(solvent 5) 0.91 0.82 0.87 










H[d6DMSO] methyl ethyl n-propyl 
H3CH2CH20 0.98-1.02 (t,3)J=7.4Hz 
cH3CH20 1.42-1.44 (t,3)J=7.lHz  
CH3H2CH20   1.79-1.88 (m,2) 
CH3CO 1.99(s,3) 2.02(s,3) 2.03(s,3) 
CH3CO 2.04(s,3) 2.08(s,3) 2.09(s,3) 
CH3CO 2.44(s,3) 2.48(s,3) 2.46(s,3) 
H2,2" 2.50-2.67 (m,2) 2.51-2.90 (m,2) 2.52-2.90 (m,2) 
CH30 4.12(s,3) 
H4',5',5" 4.21-4.26 (m,3) 4.26-4.39 (m,3) 4.27-4.32 (m,3) 
CH3CH th0 4.36-4.44 (m,2) 
CH3H20  4.49-4.55(g,2)J=7. 1Hz  
H3' 5.32-5.38 (m,1) 5.36-5.41 (m,1) 5.36-5.40 (m,1) 
H1' 6.21-6.27(t,1)J=6.6Hz 6.28-6.31 (t,1)J=6.6Hz 6.29-6.32 (t,1)J=6.6Hz 
H8 7.98 (s,1) 7.92 (s,1) 7.93 (s,1) 
NH 9.05(s,1) 8.18(s,1) 1 8.13(s,1) 
06-alkyl-2 '-deoxyguanosine [6,7,8] 
3',5 '-Bis(O-acetyl)-N2-(acetyl)-06-alkyl-Tdeoxyguanosine was dissolved in pyridine 
then concentrated in vacuo to a small volume. Pyridine (6m1) and NaOH solution 
(2.4m1, 2.5M) were added and the solution stirred rapidly at RT. After 24hr the 
mixture was treated with Dowex 50-X8 pyridinium form. The Dowex was washed 
thoroughly with pyridine (20m1) and the resulting solution evaporated in vacuo. The 
product was purified by flash chromatography (eluant: DCMIMeOH 93:7) and the 
appropriate fractions combined and evaporated in vacuo to a foam. 
methyl ethyl n-propyl 
Weight/Yield 0.84g/96% 0.75g/97% 0.70gJ98% 
Rf:(solvent 2) 0.34 0.37 0.42 
(solvent 5) 0.21 0.24 0.30 
(solvent 4) 0.65 0.68 0.73 










6H[d6DMSO] methyl ethyl n-propyl 
H3CH2CH20 0.92-0.97 (t,3)J=7.lHz 
H3CH20 1.32-1.36 (t,3)J=7.lHz  
CH3UI2CH20  1.72-1 .78(g,2)J=7. 1Hz 
H2',2" 2.21-2.64 (m,2) 2.07-2.25 (m,2) 2.13-2.20 (m,2) 
CR30 3.95(s,3)  
H5',5" 3.51-3.57 (m,2) 3.47-3.59 (m,2) 3.36-3.56 (m,2) 
CH3CHH20  4.33-4.36 (m,2) 
CH3H20 4.41-4.47(g,2)J=7.lHz  
 3.79-3.82 (1) 3.80-3.84 (m,1) 3.81-3.84 (m,1) 
 4.36-4.41 (m,1) 4.34.4.36 (m,1) 3.36-3.56 (m,1) 
OH5  4.98-5.03 (t,1) 4.96-5.21 (hr s,1) 4.90-5.20 (br s,1) 
OH3' 5.28-5.29 (m,1) 5.32(s, 1) 5.31 (s, 1) 
H1 6.17-6.24 (t,1)J=6.3Hz 6.19-6.23 (t,1)J=6.6Hz 6.19-6.23 (t,1)J=6.6Hz 
NH2 6.47(s,2) I 6.41(s,2) 6.40(s,2) 
H8 8.08 (s,1) I 8.07 (s,1) 8.07 (s,1) 
5 ',N2-Bis-(4,4'-Dimethoxytrityl)-06-alJcyl-2 '-deoxyguanosine [10,11,12] 
06-alkyl-2'-deoxyguanosine (2.5mmol) was stirred at RT in anhydrous pyridine 
(6m1) with 4,4'-dimethoxytrityl chloride (2.1g. 6.25mmol, 2.5eq), anhydrous TEA 
(1.5m1, 7.5mmol, 3eq) and DMAP (100mg). After 2hr the solution was evaporated in 
vacuo, redissolved in DCM (20m1) and washed with saturated KC1 solution (50m1), 
then 1% citric acid solution (50m1). The organic layer was extracted, dried with 
MgSO4 and concentrated in vacuo to give the product as an oil which was purified 
by flash chromatography (eluant 50:50:1 Et2OIEtOAc/TEA) then evaporated in vacuo 
to give the title compound. 
methyl ethyl n-propyl 
Weight/Yield 1.7g76/% 1.2g/53% 1.3g/57% 
Rf:(solvent 3a) 0.59 0.58 0.61 
(solvent 7a) 0.10 0.17 0.18 











öH[d6DMSO] methyl ethyl n-propyl 
H3CH2CH20 0.93-0.97 (t,3)J=7. 1Hz 
1.22-1.26 (m,3)  
CH3H2CH20  1.72-1.78(g,2)J=7.1Hz 
H2',2" 2.08-2.45 (m,2) 2.21-2.34 (m,2) 2.15-2.61 (m,2) 
OCH3 x 4 or 5 3.36-3.72(m,15) 3.73-3.78 (s,12) 3.72-3.77 (s,12) 
H4',5,5" 3.11-3.26 (m,3) 4.09-4.21 (m,3) 3.25-3.34 (m,3) 
CH3CH2H20 4.07-4.13 (m,2) 
CH3CkI20  3.73-3.78 (m,2)  
H3' 4.17-4.26 (m, 1) 4.50-4.53 (m,1) 4.71-4.73 (m,1) 
OH3 5.26-5.28 (br s,1): 4.91-4.95 (br s,1) 5.27-5.28 (br s,1) 
Hi' 6.24-6.30 (t,1)J=6.6Hz 6.17-6.22 (t,1)J=6.4Hz 6.70-6.79 (t,1)J=6.6Hz 
Ar x 6 6.76-7.33 (m,26) 6.72-7.29 (m,26) 6.81-7.39 (m,26) 
H8 7.96 (s,1) 7.54 (s,1) 7.37 (s,1) 
NH 10.63(s,1) 11.72(s,1) 7.69(s,1) 
5 ',N2-(4,4'-Dirnethoxytrityl)-06-alkyl-3 '-succinyl-2 '-deoxyguanosine [13,14,15] 
5'N2- (4,4'-Dimethoxytrityl)-06-alkyl-2'-deoxyguanosine (0.5mmol) was 
coevaporated with anhydrous DMF (3x5m1). Succinic anhydride (0.05g, 0.5mmol, 
leq), DMAP (5mgs, 0.05mmol, O.ieq) and anhydrous DMF (2.5m1) were added and 
the solution stirred at RT. After 18hr the solution was concentrated, then 
coevaporated with toluene (MgSO4 dried), and redissolved in DCM. This solution 
was washed quickly with aqueous citric acid (lOmi, 10% w/v), then water (lOmi). 
The organic layer was extracted, driedwith MgSO4, and evaporated in vacuo. The 
residue was purified by flash chromatography (eluant: DCM/MeOH/TEA 94:6:1) and 
the appropriate fractions combined and evaporated in vacuo to give the title 
compound as a foam. 
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methyl ethyl n-propyl 
Weight/Yield 0.29g/59% 0.24g148% 0.27gJ56% 
Rf:(solvent la) 0.31 0.32 0.35 
(solvent 2a) 0.54 0.57 0.61 










H[d6DMSO] methyl ethyl n-propyl 
H3CH2CH20 0.93-0.97 (t,3)J=7.lHz 
H3CH20  1.15-1.23 (t,3)J=7.lHz  
CH3H2CH20   1.72-1.78(g,2)J=7.lHz 
H2,2" 2.09-2.41 (m,2) 2.52-2.61 (m,2) 2.52-2.61  
CH2 x 2 2.51-2.58  2.15-2.16 (m,4) 2.15-2.16 (m,4) 
OCH3 x 4 or 5 3.73-3.74(m,15) 3.73-3.74 (s,12) 3.73-3.74 (s,6) 
H4',5,5" 3.30-3.39 (m,3) 3.31-3.33 (m,3) 3.31-3.33  
CH3CHQi20  4.08-4.13 (m,2) 
CHH20   2.86-2.92(g,2)J=7. 1Hz  
H3 4.17-4.23 (m,1) 4.16-4.21 (m,1) 4.19-4.22 (m,1) 
OH 4.714.75 (br s,1) 5.28-5.36 (hr s,1) 5.21-5.35 (hr s,1) 
HI, 6.18-6.20 (t,1)J=6.6Hz 6.16-6.20 (t,1)J=6.6Hz 6.17-6.20 (t,1)J=6.6Hz 
Ar x 6 6.69-7.47(m,26) 6.70-7.28(m,26) 6.70-7.28(m,26) 
H8 7.68 (s,1) 7.37 (s,1) 7.37 (s,1) 
NH 8.14 (s,1) 7.69 (s,1) 7.69 (s,1) 
Synthesis of 06-(4-carboxybenzyl)-2 '-deoxyguanosine for conjugation to carrier 
proteins (see scheme 1) 
3 ',S '-Bis(O-acetyl)-N2 -(acetyl)-06-(4-carbomethoxybenzyl))-2 '-deoxyguanosine [5] 
3',5 '-Bis(O-acetyl)-N2-(acetyl)-2'-deoxyguanosine (1.5g, 3mmol) was dissolved in 
anhydrous DCM (40m1) with gentle heating. After cooling to RT anhydrous TEA 
(1.7m1, 15mmol, Seq), 2-mesitylene suiphonyl chloride (1.4g, 6mmol, 2eq) and 
DMAP (100mg) were added. The reaction was stirred at RT for 30min when TLC 
showed complete convertion to the 06-sulphonated derivative. The solution was 
cooled to 0°C and N-methylpyrrolidine (3m1, 30mmol, lOeq) added. After 20min at 
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OOC, TLC showed conversion to the N-methylpyrrolidine derivative, lower Rf. After 
warming to RT the solution was stirred rapidly with methyl-4-
(hydroxymethyl)benzoate (3.5g, 21mmol, 7eq) and DBU (1.35m1, 9mmol, 3eq). 
After 2hr TLC showed production of a high running compound and the reaction was 
quenched with aqueous KH2PO4 (lOOmi, 1M, pH6.5) and the Organic layer extracted 
and dried with MgSO4 then evaporated in vacuo. The product was purified by flash 
chromatography (eluant: DCMJMeOH 98:2) and the appropriate fractions combined 
and evaporated in vacuo to a foam. (1.7g, 90%) Rf 0.63 (solvent 1) Rf 0.31 (solvent 
Rf 0.89 (solvent 2) [FAB] m/z (M+H)+ Found 495.16752 Requires 495.16757 
6H[CdC13] 2.01 (s, 3H, CH3CO) 2.07 (s, 3H, CH3CO) 2.38 (s, 3H, CH3CO) 2.48-
3.00 (m, 2H, H2',2")  3.84 (s, 311, COOCH3) 4.27-4.37 (m, 3H, H4',5',5") 5.35-5.38 
(m,114, H3') 5.54 (s, 2H, OCH2) 6.26-6.30(m, 1H, Hi')  7.31-7.96 (m, 5H, H8 & Ar) 
8.31 (s, 1H, NH) 
06-(4-carboxybenzyl)-2 '-deoxyguanosine [9] 
3',5'-Bis(O-acetyl)-N2-(acetyl)-06-(4-carbomethoxybenzyl)-2'-deoxyguanosine (1.7g, 
3.4mmoi) was dissolved in pyridine then concentrated in vacuo to a small volume. 
Pyridine (20ml) and 2.5M NaOH (lOml) were added and the solution stirred rapidly 
at RT. TLC showed complete conversion to a low running product after 72hr. The 
mixture was neutralised on a column of Dowex 50-X8 H+ form (20m1). The Dowex 
was washed thoroughly with pyridinelH20 (1:1) (80m1) and the resulting solution 
evaporated in vacuo. The mixture was dissolved in O.1M NaOH (15m1) and 
impurities extracted with Et20 (20m1). The required product precipitated on addition 
of 0. 1M AcOH (iml) and was extracted from the solution by centrifugation, then 
dried in vacuo. (0.3g. 22%) Rf 0.21 (solvent 2) Rf 0.55 (solvent 5) Rf 0.71 (solvent 
[FAB] m/z (M+H)+ Found 402.13348. Requires 402.13353 H[d6DMSO]  2.20-
2.27 (m, 2H, H2,2')  3.45-3.62 (m, 2H, H',') 3.80-3.86 (m,1H, H3') 4.34-4.37 (m, 
1H, Ha) 4.75-5.52 (br s, 3H, OH3, OH5', COOH) 5.52 (s, 2H, OCH2) 6.19-6.23 (t, 
J=6.lHz, 1H, Hi')  6.52 (s, 1H, H2)'7.56-7.98 (m, 4H, Ar) 8.12 (s, 1H, H8) 
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Synthesis of 06-hydroxyethyl-2 '-deoxyguanosine for conjugation to carrier proteins 
(see Scheme 2) 
Removal of protecting groups (added for oligonucleotide synthesis but not required 
for protein conjugation) 
06-(ethoxyacetyl) -2 '-deoxyguanosine [16] 
3',5'0-(l, 1,3,3 -tetraisopropyldisiloxyl)-N2-(phenylacetyl)-06-(ethoxyacetyl)-2'-
deoxyguanosine (0.7g, immol) was dissolved in anhydrous THF then concentrated in 
vacuo to a small volume. THF (2.5m1) and TBAF (1.4m1, 1M in THF) were added 
and the solution stirred rapidly at RT. TLC showed complete conversion to a low 
running product after 5mm. The reaction mixture was diluted with 
pyridine/MeOHJH20 (3:1:1 5m1) then added to Dowex 50-X8 pyridinium form (5g in 
lOmi of aforementioned 3:1:1 solution) and stirred gently for 20mm. The Dowex was 
filtered off and washed thoroughly with pyridine/H20 (1:1) (lOmi) and the filtrate 
evaporated in vacuo. The product was purified by flash chromatography (eluant 90:10 
DCM/MeOH and the appropriate fractions combined and evaporated in vacuo. The 
product was dissolved in pyridine (5m1). Conc. ammonia (lOmi) was added and the 
mixture was heated to 550C. After 72hr the solution was evaporated in vacuo and the 
product purified by flash chromatography (eluant 90:10 DCMfMeOH) to give the title 
compound. (0.16g, 83%) Rf 0.37 (solvent 1) Rf 0.61 (solvent 2) Rf 0.69 (solvent 5) 
[FAB] m/z (M+H)+ Found 312.12301 Requires 312.12297 8H[d6DMSO]  2.15-2.26 
(m, 2H, H2',2")  3.46-3.55 (m, 2H, CH2) 3.73-3.83 (m, 3H, H41,5',5") 4.36-4.44 (m, 
3H, H3'& CH2) 4.89-4.91 (br s, 1H, OH) 5.02-5.04 (br s, 1H OH3') 5.29-5.31 (br s, 
1H, OH5') 6.18-6.25 (t, J=6.iHz, 1H, Hi')  6.42 (s, 2H, NH2) 8.09 (s, 1H, H8) 
5 ',N2-(4,4'dimethoxytrityl)-06-(ethoxydimethoxytrityl)-2 '-deoxyguanosine [17] 
06-hydroxyethyl-2'-deoxyguanosine (0. 15g, 0.48mmol) was dried by evaporation of 
anhydrous pyridine (3x2m1), then dissolved in anhydrous pyridine (5m1). TEA 
(0.33ml, 0.23g, 2.20mmol, 5eq), 4,4'-dimethoxytrityl chloride (0.57g, 1.68mmol, 
3.5eq) and DMAP (20mg) were added and the mixture stirred at RT. After lhr the 
solution was evaporated in vacuo, redissolved in DCM (lOml), washed with KC1 
(lOmi), dried with MgSO4 and evaporated to a gum. The title compound was 
purified by flash chromatography (eluant DCM/TEA 99:1) (0.404g, 69%) Rf 0.63 
(solvent 3a) Rf 0.19 (solvent 7a) Rf 0.31 (solvent 8a) [FAB] m/z (M+2H)+ Found 
1219.5 1498 Requires 1219.5 1501 H[d6DMSO]  2.16-2.51 (m, 2H, H2',2")  2.89-2.93 
(m, 4H, CH2x2) 3.17-3.28. (m, 3H, H4',5',5,,)  3.71-3.85 (m, 18H, OCH3x6) 4.48-4.51 
(m, 3H, H3') 4.77-4.79 (br s, 1H OH3) 6.17-6.23 (t, J=6.2Hz, 1H, Hi')  6.67-7.43 (m, 
39H, Arx9) 7.66 (s, 1H, H8) 7.99 (s, 1H, NH) 
5 ',N2-(4,4'-diznethoxytrityl)-3 '-succinyl-06-(ethoxydimethoxytrityl)-2 '- 
deoxyguanosine [18] 
5 ',N2-(4,4'dimethoxytrityl)-06-(ethoxydimethoxytrityl)-2'-deoxyguanosine (0.32g, 
0.26mmol) was coevaporated with anhydrous DMF (3x5m1). TEA (0. 152m1, 
1.04mmol, 4eq), succinic anhydride (0.083g, 0.91mmol, 3.5eq), DMAP (7mgs, 
0.06mmol, 0.22eq) and anhydrous DMF (5m1) were added and the mixture stirred at 
RT. After 18hr the solution was concentrated, then coevaporated with toluene 
(MgSO4 dried), and redissolved in DCM. This solution was washed quickly with 
aqueous citric acid (lOmi, 10% w/v), then water (lOmi). The organic layer was 
extracted, dried with MgSO4, and evaporated in vacuo. The residue was purified by 
flash chromatography (eluant: DCMIMeOH/TEA 94:4:1) and the appropriate 
fractions combined and evaporated in vacuo to give the title compound as a 
foam.(eluant DCM,TEA 99:1) (0.235g, %) Rf 0.33 (solvent la) Rf 0.73 (solvent 2a) 
Rf 0.79 (solvent 5a) [FAB] m/z (M+H)+ Found 1318.53110 Requires 1318.53 105 
H[d6DMSO] 2.49-2.57 (m, 2H, H2',2")  2.78-2.88 (m, 4H,CH2x2) 3.10-3.58 (m, 
3H, I-14',5',5") 3.62-3.74 (m, 18H, OCH3x6) 4.22-4.24 (m, 3H, H3') 4.78-4.80 (br s, 
1H OH) 6.21-6.23 (m, 1H, Hi')  6.64-7.41 (m, 40H, Arx9 & H8) 7.74 (s, 1H, NH) 
General Method 
Conjugation of 3'-tritylated, 5'-succinylated, 06-deoxyguanosine derivatives to 
Protein (see scheme 3) 
Protein (BSA or CQ) (5mg) was dissolved in H20/pyridine 4:1 (0.5m1). The 
modified nucleoside (10mg) was dissolved in DMSOIH20 4:1 (0.5m1) and 1-ethyl-
3(dimethylaminopropyl)carbodiimide (10mg) was added. The nucleoside solution 
was added quickly by syringe to the protein solution. After 3hr at 370C the mixture 
was purified by Sephadex G-25 (equilibrated with EtOH/H20 50:50). The extent of 
conjugation was measured by change in UV absorbance over the range 220n.m.to  
300n.m. 
Detritylation of Conjugates 
AcOH (5m1, 80% in H20)  was added to each conjugate. After 6hr the mixture was 
evaporated in vacuo to approximately lml, then purified by Sephadex G-25. 
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General Method 
Preparation of modified deoxynucleotide monomers for DNA synthesis 
06alkyl dGs (see scheme 4) 
3 ',S '-Bis(O-acelyl)-2 '-deoxyguanosine [24] 
2'-deoxyguanosine monohydrate (lOg, 35mmol) was dried by evaporation of 
anhydrous pyridine (3x30m1) then dissolved in a mixture of anhydrous pyridine 
(1 1.3m1) and anhydrous DMF (180m1). Acetic anhydride (43m1, 0.42mo1, 12eqs) was 
added and the reaction stirred at RT in darkness with the exclusion of moisture. After 
48hr ethanol (20m1) was added and stirring continued for a further 20mm., after 
which the solution was evaporated in vacuo and the product recrystallised from 
ethanol/water (9:1) to give the title compound (12 g, 97%) Rf 0.13 (solvent 1) Rf 
0.63 (solvent 4) Rf 0.50 (solvent 5) [FAB] m/z (M+H)± Found 352. Requires 352 
6H[d6DMSO] 2.02 (s, 3H, CH3CO) 2.07 (s, 3H, CH3CO) 2.39-2.50 (m, 2H, H2',2") 
4.19-4.23 (m, 3H, H4',5,5") 5.32 (br d, J=6.0 Hz,1H, H3') 6.12 (dd, J=5.9Hz, 1H, 
Hi') 6.55 (s, 2H, H2)  7.94 (s, 1H, H8)  10.4 (s, 1H, Hi) 
3 ',S '-Bis(O-acetyl)-N2-(phenylacetyl)-2 '-deoxyguanosine [25] 
3',5'-Bis(O-acetyl)-2'-deoxyguanosine (lOg, 0.028mo1) was coevaporated with 
anhydrous pyridine (300m1). Phenylacetic anhydride (40g, 0. i6mol) and anhydrous 
pyridine (140ml) were added and the solution stirred under reflux, with the exclusion 
of moisture, for 30mm. After cooling to RT the solution was poured into saturated 
aqueuos NaHCO3 (400m1). The bicarbonate solution was extracted with DCM 
(300m1) and the organic layer dried with MgSO4 and evaporated in vacuo to a gum. 
The residue was purified by flash chromatography (eluant: DCMIMeOH 96:4) and 
the appropriate fractions combined and evaporated in vacuo to a foam, redissolved in 
DCM (5ml) and precipitated into diethyl ether to give the title compound (lOg, 75%) 
Rf 0.43 (solvent 1), Rf 0.19 (solvent 3) Rf 0.84 (solvent 5) [FAB] m/z (M+H)+ 
Found 473.18331 Requires473.18322 6H[d6DMSO]  2.03 (s, 3H, CH3CO) 2.09 (s, 
3H, CH3CO) 2.59-2.94 (m, 3H, H2',2")  3.81 (s, 2H, UI2Ph)  4.17-4.28 (m, 3H, 
H4',5',5") 5.30 (br d, J=6.2 Hz, 1H, H3') 6.24 (dd, J=5.91-1z, 1H, Hi')  7.29-7.36 (m, 
5H, CH?-Ph) 8.26 (s, 1H, H8)  11.9 (s, 1H, Hi') 
Phenylacetic anhydride 
Phenylacetic acid (20g. 0.14mol) and acetic anhydride (34.7ml, 0.36mo1, 2.5eq) were 
refluxed and after 2hr the solution was evaporated in vacuo and recrystallised from 
Et20 (lOOmi) to give the title compound (lOg, 86%). 
Rf 0.56 (solvent 8) M.p 72 [El] m/z (M) Found 136. Requires 136 H[d6DMSO] 
7.23-7.32 (m, 10H, Arx2) 3.6 (s, 4H, CH2x2) JR anhydride carbonyl peaks at 1875 
and 1760cm' 
3 ',S '-Bis(O-acetyl)-N2 -(phenylacetyl) -06-alkyl-2 '-deoxyguanosine [26,27,28] 
3 ',5'-Bis(O-acetyl)-N2-(phenylacetyl)-2'-deoxyguanosine (10g, 0.02mol), 2-
mesitylene suiphonyl chloride (9.4g, 0.04mol, 2eq) and DMAP (120mg, 1.0mmol) 
were stirred together at RT in anhydrous TEA (12m1, 0.lmol, Seq) and anhydrous 
DCM (lOOmi). The reaction was monitored by TLC until the starting material was 
completely converted to the 06-sulphonated derivative, with higher Rf (60mm). The 
solution was cooled to 0°C and N-methylpyrrolidine (22m1, 0.2mol, lOeq) added. 
After 20min at OOC,  TLC showed conversion to the N-methylpyrrolidine derivative, 
lower Rf. After warming to RT the solution was stirred rapidly. with the appropriate 
alcohol (0. l4mol, 7eq, methanol 5.6m1, ethanol 8.2m1 or n-propanol 10.4m1) and 
DBU (9.Oml, 0.06mol, 3eq). TLC showed production of a high running compound 
after 60mm, 90min and 200min for the methyl, ethyl and n-propyl derivatives 
respectively. Each reaction was quenched with aqueous KH2PO4 (lOOml, 1M, 
pH6.5) and the organic layer extracted and dried with MgSO4 then evaporated in 
vacuo. Each product was purified by flash chromatography eluant: DCM/MeOH 
95:5) and the appropriate fractions combined and evaporated in vacuo to a foam. 
methyl ethyl n-propyl 
Weight/Yield 7.8g/64% 4.6gJ43% 3.2g/32% 
Rf.-(solvent 1) 0.73 0.79 0.81 
(solvent 3) 0.36 0.40 0.42 











*H[d6DMSO] methyl ethyl n-propyl 
H3CH2CH20 0.95-1.02 (t,3)J=7.4Hz 
cH3CH20  1.39-1.42 (t,3)J=7.lHz  
CH3cH2CH20  1.771 .9 1(g,2)J=7.4Hz 
CH3CO 1.98(s,3) 2.01 (s,3) 2.04(s,3) 
CH3CO 2.08(s,3) 2.06(s,3) 2.09(s,3) 
H2',2" 2.47-2.68 (m,2) 2.29-2.51  2.48-2.62 (m,2) 
H2Ph 3.84(s,2) 3.92 (s,1) 4.05 (s,2) 
CH30 4.07(s,3)  
H4,5,5" 4.21-4.26 (m,3) 4.19-4.28  4.27-4.47 (m,3) 
CH3CH H20 4.27-4.47 (m,2) 
CH3th0  4.29-4.36 (m,2)  
H3 approx. 5.41 (m,1) 5.37-5.41 (m,1) 5.34-5.42 (m,1) 
H1. approx. 6.40 (br t,1) 6.31-6.39 (t,1)J=6.4Hz 6.27-6.37 (m,1) 
CH2Ph 7.21-7.30 (m,5) 7.19-7.31 (m,5) 7.22-7.33 (m,5) 
H8 8.40 (s,1) 8.01 (s,1) 7.93 (s,1) 
NH 10.71 (s,1) 9.97 (s,1) 9.98 (s,1) 
N2-(phenylacetyl)-06-alkyl-2 '-deoxyguanosine [29,30,31] 
3',5 '-Bis(O-acetyl)-N2-(phenylacetyl)-06-alkyl-2'-deoxyguanosine (6mmol) was 
dissolved in pyridine (8m1) and concentrated in vacuo to a small volume. Pyridine 
(20m1) and NaOH solution (8m1, 2.5M) were added and the solution stirred rapidly at 
RT. After 5min the mixture was treated with Dowex 50-X8 pyridinium form. The 
Dowex was washed thoroughly with pyridine (20ml) and the resulting solution 
evaporated in vacuo. The product was purified by flash chromatography (eluant: 
DCM/MeOH 93:7) and the appropriate fractions combined and evaporated in vacuo 
to a foam. 
methyl ethyl n-propyl 
Weight/Yield 1.9g/76% 2.0g/79% 2.0 80% 
Rf:(solvent 1) 0.30 0.32 0.33 
(solvent 2) 0.48 0.49 0.57 











H[d6DMSO] methyl ethyl n-propyl 
CH2CH20 CI3  0.99-1.01 (t,3)J=7.lHz 
ki3CH20 1.30-1.40 (t,3)J=7.2Hz  
CH3H2CH20  1.81-1 .94(g ,2)J=7. 1Hz 
H2',2" 2.62-2.69 (m,2) 2.34-2.56 (m,2) 2.41-2.53 (m,2) 
H2Ph 3.96(s,2) 4.05 (s,1) 3.99(s,2) 
CH30 4.07(s,3)  
3.50-3.83 (m,3) 4.17-4.22 (m,3) 4.01-4.14 (m,3) 
CH3CHCH20  4.17-4.38 (m,2) 
CH3H20 4.27-4.38(g,2)J=7.2Hz  
H3' 4.13-4.18 (m,1) 5.04-5.16 (m,1) 4.82-4.95 (m,1) 
OH5' 4.92-4.97 (hr s,1) 4.89-4.92 (t,1)J=5.2Hz 4.98-5.03 (hr s,1) 
OH3' 5.32-5.41 (hr s,1) 5.29-5.32(d,1)J=3.5Hz 5.28-5.34 (hr s,1) 
Hi' 6.32-6.39 (t,1)J7.0Hz 6.09-6.21 (m,1) 6.19-6.27 (m,1) 
CH2h 7.21-7.32 (m,5) 7.19-7.31 (m,5) 7.24-7.35 (m,5) 
H8 I 	8.44(s,1) 8.12(s,1) 1 8.09(s,1) 
NH I 	10.73 (s,1) 10.34 (s,1) I 	10.07 (s,1) 
5 '-(4,4'-Dimethoxytrityloxy)-N2-(phenylacetyl)-06-(alkyl/ethoxyacetyl)-2 '-
deoxyguanosine [32,33,34,42] 
N2-(phenylacetyl)-06-(alkyl/ethoxyacetyl)-2'-deoxyguanosine (2.5mmol) was stirred 
at RT in anhydrous pyridine with 4,4'-thmethoxytrityl chloride (ig, 3mmol, 1.2eq), 
anhydrous TEA (0.73m1, 5mmol, 2eq) and DMAP (100mg). After 60 min the 
solutitin was evaporated in vacuo, redissolved in DCM (20m1) and washed with 
saturated KCI solution (50ml). The organic layer was extracted, dried with MgSO4 
and concentrated in vacuo to give the product as an oil which was purified by flash 
chromatography (eluant: DCM/MeOH,TEA 99:0.5:1) then evaporated in vacuo. 
________________________  
methyl ethyl n-propyl ethoxy-
acetyt 
Weight/Yield 1.3g[75% 1.2g/71% 1.2g/69% 1.lg/57% 
Rf:(solvent la) 0.76 0.79 0.84 0.85 
(solvent 3a) 0.35 0.30 0.30 0.34 












6H[d6DMSO] methyl ethyl n-propyl ethoxyacetyl 
H3CH2,CH20 0.92-1.09 
(t,3)J=7.lHz  
H3CH20 1.39-1.44 (t,3) 
J=7.4Hz  
CH3CH2CH20 1.77-2.05 (q,2) 
J=7.lHz  
H2,2" 2.51-2.78 (m,2) 2.39-2.50 (m,2) 2.52-2.59 (m,2) 2.03-2.16 (m,2) 
CH3CO  2.03-2.16 (m,3) 
OCH3 x 2 3.70(s,6) 3.73(s,6) 3.71(s,6) 3.63-3.68 (m,6) 
H2Ph 3.82(s,2) 3.97(s,2) 3.99(s,2) 3.99(s,2) 
CH30 4.06(s,3)  
H4',5',5" 4.58-4.64 (m,3) 3.24-3.51 (m,3) 3.29-3.34 (m,3) '3.24-3.31 (m,3) 
CH3CHH20  4.37-4.44 (m,2)  
CH3H20 4.47-4.58 (q,2) 
J=7.4Hz  
CH2x2  2.45-2.68 (m,4)' 
H3' 3.96-4.00 (m,1) 4.04-4.19 (m,1) 4.61-4.64 (m,1) 4.55-4.59 (m,1) 
OH3 5.33-5.39 (br s,1) 4.64-4.67 (br s,1) 4.16-4.20 (br s,1) 4.78-4.81 (br s,1) 




6.41-6.49 (m,1) 6.10-6.16 (m,1) 
Ar x 4 6.72-7.30(m,18) '6.73-7.39(m,18) 6.71-7.40(m,18) 6.65-7.34 (m,18) 
8.34 (s,1) 7.96 (s,1) 	' 7.97 (s,1) 7.79 (s,1) 
NH 10.61 (s,1) 	1 10.65 (s,1) 	I 8.13 (s,1) 8.12.1s, 1) 
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5 '-(4,4'-Dimelhoxytrityloxy)-N2-(phenylacetyl)-06-(alkyl/ethoxyacetyl)-2 '-
deoxyguanosine-3 '-(2-cyanoethyl-N,N-diisopropyl)-phosphoramidite [35,36,37,43] 
5 '-(Dimethoxytrityl)-N2-(phenylacetyl)-06-(alkyl/ethoxyacetyl)-2'-deoxyguanosine 
(1.5mmol) was coevaporated with anhydrous DCM. Diisopropylethylamine (0.98m1, 
0.73g. 6mmol, 4eq) and 2-cyanoethyl N,N-diisopropylchlorophosphoramidite 
(0.45m1, 0.45g, 2.2mmol, 1.5eq) were added and the solution stirred at RT with the 
exclusion of air. After 2-3hr when TLC showed each reaction was complete, diethyl 
ether (30m1) was added and each solution was washed with NaHCO3 (30m1), then 
brine (300m1). The organic layer was extracted, dried with MgSO4, evaporated in 
vacuo to an oil then flushed with nitrogen. The product was purified by flash 
chromatography, (eluant: DCM/ethyl acetate/TEA 20:80:2) and the appropriate 
fractions combined, evaporared in vacuo, redissolved in DCM and precipitated into 
hexane (500m1, Na dried) avoiding prolonged exposure to air, to give the title 
compound as a white powder. 
methyl ethyl n-propyl ethoxyacetyl 
Weight/Yield 0.69g/54% 0.72g/57% 0.51g/40% 0.54g/41% 
Rf: (solvent la) 0.34 0.40 0.42 0.39 
(solvent 2a) 0.45 0.51 0.52 0.48 












31P[CDCI3] 149.16 no data 
(s, 1P)  
no data no data 
06hydroxyethyl dG (see scheme 5) 
N2-(phenylacetyl)-2 '-deoxyguanosine [38] 
3 ',5 '-Bis(O-acetyl)-N2-(phenylacetyl)-2'-deoxyguanosine (11 .5g, 24mmol) was stirred 
vigorously at RT with pyridine (50m1) and 2.5M NaOH (17m1). After exactly 5mm 
TLC showed complete conversion to a low running product and the solution was 
neutralised by Dowex 50-X8 pyridinium form (100m!). The mixture was evaporated 
in vacuo and the required product was precipitated by addition of MeOH. (7.4g, 
79%) Rf 0.23 (solvent 1) Rf 0.68 (solvent 2) Rf 0.75 (solvent 5) [FAB] m/z 
(M+H)Found 386.13870 Requires 386.13861 H[d6DMSO]  2.23-2.35 (m, 2H, 
H2',2") 3.46-3.88 (m, 3H, H4,,5',51,) 3.80 (s, 1H, ll2Ph)  4.36-4.39 (m, 1H, H3') 4.95- 
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5.01 (t, J=5.4Hz, 1H OHO 5.33-5.35 (d, J=3.7Hz, 1H, OH3') 6.18-6.26 (m, 1H, Hi') 
7.24-7.35 (m, 5H, Ar) 8.25 (s, 1H, H8) 11.95 (m, 2H, H1 & NH) 
3', 5 ',O-(1,1,3,3-tetra-isopropyldisiloxyl)-N2-(phenylacetyl)-2 '-deoxyguanosine [39] 
N2-(phenylacetyl)-2'-deoxyguanosine (2g, 5.6mmol) was dried by evaporation of 
anhydrous pyridine (3x5m1) then dissolved in anhydrous pyridine (15m1). 1,3-
dichloro-1,1,3,3-tetraisopropyldisiloxane (2.2m1, 2,2g, 6.8mmol, 1.2eq) was added 
and the solution stirred at RT. After lhr the reaction was quenched with MeOH 
(2m1), evaporated in vacuo, redissolved in EtOAc, washed with saturated aqueous 
NaHCO3, then evaporated to a gum. The residue was purified by flash 
chromatography (eluant: DCMIMeOH 95:5) and the appropriate fractions combined 
and evaporated in vacuo to give the title compound. (2.5g, 78%) Rf 0.79 (solvent 1 
Rf 0.51 (solvent 3) Rf 0.24 (solvent 6) [FAB] m/z (M+H)+ Found 628.29091 
Requires 628.29084 8H{CdC13] 0.72-1.60 (m, 24H, CH3x8) 2.41-2.52 (m, 2H, 
H2',2") 3.75-3.83 (m, 3H, H4',5',5") 3.86 (s, 1H, j2Ph) 3.96-3.99 (m, 4H, CH3x4) 
4.55-4.67 (m, 1H, H3') 6.02-6.07 (m, 1H, Hi')  7.28-7.35 (m, 5H, Ar) 7.89 (s, iH, 
H8) 12.08 (m, 2H, H1 & NH) 
Monoacetyl ethylene glycol 
Ethylene glycol (24g, 21m1, 0.4mol) was stirred with anhydrous pyridine (20m1) and 
acetic acid (lOg, 9.1mI, 0.1mol, 0.25eq). After 10min TLC showed presence of a 
higher running product which was purified by fractional distillation. (4.9g, 48%) Rf 
0.55 (solvent 1) Rf 0.74 (solvent 2) Rf 0.21 (solvent 3) [El] m/z (M) Found 103. 
Requires 103 H[CdC13]  1.96 (s, 3H, CH3) 3.63-3.68 (m, 2H, CH2) 4.02-4.07 (m, 
2B;CH2) 4.67 (s, iH OH) 
3 ',S 'O-(1,1,3,3-tetra-isopropyldisiloxyl)-N2.(phenylacetyl)-06-(ethoxyacelyl)-2 '-
deoxyguanosine [40] 
3',5'O-( 1,1 ,3,3-tetraisopropyldisiloxyl)-N2-(phenylacetyl)-2'-deoxyguanosine (2g, 
3mmol) was dried by evaporation of anhydrous DCM (3x5m1) then dissolved in 
anhydrous DCM (20m1). TEA (1.7ml, lSmmol,Seq), 2-mesitylene suiphonyl 
chloride (1.4g. 6mmol, 2eq) and DMAP (100mg, 0.6mmol, 0.2eq) were added and 
the reaction stirred at RT for 30min when TLC showed complete conversion to the 
06-sulphonated derivative. The solution was cooled to 0°C and N-methylpyrrolidine 
(3m1, 30mmol, lOeq) added. After 20min at 0°C, TLC showed conversion to the N-
methylpyrrolidine quaternary salt, lower Rf. After warming to RT the solution was 
stirred rapidly with monoacetyl ethylene glycol (2.2g, 2.4ml 21mmol, 7eq) and DBU 
(1.35 ml, 9mmol, 3eq). TLC showed production of a high running compound after 
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2hr and the reaction was quenched with aqueous KH2PO4 (100m!, 1M, pH6.5) the 
organic layer extracted, dried with MgSO4 then evaporated in vacuo. The product 
was purified by flash chromatography (eluant: DCM/MeOH 96:4) and the appropriate 
fractions combined and evaporated in vacuo to a foam. (0.7g, 34%) Rf 0.84 (solvent 
1) Rf 0.57 (solvent 3) Rf 0.29 (solvent 6) [FAB] m/z (M+H)+ Found 714.32755 
Requires 714.32762 H[CdC13]  1.01-1.08 (m, 24H, CH3x8) 2.02 (s 311, CH3CO) 
2.53-2.63 (m, 211, H2',2")  3.78-3.86 (m, 211, CHx2) 4.11 (s, 2H,kj2Ph) 4.16-4.20 
(m, 2}jCHx2) 4.40-4.71 (m, 3H, H4',5',5") 5.21-5.34 (m,1H, H3') 6.25-6.28 (m, 1H, 
Hi') 7.25-7.35 (m, 511, Ar) 7.97 (s, 111, NH) 8.08 (s 1H H8) 
N2-phenylacetyl-06-(ethoxyacetyl)-2 '-deoxyguanosine [41] 
3',5'0-( l, 1,3,3 -tetraisopropyldisiloxyl)-N2-(phenylacetyl)-06-(ethoxyacetyl)-2'-
deoxyguanosine (0.7g, immol) was dissolved in anhydrous THF then concentrated in 
vacuo to a small volume. THF (2.5m1) and TBAF (1.4m1, 1M in THF) were added 
and the solution stirred rapidly at RT. TLC showed complete conversion to a low 
running product after 5mm. The reaction mixture was diluted with 
pyridinefMeOHlH20 (3:1:1 5m1) then added to Dowex 50-X8 pyridinium form (5g 
in lOmi of aforementioned 3:1:1 solution) and stirred gently for 20mm. The Dowex 
was filtered off and washed thoroughly with pyridinefH20 (1:1) (lOml) and the 
filtrate evaporated in vacuo. The product was purified by flash chromatography 
(eluant 90:10 DCM/MeOH and the appropriate fractions combined and evaporated in 
vacuo to give the title compound. (0.3g, 64%) Rf 0.42 (solvent 1) Rf 0.69 (solvent 2) 
Rf 0.21 (solvent 3) [FAB] m/z (M+H)+ Found 484. Requires 484 8H[d6DMSO] 
2.23-2.34 (m, 2H, H2',2")  3.38-3.41 (m, 3H, CH3) 3.46-3.64 (m, 5H, Cl2 & 
H4',5',5") 3.81 (s, 2H, jkPh)  3.84-3.88 (m, 2H, Cl2) 4.38-4.40 (m, 1H, H3') 4.95-
5.00 (t, J=5.2Hz, 1H OH3') 5.32-5.34 (d, J=3.5Hz, 1H, 0115') 6.19-6.25 (m, 1H, Hi') 
7.25-7.36 (m, 5H, Ar) 7.97 (s, 1H, NH) 8.08 (s, 1H, 118) 
Synthesis, deprotection and analysis of oligonucleotides containing 06-alkyl dG 
Oligonucleotide synthesis was carried Out on an Applied Biosystems 380B DNA 
synthesiser on a 1.0 micromole scale following standard procedures, unless otherwise 
indicated. A total of 4 oligonucleotides were synthesised. Initially 5mer 
phosphorothioate poly T sequences were synthesised. The phosphorothioate linkages 
were introduced by replacing the oxidising agent (iodine) with tetraethyl thiuram 
disulphide on the DNA synthesiser; 49mer non-phosphorothioate sequences 
incorporating 3 of the modified nucleotides were then synthesised using the 
phosphorothioate Smers on the solid support, producing 3 related 54mers as shown 









Additionally 1 49mer, where every nucleotide possessed a phosphorothioate linkage, 






Following synthesis, sequences were deprotectedby incubation with ammonia at 
550C for 24 hr, then analysed by HPLC, on a C18. revesed phase column, using 0. IM 
NH40Ac (buffer A) and 0. 1M NH40Ac in 20% acetonitrile (buffer B), with the 
following gradient: 
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No HPLC purification was necessary. All oligonucleotides were desalted by 
sephadex G-25, then freeze dried. 
Analysis by enzyme digest 
Snake venom phosphdiesterase (50i1 of 1mg/100i1 in 1-120) and alkaline phosphatase 
(1091 of 191/19pJ in H20) were added to 10 OD units of each 54mer in 50mM 
Tris.HC1/1M NaCl (pH8, 0.5m1). The mixtures were incubated at 370C overnight, then 
analysed by reversed phase HPLC, using the above conditions. Standard solutions of 
dA,dG,dC,dT,06-MedG and diaminopurine (DAP) were subjected to HPLC under the 
same conditions to allow identification of the digested components of the 54mers. 
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Chapter 3. Production and Selection of Monoclonal Antibodies to 
06-alkyl dG 
3.1. Introduction 
3.1.1. The immune response 
The immune response protects animals from foreign materials such as viruses, 
bacteria and toxins which may enter the body. The underlying molecular 
mechanisms of the system involve cell to cell communication and secretion of 
regulatory and signalling molecules. There are 2 types of immune response, i) innate 
and ii) acquired. The former removes foreign particles by phagocytosis and 
macrophage action, but fails to recognise the same particles on repeated exposure. 
The latter response which forms the basis of many immunochemical techniques leads 
to i) the activation of lymphocytes which produce cell surface receptors and ii) the 
production of circulating antibodies. Foreign particles which initiate the production 
of antibodies are known as antigens. The first exposure of an animal to an antigen 
results in a slow immune response, and after further exposure the antibodies are 
produced more rapidly and in vast quantities. 
A vast repertoire of antibodies, with different antigen binding sites, can be 
synthesised by the immune system. There are millions of pre-determined receptor 
sites for antigens. The activation of these leads to the secretion of a specific 
antibody and stimulation of cell division of the antibody producing cells. 
The production of an antibody to a particular antigen involves macrophages, T 
lymphocytes and B lymphocytes. Immediately after entering the body, foreign 
particles are engulfed non-specifically by macrophages or similar cells collectively 
known as antigen presenting cells (APCs) (Unanue, 1978,1984). The APCs then 
fuse with lysosomes and the antigen is partially degraded. The resulting antigen 
fragments are displayed on the surface of the APC (fig 3.1). A cell surface 
glycoprotein complexes with the antigen fragments; the complex is known as the 
major histocompatibility complex (MHC) (Forman, 1984). The MHC binds 
specifically with helper T lymphocytes. The receptors on the T cells are specific for 
a particular antigen-glycoprotein complex, therefore only a small number of the total 
T cell population in an animal will respond to any one complex. Binding to the 
MIHC leads to proliferation and differentiation of T cells. This growth is helped by 
the production of interleulin 1; a growth factor produced by the APC (Dower and 
Urdal, 1987). A second growth factor, interleukin 2 (Oppenheim et al, 1986) 
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Figure 3.1. The proliferation of T cells 
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induces the T cells to reproduce exponentially. The growth factors are secreted as 
long as T cells bind to the MHC. Reduction in amounts of antigen, resulting in a 
decrease in T cell binding to the MHC arrests the production of interleukin 1 and 2 
and hence the T cell proliferation diminishes. 
During the proliferation of T cells, B lymphocytes are also being activated by the 
antigen (fig 3.2). The B cells have a specific antibody type receptor on their cell 
surface (Cambier et al, 1993). Following antigen binding the receptor and antigen 
are internalised, and the antigen is partially degraded then presented as a MHC on 
the cell surface. T cells which are specific for this complex (already abundant in the 
circulation) bind to the MHC on the B lymphocytes stimulating them to synthesise 
growth factor receptors (Coutinho et a!, 1984; Parker, 1993). The T cells then 
produce interleukin 4 (Howard et a!, 1982) which initiates the proliferation and 
differentiation of B lymphocytes. After binding interleukin 4 the B cells grow 
exponentially and begin to respond to interleukin 5 (Swain et a!, 1983) which results 
in the differentiation of B lymphocytes into plasma and memory cells. These cells 
travel through the blood and lymphatic systems and accumulate in lymphoid tissues 
(lymph nodes and spleen in mammals). Antibody is secreted in vast quantities by 
the plasma cells, which are devoted to this purpose but are short lived. In contrast 
the memory cells do not secrete antibody and remain in circulation. 
During differentiation and maturation of the B cells, mutations occur which lead to 
the production of antibodies with differing affinities (Kishimoto, 1985). The cells 
producing high affinity antibodies proliferate more readily as the B cell surface 
receptor binds more efficiently to the antigen. Class shifting also occurs during 
differentiation (Harreman, et al, 1993). Large 1gM antibodies which are produced 
initially are limited in their movements across membranes and are therefore often 
replaced by smaller IgG antibodies. These IgGs often have higher affinity due to the 
maturation process. When the antigen is eliminated by the action of antibodies, the 
plasma cells and hence antibody production decline. A second exposure to the same 
antigen results in activation of the memory cells and a secondary response occurs 
immediately. The presence of many helper T cells and the memory B cells ensure 
that the first antibodies to be produced are of high affinity and are IgGs. 
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Figure 3.2. The production of antibodies by B-cells 
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3.1.2. Polyclonal and monoclonal antibodies 
A polyclonal antibody response occurs following the introduction of an antigen to an 
animal (i.e. many different antibodies are produced, each from a single stimulated 
lymphocyte and its clonal progeny). The antibodies may be of different classes (i.e. 
IgG, 1gM, IgE, IgA, IgD) have different affinities, or recognise different epitopes on 
the.antigen. Despite this, immunisation procedures can be controlled to favour the 
predominant production of an antibody of a particular class, specificity and affinity. 
Polyclonal antibodies can be useful in recognising multiple determinants and in 
immunoprecipitation experiments (Dunbar and Skinner, 1990). However the type, 
specificity and affinity of these antibodies can alter over time due to the in vivo 
maturation response, previously discussed. Consequently, polyclonal antibodies are 
disadvantageous for immunoassay and immunoaffinity techniques, which require the 
constant supply of an antibody with a pre-defined specificity and affinity. 
The development of hybridoma technology, by Kohler and Milstein (1975) allows 
the continuous production of an antibody with a pre-defined specificity. This is 
achieved by fusing an antibody producing B lymphocyte (which cannot survive in 
tissue culture), with a non-antibody producing myeloma cell (a B tumour cell 
specially adapted to efficient growth in culture). The hybrid possesses the antibody 
secreting capacity of the B lymphocyte, and the longevity of the myeloma. 
Hybridomas can be grown in culture, or be reintroduced to an animal and grow as an 
antibody producing tumour. Antibodies produced by this technique are referred to as 
monoclonal, since the total antibody present comes from a single lymphocyte and its 
identical progeny. The antibodies produced are therefore identical in structure and 
function. The production of monOclonal antibodies (MAbs) is described in many 
texts (Kennett et al, 1980; Kohler, 1980; Goding, 1986; Brown and Ling, 1988) 
MAbs are advantageous for immunoassay and immunoaffinity experiments for 3 
major reasons: i) a single antibody recognises one determinant, therefore there is 
minimal cross reactivity in assays, ii) large quantities of an antibody can be obtained 
and easily purified and iii) an antibody with specific characteristics can be selected 
during screening procedures. 
3.1.3. The production of monolconal antibodies 
The production of monocloñal antibodies can be divided into 4 separate techniques, 
i) immunisation, ii) screening, iii) hybridoma production and iv) cloning. After 
immunisation and boosts, test bleeds can be taken to allow a screening technique to 
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be developed (fig 3.3). On confirmation (by screening techniques) that the antibody 
is present in the sera, the appropriate lymphoid tissue (i.e. the spleen) is removed 
from the animal. The animal is usually re-exposed to the antigen to obtain 
maximum antibody production prior to this operation. The splenocytes are extracted. 
and fused with myeloma7 cells, and after a period of 1-2 weeks the resulting 
hybridomas can be screened for production of a specific antibody. Hybridomas 
producing the desired antibody are cloned by limiting dilution to obtain a single 
clone secreting the antibody of interest. 
immunisation 
(2weeks) 
boost 	 immunisation 
and 




boost (once or twice) 
remove lymphoid tissue 
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1 
culture cell-line and 
extract antibdy 
Figure 3.3 An outline of monoclonal antibody production 
3.1.3.1. Immunisation and bleeds 
There appears to be no universal immunisation procedure, as different antigens may 
require completely different protocols to ensure optimum antibody production. It is 
important that the splenocytes and myelomas, to be fused, come from the same strain 
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of animal. The myeloma cell lines commonly available are balb/c in origin, 
therefore immunisations for monoclonal antibody production are generally carried 
Out in these mice. 
Soluble antigens are mixed with an aqueous adjuvant mixture prior to immunisation. 
Freunds adjuvant, 'complete' or 'incomplete', is normally used for small molecules 
(Freund, 1947). The initial immunisation is carried out in 'complete' which contains 
mineral oil, and heat killed Myobacrerium tuberculosis; further boosts are conducted 
in 'incomplete' which does not contain bacteria. The oil is believed to form an 
emulsion protecting the antigen from rapid degradation in vivo. The bacteria contain 
a muramyl dipeptide toxin which leads to non-specific stimulation of the immune 
response (Ellouz et al, 1974). The induction of MAbs does not require 
immunisation with a pure antigen, unlike immunisations to produce polyclonal 
antibodies. The route of injection may influence the type of antibody response. 
Adjuvant-antigen mixtures are injected subcutaneously (200tl maximum) or 
intramuscularly (5O.t1 maximum), to favour slow antigen release to the local lymph 
nodes. 
It is essential to ensure the presence of specific antibody before the final boosts and 
removal of the spleen. This is determined by taking a preliminary bleed, normally 
from the tail vein of the mouse, and screening the sera for antigen binding activity. 
3.13.2. Screening of antibodies 
The screening assay is used at 3 stages in the production of monoclonal antibodies: i) 
subsequent to immunisation to test for the presence of specific antibody, ii) 
following fusion of the splenocytes and myelomas, to select appropriate hybridomas 
and iii) after cloning to select a monoclonal cell line producing the antibody of 
interest. Many cell lines are generated during a fusion and screening experiments 
may be repeated many times. The ideal assay is therefore simple, easily reproduced 
and rapid so that immediate attention can be given to selected cell lines. 
Most screening assays involve 2 stages. Firstly, antibodies are tested for activity 
against the antigen and, secondly, those giving positive results are retested against a 
range of antigens to ensure that the antibody binds selectively to the antigen of 
interest. These tests are referred to respectively as non-competitive and competitive 
assays. Several specific screening assays have previously been discussed in chapter 
1. ELISA (Wisdom, 1976; Voller, 1979) is generally regarded as the most 
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convenient assay as it does not require the use of radiolabeled substrates and has 
been shown to be more sensitive than other assays (Poirier et al, 1980; Santella et al, 
1988). 
Non-competitive ELISA can be carried out in 96 well plastic microtitre plates, or on 
nitrocellulose or nylon membranes. A reagent is added, incubated, then washed 
from the plate or membrane (fig. 3.4). 
1) coat with 
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Figure 3.4. Non-competitive ELISA 
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Firstly the antigen is coated on the wells of the plate, or dotted onto a membrane. 
After incubation and washing the unoccupied sites on the plate/membrane are 
blocked (usually with a protein) to prevent non-specific binding of the antibody, to 
uncoated areas (Trivers et al, 1983). The antibody of interest is then incubated with 
the coated plate or membrane. After allowing antibody-antigen binding to reach 
equilibrium excess antibody is removed by washing. An enzyme conjugated second 
antibody, which binds to the first antibody, is then added. The conjugated enzyme, 
commonly alkaline phosphatase or horseradish peroxidase, is capable of converting a 
substrate to give a coloured product. The final step of the assay involves the 
addition of the appropriate substrate and the measurement of the resulting colour. 
The amount of colour is proportionate to the quantity of antibody bound to the 
antigen on the microtitre well or membrane. Normally an antibody is diluted across 
a plate or membrane allowing a characteristic dilution curve to be plotted. The 
antibody titre (the dilution at which the antibody half maximally binds to the plate) 
can be determined from this curve. An estimate Of titre is necessary for carrying out 
a competitive assay. 
Competitive ELISA (fig. 3.5) which must be carried out in microtitre wells is 
essentially similar to the non-competitive assay. A pre-determined concentration of 
antibody (from non-competitive ELISA) is mixed with a known amount of free 
antigen before being added to the plate. If the antibody is specific for the added 
antigen, the amount of antibody binding to the antigen on the plate decreases. This 
decrease is determined by direct comparison with a sample with no antigen added 
and the percentage inhibition by the free antigen can be calculated. A dose response 
effect can be obtained by mixing decreasing amounts of antigen with the antibody. 
If a small amount of free antigen prevents antibody binding to the coated plate the 
antibody has high specificity and affinity for that antigen. These assays allow the 
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Figure 3.5 Competitive ELISA 
3.1.3.3. Hybridoma production 
The fusion of splenocytes with myelomas is not a spontaneous process. Fusion is 
commonly induced by the presence of polyethylene glycol (PEG), by a mechanism 
which is poOrly understood (Pontecorvo, 1975). It has been suggested that a 
contaminant in the PEG plays a role in the fusion process (Wojciezsyn et al, 1983). 
After the fusing of the cell membranes heterokaryons (multinucleate cells) are 
formed. The next cell division produces daughter cells with a fused nuclei 
containing a share of the genetic information from a myeloma and a splenocyte. In 
addition to the desired splenocyte-myeloma hybrids there are undesirable products 
including splenocyte-splenocyte and myeloma-myeloma hybrids, and also multiple 
cell products. Splenocyte-splenocyte hybrids and unfused splenocytes cannot 
survive in culture and die within 7-10 days. 
Myeloma-myeloma hybrids and unfused myelomas do not die naturally. Their 
elimination is achieved by a selection procedure devised by Littlefield in 1964. 
Aminopterin (a folic acid antagonist) is added to the cell culture medium to block the 
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main cellular DNA biosynthetic pathway. The desired hybridomas can continue to 
synthesise DNA via an alternative salvage pathway, in which - the enzymes 
hypoxanthine-guanine phosphoribosyl transferase (HGPRT) and thymidine kinase 
play a role. The former converts hypoxanthine and guanine to guanosine 
monophosphate, and the latter thymine to deoxythymidine monophosphate (fig 3.6). 
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HGPRT = hypoxanthine-guanine phosphoribosy Iransi 
TK = thymidine kinase 	IVIP = monophosphate 
DP =diphosphate TP_triphosphate 
Figure 3.6. The role of HGPRT and TK in cellular DNA synthesis 
Hypoxanthine and thymidine are added to the culture medium (in addition to the 
aminopterin) to ensure the survival of the hybridomas by this pathway. The 
myeloma cells routinely used in fusions are previously cultured to be deficient in the 
HGPRT enzyme (the most commonly used myeloma cell lines, sp2/OAgl4 and X63-
Ag8.653 are commercially available). The salvage pathway is non functional in 
these cells, so that after the addition of aminopterin the myelomas die. However a 
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myeloma fused with an HGPRT positive splenocyte will synthesise DNA by the 
salvage pathway and hence survive. 
There is some variation in fusion techniques, but most methods are based on the 50% 
PEG stirring procedure of Gaifre et al (1977), or the 30% PEG spinning. procedure 
of Geftre et al (1977), which was adapted by Kennett in 1978. Generally 108 
lymphocytes (derived from 1 mouse spleen) are mixed with approximately 107  
myeloma cells which must be in the exponential phase of growth. The cells are 
centrifuged to form a pellet, then diluted by the addition of PEG (30-50%). 
Temperature, pH, myeloma:splenocyte ratio, the presence of contaminants such as 
erythrocytes and the molecular weight of the PEG, are thought to influence the 
success of the fusion (Zola and Brooks, 1982). The actual fusion of the cells is 
normally carried out in serum free medium, then the fused products are immediately 
introduced to medium containing growth supplements (i.e. foetal calf serum) and 
antibiotics to prevent infections, then the hypoxanthine, aminopterin and thymidine 
(HAT) medium is added. The serum is believed to provide minerals and hormones 
essential to cell growth, but the exact components which aid cell growth are not 
known (Barnes and Sato, 1980). 
The hybrid products are distributed into microtitre wells, to increase the chances of 
obtaining only one clonal product per well. The number and size of wells used for 
this purpose varies. Gaifre and Milstein (1981) used 48 x imi wells. The cells are 
normally supplemented every 2-3 days by the removal of half the medium and 
addition of fresh material, containing HAT. This removes waste material in addition 
to diluting Out antibody that is being released by the dying unfused splenocytes. 
Myeloma cells die within one week in HAT solution, therefore its addition can be 
discontinued at this point. Aminopterin is metabolised slowly by cells, whereas 
hypoxanthine and thymidine are metabolised more quickly. For this reason, 
hypoxanthine and thymidine (HT) medium is added to the cells for several days after 
discontinuing HAT addition, as the salvage pathway remains to be the main 
biosynthetic route for DNA synthesis while traces of aminopterin remain. 
3.1.3.4. Cloning 
The wells containing cells which are producing the antibody of interest are identified 
by screening procedures. The contents of these wells are cloned by limiting dilution 
to prevent overgrowth of the desired cells by non-secreting hybrids. The cloning 
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procedure aims to dilute the cells on a microtitre plate and achieve wells which 
contain only one clone (visible by light microscope). After these single cells have 
proliferated screening techniques may be employed to identify those producing the 
desired antibody. Normally it is necessary to clone several times before obtaining a 
single healthy clone producing the desired antibody. The growth of hybridoma cells 
at high dilutions is normally unsuccessful, but growth can be aided by the addition of 
mouse thymocyte feeder cells (Lernhardt et al, 1978). 
Cells producing monoclonal antibodies can be grown continually in culture and 
expanded to larger wells and flasks. A culture medium change is required every 2-3 
days. Larger quantities of antibody can be produced by growing the hybridomas as 
tumours in animals. In addition cells can be frozen and stored in liquid nitrogen for 
several years with a good recovery rate (Goding, 1986). Purification of the antibody 
is normally required before use. The traditional method involves precipitation of the 
antibody in high salt concentrations, but this can lead to contamination bythe 
precipitation of other serum proteins. Gel filtration, affinity chromatography and 
ion-exchange chromatography are also employed in antibody purification schemes 
(Ey et al, 1978; Bruck et al, 1982). It is important to determine the class and 
subclass of an antibody as this influences the biological and physical properties, in 
addition to determining the purification technique employed. These can be 
determined by simple immunochemical assays. 
3.2. Results and Discussion 
3.2.1. Immunisation 
The 06-alkyl dG derivatives which were conjugated to a protein or incorporated into 
an oligonucleotide were suitable for both the immunisation and screening procedures 
required for the production of a class specific monoclonal antibody. The ability to 
synthesise such compounds created the potential for a vast array of immunisation, 
screening and fusion protocols. There may have been numerous ways of producing 
and obtaining the desired 06-alkyl dG monoclonal antibody. However the most 
successful route to this end was impossible to determine prior to experimentation. 
Most of the 06-alkyl dG compounds (table 3.1) were therefore used for 
immunisations to allow the identification of the best antigens. Each antigen was 
administered to at least 2 mice. The mice with the highest antibody response were 
employed in fusion experiments. 










oligo Me 2 
oligo Et 2 
oligo n-Pr 2 
oligo MeCP 2 
oligo Me = 3' phosphorothioate (PS) 54mer incorporating 06-MedG 
oligo Et = 3' PS 54mer incorporating 06-EtdG 
oligo nPr = 3' PS 54mer incorporating 06-n-PrdG 
oligo MeCP = complete PS incorporating 06-MedG 
3.2.2. Initial screening and immunoassay development 
In the time available for this study it was not possible to test each immunised mouse 
for antibody production, neither was it possible or necessary to use all mice for 
E:J 
fusion experiments. Bleeds from oligonucleotide immunised mice were tested to 
estimate the success of antibody production by this novel method. Additionally, 
three of the 06-MedG-BSA, one of the 06-hydroxyEt dG-BSA and one of the 6.. 
CBdG-BSA immunised animals were bled. The sera were screened by competitive 
ELISA to determine the antibody titre, and non competitive ELISA to determine the 
antibody specificity. 
ELISA requires a coating of antigen on each microtitre well of a plastic plate as 
previously described. Free nucleosides do not normally bind to this surface and 
protein conjugates, which bind non-covalently by an unknown mechanism, are often 
used. The 06-alkyl dG-protein conjugates were considered suitable for screening 
antibodies raised to the oligonucleotide antigens. Antibodies specific for the 
thymidine residues in the oligonucleotides went unrecognised in this assay, whereas 
06-alkyl dG antibodies cross-reacted with the 06-alkyl dG derivative of the protein 
conjugate on the plate. CQ conjugates were used to screen the serum of the O6 
alkyl dG-BSA conjugate immunisations. 
At this stage the competitive ELISA was not designed to test for class specificity, so, 
for example serum from a mouse subjected to an 06-MedG antigen was also 
screened and tested for inhibition with this derivative. A lOp 1/ml solution of each 
free 06-alkyl dG nucleoside was used to calculate the percentage inhibition of 
antibody binding to the plate. The actual amount of inhibition was therefore not of 
great importance. However <10% to 0% inhibition generally indicated that minimal 
amounts of specific antibody were being produced, and higher amounts of inhibition 
suggested that a significant amount of specific antibody was present. The 
concentration of antibody used for this purpose (i.e. the antibody titre) was 
determined from the dilution curves which were plotted from the results of the non-
competitive ELISA (see fig. 3.7 for examples). 
Comparison of the antibody titres indicated a variation in antibody response between 
mice (table 3.2). For example, the immunisation of two mice with an 
oligonucleotide containing 06-EtdG resulted in a high response in mouse 'a', titre 
1:1200, and a low response in mouse 'b', titre 1:500. This variation made it difficult 
to determine 'good' and 'bad' antigens However, on balance, there appeared to be a 
significantly higher titre and percentage inhibition in the mice immunised with 
oligonucleotide antigens, particularly the complete phosphorothioate 
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Figure 3.7. Variation in antibody response and titre 
attributable to, i) resistance to enzymatic degradation, resulting in persistence of the 
oligonucleotide in the mouse after immunisation and ii) the presence of the sulphur 
atom which makes the phosphorothioate oligonucleotide less like a 'self molecule'. 
However the sample size was too small to draw unambiguous conclusions. 
Table 3.2. Initial screening results from non-competitive and competitive ELISA, 















oligo Me/a 06-MedG-BSA 1:200 06-MedG 0 
/b " 1:500 " 6 
oligo Et/a 06-EtdG--BSA 1:1200 06-EtdG 32 
/b " 1:500 " 19 
oligo n-Pr/a 06-n-PrdG-BSA 1:800 06-n-PrdG 6 
/b it 1:1100 It 25 
oligo MeCP/a 06MedG-BSA 1:1100 06-Me dG 43 
/b " 1:1300 " 24 
06-MedG-BSAIa 06-MedG-CG 1:800 06-MedG 20 
/b it 1700 " 34 






 hydroxyEtdG  
38 
06-CBdG-BSA ía I 06-MedG-C'yG 	1  1:1000 	1 06-MedG 	1 19 
The 3' PS oligonucleotide containing 06-MedG elicited the weakest immune 
response (1:200 mouse 'a', and 1:500 mouse 'b') (table 3.2). It is unlikely that the O6 
methyl group created a less antigenic compound than higher alkyl groups, as the 06 
MedG-BSA antigen showed a high titre. The surprisingly low titre may have been 
due to inter-mouse variation, or degradation of the antigen. 
The results shown in table 3.2- indicated that in all cases, except for the 3'PS Me 
oligo, a specific antibody response occurred. Mice demonstrating a high antibody 
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response (high titre), and the presence of a specific antibody (high inhibition) were 
used in fusion experiments. 
3.2.3. Fusions and cloning 
A total of eight fusions were carried out. In all cases approximately 108 splenocytes 
were mixed with 107  myelomas and 40% PEG was added to initiate the fusion 
reaction. The resulting splenocyte/myeloma/hybridoma mixture was divided into the 
inner 60 wells of six, 96-well sterile microtitre plates. The cells were cultured for 14 
days to favour the proliferation of the hybridomas. Fusions were generally 
considered successful if 90% of the wells contained hybridomas. The hybridomas 
were then screened to ascertain the presence of the desired antibody (table 3.3). 
Initially, non-competitive ELISA was employed to detect specificity towards the O6 
alkyl dG used for immunisation. Negative wells were immediately eliminated. 










oligo Et/a failed - - 
oligo n-Pr/a 10 2 +ve wells 06-n-PrdG-BSA 
oligo MeCP/a 90 23 +ve wells 06-MedG-BSA 
06 MedG-e  90 31 +ve wells O6-MedG-CG 
/b 90 35 +ve wells  
/c 90 11 +ve wells  
06-hydroxyEtdG- 
BSA/a 
90 59 +ve wells 06-hydroxyEtdG- 
 C'G 
06-CB-BSA /a 90 34 +ve wells 06-n-PrdG-CG 
Positive wells were retested by competitive ELISA with the initial 06-alkyl dG and 
a second or third 06-alkyl dG to identify wells with hybridomas producing a class 
specific antibody. During this procedure cells were also tested for cross reactions 
with dG. Hybridomas producing antibodies which cross-reacted with dG were 
discarded. Cells producing group specific antibodies (i.e. an antibody which 
recognised only one 06-alkyl .dG derivative) were also identified, cultured, then 
stored at -700C, for future studies. 
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The 2 positive wells from the oligo n-Pr fusion and the 34 positive wells from the 
06-CB-BSA fusion showed no inhibition in a competitive assay with 06-MedG, 
EtdG or 06-n-PrdG. One of the three 06-MedG-BSA fusions became infected and 
was discarded. A second showed inhibition with 06-MedG and 06-EtdG, but also 
showed the same extent of inhibition with dG, and was also discarded. A small 
number of the positive hybridomas from the three remaining fusions demonstrated 
inhibition with more than one 06-alkyl dG derivative. Only wells which showed 
>30% inhibition were considered, and are described below. 
oligo MedG CP fusion: three wells demonstrated inhibition with 06-MedG, two 
of which also showed inhibition with 06-EtdG, wells 5D8 and 6E5 
06-MedG-BSA fusion: four wells demonstrated inhibition with 06-MedG; one of 
which also showed inhibition with 06-EtdG and 06-n-PrdG, well 2C8 
C) 06-hydroxyEt dG-BSA fusion: eleven wells demonstrated inhibition with 06 
hydroxyEt dG, ten of which also showed inhibition with 06-EtdG. Nine of these 
wells demonstrated inhibition with 06-n-PrdG, and two of these showed inhibition 
with 06-MedG, wells 2G2 and 2E3. 
Immediate attention was given to cells from wells 2C8, 2G2 and 2E3, as results 
suggested that cells from these wells may be secreting class specific antibodies. 
They were expanded into 2m1 wells, and aliquots of approximately 200 cells from 
each well were mixed with feeder thymocytes and cloned by limiting dilution. 
Monoclonal wells were identified under a microscope then tested by ELISA. One 
positive monoclonal well from each clone plate was chosen, and recloned. 
Monoclonality of the chosen cell lines was confirmed by ELISA on the third or 
fourth generation of clone plates, when the presence of any number of clones in a 
well correlated with the amount of colour produced on screening. An absence of 
cells resulted in no colour. The detailed cloning procedures and results.are described 
for 2C8, 2G2 and 2E3, in figs. 3.8, 3.9 and 3.10 respectively. 
The cells from wells 5D8 and 6E5 which recognised only 06-MedG and 06-EtdG 
were expanded into 2m1 wells, then frozen and stored for future reference. 
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Figure 3.10. Cloning of 2E3 
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3.2.4. Characterisation of 2C8C6H5, 2G2B1OF1 and 2E3C8E3 
The three monoclonal cell lines were grown in large cell culture flasks for 4-6 
weeks. The number of cells in each flask was maintained at a fairly constant level 
by the removal of some cells every 2-3 days. The supernatant was removed, 
accumulated and stored at 40C,and fresh medium was added to the cells. 
3.2.4.1. ELISA to determine comparative antibody affinity for each 06-alkyl 
dG derivative 
These experiments compared the affinity of each of the three monoclonal antibodies, 
for each 06-alkyl dG by non-competitive and competitive assays. There were many 
possible assay designs, in terms of, i) the 06-alkyl dG protein conjugate immobilised 
on the plate, and ii) the free 06-alkyl dG derivative competing for the antibody. 
Both factors strongly influence the results. For example, an antibody with high 
affinity for 06-EtdG would require a large amount of 06-MedG or 06-n-PrdG to 
obtain inhibition on an 06-EtdG coated plate. Furthermore, 06-EtdG would then 
exhibit more inhibition on an 06-MedG or 06-n-PrdG coated plate, than on an 06 
EtdG coated plate. To avoid over-estimating results in this way, competitive 
inhibition assay were carried out on plates coated with the 06-alkyl dG for which the 
antibody exhibited highest affinity. 
Results obtained from the competitive ELISAs during cloning, indicated that 
2C8C6H5 had marginally higher affinity for 06EtdG, and 2G2B 1OF1 and 2E3C8E3 
had marginally higher affinity for 06-hydroxyEt dG. 2C8C6H5 was therefore tested 
on an 06-EtdG-CyG plate and 2G2B1OF1 and 2E3C8E3 on an 06-hydroxyEtdG-
Cy(3 coated plate. 
2C8C6H5 
This antibody resulted from an 06-MedG-BSA immunisation. Competitive ELISA 
showed that 2C8C6H5 was inhibited by 06-MedG, 06-EtdG and 06-n-PrdG, and 
exhibited no inhibition with dG (table 3.4). 
Compared to dG, the 06-alkyl dG derivatives have a different structural arrangement 
around the N1  of the purine ring. It was possible that the antibody was specific for 
this area of 06-alkyl dG. Differing affinity of the antibody towards each 06-alkyl 
derivative suggested that specificity towards the alkyl group was also involved. 
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Table 3.4 Inhibition of 2C8C6H5 by 06-alkyl dG derivatives at 3 concentrations, 
showing concentration giving 50% inhibition (IC50) 
% inhibition by:  
Cone. 
Molar 
06-MedG 06-EtdG 06-n- 
 PrdG hydroxyEtdG 
dG 
40x10 6 52 93 61 0 0 
4x10 6 29 76 43 0 0 
0.4x10 6 15 20 16 0 0 
IC50 37.8 x 10-6 1.94 x 10-6 18.5 x 10-6 - 
I Molar 
It was surprising to find that 2C8C6H5 exhibited higher affinity for 06-EtdG than 
for the original antigen, 06-MedG. It was possible that, i) the kinetics of antibody-
antigen binding for 06-MedG were slow, or ii) 06-EtdG was easily accommodated 
in the antibody binding site, whereas the methyl derivative may have been slightly 
small. Following the same principle the n-propyl derivative may have been slightly 
large, and the hydroxyEt derivative too large to allow antibody binding. In the case 
of the latter derivative the polar electronegative hydroxyl group may also have 
prevented antibody binding. 
An additional experiment investigated the amount of inhibition demonstrated by 06 
MedG competing for 2C8C6H5 antibody on an 06-MedG-CG coated plate. Under 
these conditions 24.8 x 10 6M gave 50% inhibition, compared to 37.8 x 10 6M 
required to give inhibition on an 06-EtdG-CG coated plate. Again the ethyl and n-
propyl derivatives exhibited the highest inhibition. 
2G2B1OF1 and 2E3C8E3 
These antibodies resulted from an 06-hydroxyEtdG immunisation. 2G2B 1OF1 
exhibited inhibition with 06-MedG, 06-EtdG, 06-n-PrdG and 06-hydroxyEtdG and 
showed no specificity for dG (table3.5). 2E3C8E3 was also inhibited by each of 
these four 06-alkyl dG derivatives but showed some cross reactivity with dG (table 
3.6). The inhibition of 2E3C8E3 by dG did not demonstrate a characteristic dose 
response curve (fig 3.12), as maximal inhibition was 28% at 40 x 10 6M, and zero 
inhibition was not observed within the limits of the assay. It is therefore possible 
that 2E3C8E3 adhered non-specifically to dG. It may also be possible that antigen 
binding site of 2E3C8E3 was extremely flexible. The screening procedures to obtain 
an antibody which recognises more than one antigen may have favoured the 
selection of an antibody with low specificity for one molecule. It may be that this 
antibody recognised part of the dG molecule, which resembled part of an 06-alkyl 
dG, and bound loosely with this area. 
2E3C8E3 demonstrated 100% inhibition with some 06-alkyl dGs which initially 
suggested that this was the highest affinity antibody. However, comparison of the 
dose response curves (figs 3.11 and 3.12) and the IC50 values indicated that both 
2E3C8E3 and 2G2B1OF1 exhibited similar affinities for each 06-alkyl dG. The 
greatest variation between the antibodies was shown with 06-MedG, as 2G2B 1OF1 
gave IC50 at 8.31 x 10 6M , while 2E3C8E3 gave 1050 at 7.92 x 10 6M with this 
derivative. This variation may have been due to experimental error. The 
concentration of 06 EtdG giving 50% inhibition was <0.16 x 10i3M for both 
antibodies, but exact values were not determined as the experiment could not be 
repeated under exactly the same conditions, due to the limited amounts of available 
plate coating material. 
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Table 3.5 Inhibition of 2G2B 1OF1 by 06-alkyl dG derivatives at 9 concentrations, 
showing concentration giving 50% inhibition 
% inhibition by:  
Conc. 
Molar 
06-MedG 06-EtdG 06-n- 
PrdG 
06 
hydroxyEtdG I  
40x10 6 95 95 95 93 0 
20x10 6 85 95 95 92 	- 0 
10 	10 6 60 95 95 90 0 
5x10 6 37 95 95 83 0 
2.5 x 10-6 14 95 95 70 0 
1.25 x 10-6 0 95 85 50 0 
0.62 x 10 6 0 95 78 15 0 
0.31 x 10 6 0 	1 90 65 10 0 
0.16x 10-6 0 	1 83 43 4 0 













10 5 	2.5 	125 	0.62 	0.31 	0.16 	0.08 	0.04 
concentration 
(rig/ml) 
Figure 3.11. Dose response curves for 2G2B 1OF1 
Table 3.5 Inhibition of 2E3C8E3 by 06-alkyl dG derivatives at 9 concentrations, 
showing concentration giving 50% inhibition 








40 x 10-6 84 100 100 100 28 
20x10 6 83 100 100 100 28 
10 	106 65 100 100 100 25 
x 10-6 38 100 100 100 25 
2.5 x 10-6 14 100 100 97 23 
1.25 x 106 0 100 100 48 10 
0.62x10 6 0 100 85 25 10 
0.31 x 10-6 0 100 74 10 10 
0.16x 10-6 0 97 50 0 10 
















5 	2.5 	1.25 	0.62 	e.31 	0.16 	0.08 	0.04 
concentration 
(gig/ml) 
Figure 3.12. Dose response curves for 2E3C8E3 
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2G2B 1OF1 and 2E3C8E3 showed an overall higher affinity for the 06-alkyl dG 
derivatives than 2C8C6H5. IC50s indicated a 5-10 fold lower affinity of the latter 
antibody (tables 3.4, 3.5 and 3.6). It was surprising to find that antibodies 
2G21310171 and 2E3C8E3, produced by an 06-hydroxyEt dG immunisation, had 
higher affinity for 06-EtdG and 06-n-PrdG, than for 06-hydroxyEt dG. Again, 
least inhibition was demonstrated with 06-MedG. These antibodies therefore 
followed the pattern set by 2C8C6H5, except for recognition of 06-hydroxyEt dG. 
This implies that for an antibody to cross react with hydroxy alkylated dG, the 
hydroxyl group may have to be present at the time of immunisation. 
To summarize: 
2E3C8E3 recognised four 06-alkyl dG derivatives, in the order 06-EtdG> 06-n-
PrdG> 06-hydroxyEtdG> 06-MedG, but also cross-reacted with dG. 
2G2B 1OF1 also recognised these four 06-alkyl dG derivatives in the same order, 
had similar affinity and had the advantage of exhibiting no cross reactivity with dG. 
2C8C6H5 was the lowest affinity antibody, recognising only three 06-alkyl dG 
derivatives, in the order 06-EtdG> 06-n-PrdG> 06-MedG. 
3.2.4.2. Dot Blots to determine comparative antibody affinity for each 06-alkyl 
dG derivative 
The antibodies were tested by dot blot assays to give some indication of the relative 
affinties towards each antigen in an alternative assay. Dot blots provided a quick 
and simple result as, i) different 06-alkyl dG derivatives were not competing for the 
antibody and ii) the oligonucleotide antigens were immobilised for screening, so the 
exact number of 06-alkyl dG derivatives per oligonucleotide' was known. The 
affinity of antibodies 2G2B1OF1, 2E3C8E3 and 2C8C6H5 for 06-MedG, 06-EthdG 
and 06-n-PrdG were tested at concentrations of 10-10 to 10 6M. 06-hydroxyEt dG 
binding was not investigated as an oligonucleotide incorporating this derivative was 
not available. 
For all three antibodies the point at which the antibody no longer recognised the 
antigen was at a concentration between 10-8 and 10 7 M (fig. 3.13). The results 
showed that in this assay system the variation in antibody affinity for each 06-alkyl 
dG derivative was no greater than a factor of 10. In addition, the results suggested 
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Figure 3.11 Dot blots showing the reaction of 2C8C6H5, 2G2B 10F1 and 2E3C8E3 
with O6alkyl dO oligonucleot ides 
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3.2.4.3. The effect of antibody class on affinity 
The affinities of monoclonal antibodies rely heavily on the properties of the amino 
acids involved in the antigen binding site. In addition, the structure of the entire 
antibody molecule, i.e. the class or sub-class of the heavy or light chain, also affects 
the binding to antigens. Antibody class-typing experiments determined that 
2G2B1OF1 and 2E3C8E3 were bivalent IgG molecules, and 2C8C6H5 was a 
decavalent 1gM molecule (i.e. has 10 antigen binding sites). IgGs are the most 
commonly produced antibody in an animal following repeated exposure to an 
antigen, and normally exhibit higher affinity than IgMs. IgMs are normally only 
produced following the initial exposure to an antigen, although it has previously 
been observed that an 1gM response is elicited continually when an antigen contains 
a high hapten substitution (Erlanger, 1980). 
IgMs are rejected by some researchers, as they commonly produce excellent results 
with one assay technique but fall to recognise the antigen with another. The 
variation in results between the non-competitive ELISAs and the dot blot assay for 
2C8C6H5 were probably due to the multivalency of the antibody. Low inhibition in 
the non-competitive ELISA was perhaps due to the large amount of inhibitor 
required to block the ten binding sites to prevent this antibody binding to the plate. 
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3.3 Experimental 
Phosphate buffered saline (PBS) tablets were obtained from Oxoid (Unipath); 
peroxidase conjugated rabbit immunoglobulins to mouse immunoglobulins (second 
antibody) from DAKOPATTS (Denmark), Hibond nylon membrane from 
Amersham and immunoplates, maxisorb f96 cert and tissue culture plates from 
Nunc, Gibco. All other cell culture plasticware was obtained from Costar. Cell 
culture media was obtained from ICN Flow (except Gibco myoclone plusfoetal calf 
serum). Polyethylene glycol (PEG 1500) was obtained from Sera-Lab and all other 
reagents from Sigma. Plates were read on a Molecular Devices kinetic microplate 
reader using a Softmax computer program. 
Buffers and Cell Culture Media 
PBS (pH 7.4) 	 from tablets (Oxoid) 1 per lOOml dH20. 
PBSII'ween (PBS/Tw) 0.05% w/v Tween 20 in PBS pH 7.4. 
Coating buffer 
(pH 9.8) 	 sodium carbonate (0.015M) and sodium bicarbonate 
(0.03M) 
ABTS 	 substrate, 0.63mg/ml in citrate phosphate buffer (0. 1M, 
pH 4.3) containing 0.0036% hydrogen peroxide. 
Serum free medium (1): RPMI 1640, penicillin 
(lOOIu/ml),streptomycin (lOOug/ml). 
Complete medium 	serum free with. L-glutarnine (2mM), sodium 
pyruvate(lmM), 10% v/v myoclone plus foetal calf serum, 
fungizone (2.5ug/ml). 
Serum free medium (2): complete without myoclone foetal calf 
serum. 
HAT medium 	complete with 1:50 dilution of HAT stock (=5mM 
hypoxanthine, 20uM aminopterin, 800uM thymidine) to 
give final conc of lOOuM hypoxanthine, 0.4uM 
aminopterin, l6uM thymidine. 
HT medium 	 as HAT medium without aminopterin. 




96-well microtitre plates were coated with 100tl/wel1 of the required 06-alkyl dG 
conjugate (ltg/mI in bicarbonate buffer [1.59g Na2CO3 + 2.93g NaHCO3I1 dH20]) 
overnight at 40C. The coating solution was then removed by washing with PBSTI'w 
(3x). Serum or culture supernatant (lOOp.1/well) was added and after 2 hr incubation 
at RT the plates were washed with PBSITw (3x). Peroxidase-conjugated rabbit anti-
mouse IgG immunoglobulin (1/1000 dilution, 100il/we1l) was added and the plates 
incubated for a further 1 hr then washed again with PBS/Tw (5x). The presence of 
specific antibody was indicated by the development of a green colour (intensity of 
which is directly related to the amount of antibody present) on the addition of ABTS 
(enzyme substrate solution 0.6mg/mi, lOOp.i/well). This colour was quantified 
spectophotometrically by A405 minus A490 on a microtitre plate reader. 
Competitive inhibition assay 
A limiting amount of serum or culture supernatant (the dilution which half 
maximally bound the antibody, determined by non-competitive ELISA) was 
incubated with decreasing concentrations of each free 06-alkyl dG derivative. After 
10min each mixture (100t1/ml) was applied to a coated plate and incubated for 2hr 
at RT. Washing, addition of 2nd antibody and substrate were carried out as 
previously described. Wells with free 06-alkyl dG derivative were compared with 
control wells without free 06-alkyl dG and the %age decrease in colour measured. 
Dot blot assay 
Wash solutions 
PEE= PBS containing 1mM EDTA and 1mM EGTA. 
PEET= PEE containing 0.5% Tween 20. 
Each 54mer (2mg) was dissolved in dH20 (50p.i) to give 40mg/mi solutions. 10 
fold dilutions were made and 0.5p1 of each solution spotted onto a nylon membrane 
giving coating concentrations of 1 x 10-6M to 1 x 1O-10M of each oligonucleotide. 
The membrane was exposed to UV irradiation for 5min to allow attachment of the 
oligonucleotides (via thymine residues) followed by incubation for 30min at RT with 
10% w/v fat free skimmed milk in PEE (lOmi), to block the uncoated areas of the 
membrane. After washing with PEET (20m1) then PEE (20m1) the membrane was 
incubated at RT with antibody solution (1:1000 in PBS, lOmi). After 30min the 
membrane was washed as before, then incubated at RT with 2nd antibody (1:1000 in 
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PBS, lOmi) for 30mm, followed by washing. 3,3'diaminobenzidine tetrachloride 
(lOmi of 0.5mg/mi in 20mM Tris.HC1 with 0.06% hydrogen peroxide) was 
incubated with the membrane for 10-30mm, to allow the colour reaction to proceed. 
The reaction was stopped by washing the membrane as before. 
Typing of antibody 
Each antibody was tested by non-competitive ELISA with, i) IgG second antibody 
and ii) 1gM second antibody (1:1000 100jxI/we11). On the addition of ABTS test i) 
gives a stronger colour with an IgG and test ii) gives a stronger colour with an 1gM. 
Immunisation Procedure 
250tl of a 1mg/mi solution of each antigen was emulsified with 350tl of complete 
Freunds adjuvant. For each antigen 2 or 3 BALB/c mice were immunised 
subcutaneously with 200il the above mixture (=100.tg antigen/mouse). After 21 
days booster injections were given (100mg antigen/mouse in incomplete Freunds 
adjuvant). Serum was screened by non-competitive ELISA for specific antibody. 2 
pre-fusion boosts, consisting of 100ig antigen made up to 200p.l total volume with 
PBS were carried Out on the fourth and third days prior to fusion, by intraperitoneal 
injection. 
Cell Fusion 
Spleen Cell Preparation 
Pre-fusion boosts were carried out as previously described. The mouse was then 
killed by ether anaesthesia and a sterile dissecting kit used-to remove the spleen 
which was then placed in cold serum free (SF) medium. The following operations 
were carried out in a laminar flow cabinet. The spleen was transferred to a sterile 
petri dish and the fatty tissue removed. A superficial longitudinal cut wag made 
along the length of the spleen with a scalpel. The splenocytes were dispersed by 
injecting SF medium (370C) through 2 lOml syringes with 25 gauge needles, along 
the length of the spleen. The medium containing the cells (typically 108) was 
centrifuged at 400g for 5min and the resulting pellet resuspended in SF medium 
(5m1). 
Myeloma cell preparation 
Sp2 or 653 myeloma cell lines were grown and maintained at approximately 0.5-1 x 
107 cells/nil in complete medium (20m1) in 250m1 rectangular flasks. 
Approximately 5 x 107 cells were used for each fusion. Immediately before each 
108 
fusion the cells were scraped from the flask surface, divided into 3 20m1 universal 
containers and centrifuged at 400g for 5 min to produce 3 pellets which were each 
resuspended in SF medium (5m1/pellet). 
PEG fusion 
Before commencing the fusion all culture medium required was allowed to warm to 
37°C in appropriate syringes as follows: 6x1Oml of SF medium, 6x6m1 of complete 
medium and 6x0.3m1 of PEG. 
The myeloma and splenocyte cell suspensions were combined (=20m1) then divided 
equally into 6 20m1 universal containers, each of which was centrifuged at 400g for 
5 min to produce 6 pellets. After complete removal of the supernatant each pellet 
was agitated with a 25 gauge needle, followed by the addition of PEG over a period 
of 30 sec. Without delay each mixture was diluted over a period of 60 sec. with SF 
medium (lOml) followed by centrifugation at 400g for 5mm. Each pellet was 
resuspended in complete medium (6m1) then applied to the inner 60 wells 
(100tl/well) of a 96 well microtitre plate. The plates were placed in a 37°C CO2-
incubator, then after 3-4 hr. HAT medium was added (100tl/well). Every 2-3 days 
100tl was carefully removed from each well and replaced with lOOi.il of fresh HAT 
medium, ensuring immediate return of the plates to the incubator. After 10 days 
each well was tested by non-competitive ELISA to identify wells producing antibody 
of interest. Cells in wells giving positive results were expanded to 2m1 wells and 
competitive ELISA was carried Out. Wells showing high inhibition were cloned. 
Thymocyte cell preparation 
A 4-6 week old BALB/c mouse was killed by ether anaesthesia. Using sterile 
dissecting instruments an incision was made along the mid-line of the thorax to the 
neck region. The thoracic cavity was opened and the 2 thymus lobes, lying anterior 
to the heart, were carefully removed and placed in cold SF medium in a 20m1 sterile 
container. After transfer to a petri dish containing SF medium (lOml) the thymus 
was teased with forceps allowing the thymocytes to be released. The cell containing 
medium was centrifuged at 400g for 5min and the pellet resuspended in complete 
medium (20m1). 
Cloning by limiting dilution 
This procedure aims to dilute cells in a 96-well microtitre plate to achieve 2-3 rows 
with 1 cell/well. 4ml of thyrnocyte suspension was added to approximately 200 
hybridomas. 2.4m1 of this mixture was distributed evenly over rows A and B of a 
109 
96-well microtitre plate (theoretically 5 cells/well). Another 2.4ml of thymocyte 
suspension was added to the remaining 1.6m1 hybridoma mixture and after gentle 
mixing 2.4m1 was distributed evenly over rows C and D (2 cells/well). The 
remaining 1.6m1 of mixture was mixed with a further 1.6m1 of thymocyte suspension 
and again 2.4m1 was distributed over rows B and F (1 cell/well). Finally the 
remaining 0.8m1 of hybridoma mixture was mixed with the remaining 1.6ml of 
thymocyte suspension and the resulting 2.4m1 distributed over rows  and H (1 
cell/2 wells). 150.tl of complete medium was added to each well before culturing 
the plate at 370C in a CO2-incubator. After 10-14 days the number of clones/well, 
visible microscopically, were recorded and the culture supernatants screened by non-
competitive ELISA. Positive wells of monoclonal origin were expanded to 2ml 
wells. Cloning was repeated twice for each cell line to confirm monoclonality, 
which was indicated by antibody production in 100% of cell containing wells. 
Monoclonal cell lines were expanded into flasks and maintained at 0.5-1 x 107 
cells/ml changing medium every 2-3 days. At each stage of cloning cells were 
frozen for safety. 
Freezing cells 
Freezing medium (90% foetal calf serum + 10% DMSO) was prepared and cooled 
on ice. For each cryotube 106 cells were centrifuged at 400g for 5mm. The 
supernatant was discarded and the pellet resuspended in 0.5m1 ice cold freezing 
medium then transferred to a cold cryotube. Cryotubes were placed in a polystyrene 
box and stored at -70°C overnight, then transferred to liquid nitrogen for long term 
storage. 
Transferring cells to serum free culture conditions 
Complete medium (10% serum) was removed from hybridomas growing in 200m1 
culture flasks and medium containing 7.5% serum was added (20ml). After 2 days 
the cells were examined microscopically and the cell culture supernatant was tested 
by competitive ELISA. Healthy hybridomas which continued to secrete antibody 
were introduced to media containing decreasing amounts of serum i.e. 5%, 2.5%, 
1% then 0, over a period of at least 4 wks. At each stage cells were tested for 
antibody production. 
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Chapter 4. Preparation and Application of Immunoaffinity Columns 
for the Purification of 06-alkyl-2'-deoxyguanosine 
4.1 Introduction 
Immunoaffinity chromatography (IAC) is considered to be one of the most powerful 
techniques for the purification of chemical and biological material to which 
antibodies can be induced. A single step experiment can result in purification factors 
of 2000-20 000-fold (Goding, 1986). Prior to the advent of monoclonal antibodies, 
polyclonal antibodies were employed as immunoaffinity reagents, enabling the 
purification of many enzymes and proteins implicated in medical disorders 
(Livingston, 1974; Robb et al, 1976). Problems with quality of antibody, low 
binding capacity and specificity, discouraged the widespread application of the 
technique. The development of monoclonal antibodies with precise characteristics 
eliminated these shortcomings. Monoclonal antibodies are now widely applied in 
affinity chromatography, and have been used to purify cell surface antigens (Parham, 
1979), vaccines (van Wesel and van der Marel, 1982) and many biologically 
important proteins (Secher and Burke, 1980; Mescher et al; 1983; Bigio et al, 1989). 
4.1.1. Principles of immunoaffinity purification 
IAC is a separation technique and relies on specific antibody-antigen binding and the 
dissociation of the antibody-antigen complex (Wilchek, et al, 1984). It can be 
divided into 3 steps: i) immobilisation of the antibody on a solid support (matrix), ii) 
binding of the antigen to the antibody-matrix, and iii) elution of the antigen. 
Generally, the antibody-matrix is packed into a column and a crude mixture 
containing the desired 'antigen' is applied. As the antigen comes into contact with 
the antibody, binding results. The remaining material in the crude extract elutes 
from the column, aided by washing. The purified antigen is then dissociated from the 
antibody-matrix by introducing a change (e.g. pH, polarity, denaturants) to the 
column environment. An overview of the procedure is described in figure 4.1. The 
antibody-matrix can also be stirred with the crude mixture to extract the desired 
antigen (the stirred tank method, Chase, 1984), although the column method is more 
common for laboratory scale experiments (< lOOmgs), (Yarmush et a!, 1992). 
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Figure 4.1. Overview of immunoaffinity purification 
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4.1.1.1. Preparing immobilised antibodies 
Many solid supports and coupling methods have been investigated for the 
immobilisation of antibodies (reviewed by Chase, 1984; Yarmush, 1985; Yarmush et 
al, 1992). The most popular method for covalently attaching antibodies to a solid 
support is via an activated bead (Scouten, 1987). Alternatively, the antibody can be 
activated. The former method offers a wider range of possibilities as the beads can 
withstand harsher activation conditions than the antibodies. Agarose, (figure 4.2) in 
the form of a bead, is the most commonly employed matrix. It possesses ideal 
qualities for a matrix such as, minimal non-specific adsorption, absence of charged 
groups and high porosity, which provide a high surface area (Yarmush et al, 1992). 
In addition, it is chemically stable and contains functional groups which can be 
activated. Most commercially available agarose has been chemically and 
mechanically stabilised by the addition of a cross-linking agent. The cross-linked 
product is often referred to as Sepharose. 
HO 	 0 
OH 
OH 	 0 
Figure 4.2. Agarose 
There are many methods for the activation of agarose. Cyanogen bromide (CNBr) 
activation (fig 4.3a), which was the most popular for a long period of time, is simple, 
can be carried out in an aqueous environment, and results in high loading on the 
agarose (Axen et al, 1967; March et al, 1974). However, following the 
immobilisation of the antibody on the matrix an unstable isourea bond is formed 
(Wilchek, 1975; Lasch and Koelsch,1978). An extra charge is introduced by the 
presence of this bond, subsequently causing the matrix to act as an ion exchanger at 
low salt concentrations (Goding, 1986). Additionally, over a period of time the 
antibody begins to leak from the support (Lowe, 1979). Leakage is accelerated on 
exposure to high temperatures, extremes of pH and exposure to nucleophiles 
(Wilchek, 1975). Triazine activation of agarose (fig 4.3.b) which yields a stable and 
neutral antibody-matrix linkage (Lang et al, 1977), is a modern alternative to CNBr 
activation. It has the added advantage of exhibiting high coupling, immobilising at 
least 90% of the antibody in most cases. This is due to the ability of the activated 
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matrix to react with amine, thiol and hydroxyl groups of the antibody, producing 
triazine ether bonds (Lily et al, 1976). The only obvious disadvantage of this 






















Figure 4.3. Activation of agarose 
CNBr and triazine activation methods involve the addition of an active group to the 
agarose. In contrast, periodate activation (fig 4.3c) involves the alteration of the 
agarose backbone to produce an activated group (Fischer, 1985). Periodate converts 
an agarose diol to a dialdehyde, which reacts with the amine groups of the antibody. 
Following the addition of the antibody an unstable imine is produced and reduction 
by borohydride is necessary to produce a stable antibody-matrix-complex. Of the 3 
activated supports described, only periodate activated sepharose is not commercially 
available, as the dialdehydes may be reduced on storage. There are many more ways 
in which agarose can be activated, some are described in table 4.1. 
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Table 4. 1. Methods for the activation of agarose for antibody coupling 
Activating reagent Reference Disadvantage 
Carbonyl-diimidazole Bethal et al 1979 none known 
Nilson & charged at neutral 
p-Toluene suiphonyl Mossbach, 1980 & pH 
chloride 1984  
Hydroxysuccinimide Cuatrecasas & non-specific 
Parik, 1972 binding 
Epichlorohydrin Porath & Axen long activation 
1976 time 
It is important that the monoclonal antibody to be coupled to the activated support is 
pure. It is generally accepted that ammonium sulphate precipitation yields antibody 
of sufficient purity. However, extensive dialysis is required to extract ammonium 
sulphate, as the presence of ammonia ions inhibits the coupling reaction (Goding, 
1986). The predominant reaction of antibodies with the activated support is 
nucleophilic attack by the lysine amino groups of the antibody. This reaction is 
rapid at slightly alkaline pH, as the amino groups are not protonated. Over-coupling 
of the antibody can lead to inactivation of the antibody binding sites (Cuatrecasas 
and Anfinsen, 1971), presumably due to steric hindrance. It is important to 
inactivate any uncoupled active groups and to wash the antibody-matrix complex 
extensively prior to loading of the antigen. The amount of antibody immobilised on 
the activated support can be estimated by recording the A280 of the antibody solution 
before and after the coupling reaction, providing there are no by-products of the 
reaction which absorb at this wavelength. 
4.1.1.2. Loading of antigen and washing 
Immobilisation of the antibody, results in an alteration of the kinetics of antibody-
antigen binding, therefore it takes longer for equilibrium to be reached. The time 
taken for the antigen solution to travel through the column (flow rate) is normally 
sufficient for high affinity antibodies to capture the antigen. However, low affinity 
antibodies have been shown to bind minimally in this time, making it necessary to 
use an excess of antibody-matrix for equilibrium to be reached (Harlow and Lane, 
1988). It is important for the column capacity to be greater than the amount of 
antigen to be bound, as under these conditions flow rate is no longer important 
(Yarmush et al, 1992). In many cases where the column capacity is less than the 
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amount of antigen loaded, a break-through of antigen occurs at the column outlet 
(Chase, 1984). For large scale immunoaffinity purification, i.e. in industrial use it is 
essential that loading of the column is maximised, to avoid wasting antibody or 
antigen (product). In these cases column capacity and antibody-antigen equilibrium 
are calculated theoretically (described by Yarmush et al, 1992). 
It is generally desirable to remove contaminants from the crude antigen mixture 
before loading the column. Aggregated materials and debris may block the column, 
and impurities such as enzymes and proteins may degrade or non-specifically bind to 
the support. 
After the loading solution has travelled through the column the unbound material is 
removed by extensive washing. This procedure also removes some of the material 
which has bound non-specifically to the support by ionic and hydrophobic 
interactions. Modified wash buffers have been developed for the removal of 
impurities, e.g. detergent containing buffers remove impurities bound by 
hydrophobic interactions (Smith et al, 1982) and non-specifically bound proteins are 
removed by alterations in pH (Schneider et al, 1982). However, deleterious effects 
on the anibody-antigen binding have been observed during the use of modified 
buffers (Stailcup et al, 1981). 
4.1.1.3. Elution of the antigen 
The elution step involves the dissociation of the antibody-antigen complex to obtain 
the pure antigen. It has been shown that the ease of dissociation does not depend on 
the affinity of the antibody (Parham, 1983). The antibody-antigen interactions can 
be disrupted by, i) treating with harsh conditions or, ii) adding an excess of a 
compound that mimics the antigen. The latter is not commonly used as displacement 
of the antigen may take several hours resulting in a broad elution profile. In addition, 
there is often contamination by the displacing reagent (Harlow and Lane, 1988) 
rendering the product too impure for further use. Conditions for technique 'i)' must 
be carefully chosen to avoid degradation or denaturation of the an 	Most 
elution methods rely on the reversible denaturation of antibodies. Most proteins, 
including antibodies, have been shown to alter in tertiary structure in the presence of 
many chemical reagents, and renature after the removal of the reagents (Hager and 
Burgess, 1980). Due to the differing properties of antibodies it is necessary to carry 
out a range of tests to identify suitable elution conditions. 
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The most popular method of dissociation is to change pH. Low pH (i.e. 100mM 
glycine, pH 1.8) is generally preferred, as high pH (i.e. 100mM phosphoric acid, pH 
12.5) can potentially cause irreversible denaturation of antibodies (Tanford, 1968). 
Chaotropic ions disrupt water structure, break hydrogen bonds and weaken 
hydrophobic interactions. These ions disrupt antibody-antigen binding in the 
following order (Goding, 1986): 
SCN- >1 >C104 >NO3 >Br >Cl >CH3COO >S042 >P043  
Ba2+ >Ca2+ >Mg2+ >Li+ >Na+ >K+ >Cs+ >NH4+ 
Thiocyanate is the most effective chaotropic ion, but it is difficult to remove this ion 
completely and the small traces can render the column unusable (Harlow and Lane, 
1988). Organic solvents, which alter the polarity of the elution solvent (e.g. 
pyridine, acetonitrile, DMSO,.dioxane ethylene glycol and aqueous acetone) can be 
used, and columns can normally be reused if they are washed extensively 
immediately after the elution of the antigen. The protein denaturants commonly 
used are 5 to 8M urea and 4 to 6M guanidine-HC1. These reagents are normally 
employed when all other methods of antibody-antigen dissociation fail, because 
irreversible antibody denaturation commonly occurs (Goding, 1986). 
4.1.2. Application of immunoaffinity columns 
During the last several years IAC has been applied to allow the detection and 
quantification of modified DNA derivatives. It has generally been used as a 
purification step in combination with 32P-postlabelling, HPLC, flourescence 
techniques, or electrochemical methods for the quantification of 06  and 7-alkyl dG, 
methyladenine and benz[a}pyrene diol epoxide DNA derivatives. The characteristics 
of the columns used in some of the studies are described in table 4.3. The column 
capacity varies between studies and is largely dependent on the orientation of the 
antibody on the sepharose and the affinity of the antibody. 
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Table 4.3. Recent applications of immunoaffinity chromatography 
DNA derivative Matrix Column Antigen Reference 
(sepharose) capacity# recovery  
06-butylguanine CNBr 1.53nmol/ 62+/- 5% Bonfanti et 
1.25mg Ab  a!, 1990 
benzo[a]pyrene 
diol epoxide CNBr no information 85-100% Manchester et 
derivatives  given  al, 1990 
CNBr 1.4nmol/mg 
Ab 
hydrazide 1.5nmol/mg 06-methyl guanine >95% Cooper eta!, 
Ab 1992 
periodate 6.2nmol/mg of 
Ab  
7-methyl protein A 606pmol/mI >90% Bianchini et 
deoxyguanosine 	f sepharose*  a!, 1993 
# the amount of DNA derivative which binds to the immobilised Ab 
*Ab loading not known 
It was anticipated that similar results to those shown in table 4.3 could be achieved 
by immobilising the 06-alkyl dG class specific antibodies (produced in chapter 3), in 
order to allow the purification of 06-alkyl dG from native DNA. 
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4.2. Results and Discussion 
Antibodies 2C8C6H5 and 2G2B lOFi were chosen to be employed in IAC 
experiments. In general, low affinity antibodies, such as IgMs (i.e. 2C8C6H5) are 
considered unsuitable for IAC. However, 2C8C6H5 was the first class specific 
antibody to be generated during the project, therefore many initial IAC experiments 
were conducted with this product. In addition, ELISA and dot blot assays indicated 
that the affinities for the 06-alkyl dGs by this antibody were only 10-fold lower than 
affinities exhibited by 2G2B 1OF1 antibody. Due to the similarities between 
2G2B1OF1 and 2E3C8E3 only the former was investigated for IAC experiments 
The chosen antibodies were purified from the cell culture supernatant by ammonium 
sulphate precipitation. The purity of 2C8C6H5 was enhanced by growing the cell 
line in serum free media, prior to precipitation. The change in cell culture conditions 
was introduced gradually (over a course of 4-6 weeks) and the supernatant was tested 
at each stage to ensure that the antibody maintained specificity and affinity towards 
06-alkyl dG, despite the change in cell culture environment. Following 
precipitation, minimal contaminant serum proteins were present, which allowed a 
more accurate calculation of the amount of antibody. Cell line 2C8C6H5 gave an 
average antibody production of 40-50j.ig./ml of supernatant, whereas 2G2B 1OF1 
(which was not introduced to a serum free environment) gave an average overall 
protein product of 50-60tg/ml of supernatant. These amounts varied depending 
upon the number of healthy cells present at the time of collecting the culture 
supernatant. 
4.2.1. Immobilisation of 2C8C6H5 on three types of sepharose and purification 
of 06-alkyl dG 
The performance of immobilised antibodies has been shown to be dependent upon 
the nature of the solid support (Cooper et a!, 1992). Therefore 3 different types of 
activated sepharose: CNBr, tnazine and periodate, were examined. This allowed 
comparison of the amount of antibody immobilised and the relative amount of 
antigen captured by the immobilised antibody. Firstly, 2C8C6H5 was immobilised 
on each activated sepharose following the manufacturers' instructions. The extent of 
immobilisation varied greatly between the activated supports (table 4.4). 
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Table 4.4. Comparison of sepharose binding characteristics of 2C8C6H5 antibody 




CNBr ig 9.8mgs 75% 
TrAS ig 29mgs 90% 
PIAS I 	ig I 	2mgs 1 	35% 
The coupling efficiency gave an indication of the amount of antibody immobilised as 
a percentage of the total amount of antibody exposed to the solid support. Triazine 
activated sepharose (TrAS) appears to have bound significantly larger amounts of 
antibody than cyanogen bromide activated sepharose (CNBrAS) and periodate 
activated sepharose (PIAS). TrAS was exposed to higher levels of antibody which 
may have resulted in more antibody coupling. All 3 types of sepharose couple to 
amine groups of antibodies, but TrAS also couples with antibody hydroxyl and thiol 
groups, which may explain the high antibody loading on this support. Similar 
coupling efficiencies were expected for CNBrAS and PIAS, as both bind antibodies 
via amine groups. However the latter exhibited approximately 50% less binding. 
PIAS, which is not commercially available, was synthesised prior to the experiment 
and it is possible that this support possessed less activated groups than the 
commercially available CNBrAS (which will be synthesised routinely at optimal 
conditions). 
The column capacity for each antibody matrix was estimated by loading 1O.tg of an 
06-alkyl dG derivative, washing the column, determining the amount of 06-alkyl 
dG in the wash, eluting the bound material from the column, and determining the 
amount of 06-alkyl dG in the eluted sample. 06-EtdG was used for these 
experiments as the antibody has highest affinity for this derivative. Initial 
experiments were conducted on CNBrAS-antibody and PIAS-antibody complexes, 
and the presence of 06-EtdG in the wash and elution samples was determined by 
competitive ELISA. The samples were tested for ability to inhibit 2C8C6H5 
antibody binding to the plate. The samples that show inhibition contain 06-EtdG. 
The wash and elution samples were collected in fractions and the inhibition 
demonstrated by each is shown in table 4.5. 
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Table 4.5. % Inhibition shown by wash and elution fractions from CNBr-antibody 
and PIAS-antibody IACs. 
Support Fraction % Inhibition 
of 2C8C6115 
CNBrAs 
wash 1 50 
wash 2 38 
wash 3 21 
wash 4-10 0 
elution 1-2 0 
elution 3 45 
elution4 15 
elution 5-10 0 
PIAS 
wash 1-10 0 
elution 1-6 0 
elution 7 68 
elution 8 50 
elution 9 30 
elution 10 0 
CNBrAS-Ab bound 06-EtdG (shown by the inhibition in elution fractions 3 and 4, 
table 4.5). However higher inhibition shown by the wash samples 1, 2 and 3 
indicated that not all of the 06-EtdG derivative has bound. Further experiments with 
CNBrAS involved tumbling 06-EtdG with the support over a range of times (i.e. 
10-120mm), but identical results were obtained. PIAS demonstrated no inhibition in 
the wash samples and high inhibition in the elution samples (table 4.5). 2C8C6H5 
immobilised on PIAS was therefore more effective at extracting 06-EtdG, than 
2C8C6H5 immobilised on CNBrAS. In addition, the PIAS column was reusable, 
whereas the antibody bound to the CNBrAS became less active during subsequent 
usage. CNBrAS was therefore omitted from further investigation. 
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The 06-EtdG in each fraction could not be quantified from these inhibition results. 
In addition, it was possible that small amounts of 06-EtdG were present in samples, 
but at levels too low to result in inhibition. The calculated amount of 06-alkyl dG 
that 2mgs of antibody (the amount immobilised on the PIAS) can theoretically bind, 
is less than 1Otg'. Consequently, not all of the lOjig applied to the column was 
binding to the column, and a small amount of 06-EtdG was unaccounted for. The 
wash and elution samples from subsequent IAC experiments with PIAS and TrAS 
were therefore examined by HPLC analysis to estimate the ratio of bound to 
unbound 06-alkyl dG. HPLC allowed smaller amounts of 06-alkyl dG to be 
detected. 
4 .tg of 06-EtdG were applied to a PIAS-antibody and a TrAS-antibody column. 
The presence of 06-EtdG in only the elution sample from the PIAS (fig 4.4a) 
indicated that this support was capable of binding 4.tg of this derivative. This is 
almost maximal binding for the 2 mgs of antibody immobilised on this support 
(maximum calculated to be 6.6p.g). In comparison, the majority of the 06-EtdG was 
present in the wash sample after being applied to a TrAS-Ab column (fig 4.4b). A 
small amount of 06-EtdG (< l.tg) was present in the elution sample. As 29mgs of 
antibody were immobilsed on this support higher binding of 06-EtdG was expected. 
Extensive use of TrAS would result in rapid consumption of antibody, and the 
subsequent purification of small amounts of 06-alkyl dG. 
The finding that 2mgs of antibody, immobilised on PIAS, bound more 06-EtdG than 
29rngs of antibody immobilised on TrAS may be attributable to the orientation of the 
antibody on the support. TrAS, which binds the antibody via amine, hydroxyl and 
thiol groups, is likely to bind a higher amount of antibody than PIAS which binds 
antibody via only the amino groups. This may result in i) an excess of binding via 
antibody binding sites, rendering them inactive, or ii) binding at many areas of the 
antibody causing a distortion in the overall shape, ultimately affecting the 3 
dimensional structure of the antibody binding sites. The immobilisation in this study 
was further complicated by the use of an 1gM, which probably bound to the 
sepharose via many sites and became distorted. 
(Mw of an 1gM = 900 000, therefore 2mgs = 2.22 x 10 9mo1 
Assuming that the 10 binding sites of the 1gM are available to capture antigen, then 2.22 x 10 8mo1 
of antigen should be bound. 














The results of antibody immobilisation and subsequent 06-EtdG capture are 
summarised in table 4.6. 
Table 4.6. Comparison of 3 types of activated support (summary) 
Efficiency of Ab Column 
Support immobilisation capacity Comments 
PIAS poor 4.tg/ almost 1:1 Ab to 06-EtdG 
2mg Ab binding, column reusable 
TrAS excellent <lp.g/ poor 06-EtdG binding, high 
29mg Ab Ab consumption 
CNBrAS average 1-59g/ reasonable 06-EtdG binding, 
10mg Ab column not reusable 
4.2.2. Recognition of 06-MedG, 06-n-PrdG and dG by PIAS-2C8C6H5 
The capture of 06-MedG and 06-n-PrdG by PIAS-2C8C6H5 was tested by applying 
4tg of each to the column. Approximately 75% of 06-MedG was observed in the 
wash fraction, and the remaining 25% in the elution fraction (fig. 4.5a), therefore 
1.Lg bound to the support. Similarly, 06-nPrdG was present in both the wash and 
elution fractions at a ratio of 1: 1 (fig. 4.5b), indicating that 2p.g of 06-n-PrdG 
bound to the support. These figures and the 06-EtdG figures, showed that 
immobilised 2C8C6H5 had lowest affinity for 06-MedG, a 2-fold higher affinity for 
06-n-PrdG, and a 4-fold higher affinity for 06-EtdG (table 4.7). The comparative 
affinities of 2C8C6H5 for 06-alkyl dG followed a similar pattern as that shown by 
competitive ELISA in chapter 3. 
Table 4.7. Amount of each derivative binding to PIAS-2C8C6H5 
Amount in: 
Derivative Wash Elution 
06-MedG l.tg 3.tg 
0 4j.ig L
06-EtdG 










Figure 4.5. Binding of a) 06MedG and b) 06nPrdG to PIAS-2C8C6H5 
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The columns were tested for non-specific binding to dG, following the procedure for 
binding of 06-alkyl dG derivatives. The majority of the dG sample is present in the 
wash fraction (fig 4.6), therefore minimal non-specific binding was occurring. 
4.2.3. Extraction of 06-alkyl dG from of an excess of dG 
The ultimate purpose of the immunoaffinity columns was to extract 06-alkyl dG 
from native DNA samples. It -was firstly important to test the efficiency of the 
columns in distinguishing 06-alkyl dG derivatives from other DNA components, in 
particular dG. 
4.2.3.1. Three-fold excess of dG 
A mixture containing 06-MedG, 06-EtdG and 06-n-PrdG (lp.g of each) and a 3-
fold excess of unmodified dG (9tg) was applied to the PIAS-2C8C6H5 antibody 
column. After washing and elution 06-EtdG and 06-n-PrdG were detected in the 
elution sample, indicating that these derivatives bound efficiently to the column in 
the presence of an excess of dG (fig. 4.7). In contrast, 06-MedG showed minimal 
binding to the column, as most of this derivative was present in the wash sample (fig. 
4.7). Previous experiments showed that lj.tg of 06-MedG could be bound to this 
column in the absence of other 06-alkyl dGs or dG. In the present experiment the 
immobilised 2C8C6H5 preferentially extracted the larger 06-alkyl dGs. This may 
be advantageous as 06-MedG is believed to be present at higher frequencies than 
06-EtdG and 06-n-PrdG in DNA (Chambers, 1991). Therefore, an antibody with 
lower affinity for 06-MedG and greater affinity for the higher alkyl derivatives may 
recognise large amounts of 06-MedG at similar efficiencies to smaller amounts of 
06-EtdG and 06-n-PrdG. 
4.2.3.2. 108-fold excess of DNA 
06-alkyl dG has been shown to occur in human DNA samples in amounts varying 
from 0.01 to 0.7p.mol per mole of dG (Foiles et al, 1988; Hall et a!, 1991). Exact 
levels of 06-alkyl dG in human samples are not clear, but techniques which allow a 
minimum detection limit of 1 06-alkyl dG in 108  normal DNA residues are 
generally considered sufficiently sensitive (Cooper et a!, 1992). 
The amount of 06-alkyl dG previously employed in IAC experiments in this study 
(i.e. 1-4.ig) would have required the presence of 100-400g of normal DNA to mimic 
a 'real' situation with a 108  excess of DNA. It was therefore necessary to 
dramatically decrease the amount of 06-alkyl dG applied to further evalidate the 
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wash elution 
Figure 4.6. Binding of dG to PIAS-2C8C6H5 
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shows relative amounts 




Figure 4.7. Binding of 06MedG, 06EtdG and 06nPrdG to 
PIAS-2C8C6H5 in the presence of a 3-fold excess of dG 
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immunoaffinity column. This meant using an amount of 06-alkyl dG which could 
not be efficiently detected by HPLC. Tritium labelled 06-alkyl dG was therefore 
synthesised, as small amounts of radioactivity can be easily detected. 06-MedG was 
chosen to be labelled, as it was assumed that any binding of this derivative also 
implied binding of 06-EtdG and 06-n-PrdG, since the antibody had higher affinity 
for the latter 2 derivatives. 
Approximately 1000dpm of 1',2'-3H-06-MedG (1 x 10 14mo1), in an excess of 108  
of normal DNA (1 x 10 6mol), was loaded onto and eluted from the column. HPLC 
analysis combined with scintillation counting determined the composition of the 
wash and elution fractions. The normal DNA residues did not bind non-specifically 
to the column, shown by their presence in only the wash sample (fig. 4.8). The 
distribution of the radioactivity between the wash and elution samples, indicated that 
approximately 10% of 3H-06-MedG bound to the column. A maximum of 10% 
binding may be due to, i) the presence of the excess of normal DNA which may 
partially obscure 06-MedG from the antibody, or ii) the affinity of the immobilised 
antibody which may be too low to recognise very small amounts of 06-MedG. 
The ability of immobilised 2C8C6H5 to recognise small amounts of 06-MedG in the 
absence of normal DNA, was investigated. Immobilised 2G2B 1OF1 was also 
investigated in this experiment, to allow a comparison of the extent of binding by 
each immobilised antibody. It was important to consider the amount of antibody 
immobilised and the theoretical binding of each column. Column capacities of 20% 
of the theoretical. binding are generally reported (Campbell et al, 1981). The 
following calculations, therefore assume that only 20% of the antibody binding sites 
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Figure 4.8. HPLC of the wash and elution fractions when adding 
3HO6MCdG and deoxynucIeosjde to 2C8C6H5-PIAS. in a ratio 
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(1.5 x 10 0mol) 1gM 
	
(jL9 x 10 9mo1) IgG 
Ab : Ag binding 	 1 :10= 	 1: 2 = 
1.5 x 10-10:1.5  x 10 9mo1 	x 10ff:?3.1,x  10tho1 
Assuming 20% max. total 	 - 
theoretical antigen binding = 3 x 1040mo1 	 x 10 moI 
From these calculations, a column containing 0.25m1 of 2C8C6H5-sepharose or 
-10 2G2B1OF1-sepharose, should theoretically bind 3 x 10-10  mol and 7.4 x 10,-mol of 
06-MedG respectively. To cover this range of concentrations H-06-MedG was 
applied to the columns in 10-fold dilutions from 1 x 1044mo1 to lx10 6mol. For 
both 2C8C6H5 and 2G2B 1OF1 the maximum amount of binding of 06-MedG was 
no greater than 8% of the total amount of 06-MedG added (table 4.8). 
Table 4.8. Binding of H-06MedG to PIAS-2C8C6H5 and PIAS-2G2B 1OF1 
2C8C6H5 2G2B1OF1 
Amount of 3H- 
06-MedG 
added 





Amount of 3H- 
06-MedG 
 bound  
% 
bound 
lx 10-14 4x1046  4.0 ND ND 
1 x 10-13 5.5 x 10-15 55 ND 
1 x 10-12 3.9 x 10-14 3.9 6 x 10-15 0.6 
1 x 10-11 3.8 x 1043 5.4 8 x 10-14 0.8 
1 x 10-10 4 x 10-12 4.0 4.6 x 10-12 4.6 
1 x 10-9  7 x 10-11 7.9 4.5 x 10-11 45 
1 x 10-8 2.1 x 10-10 2.1 4.6 x 10 4.6 
1 x 10-  ND ND 5 x 10-10 0.5 
lx 10-6 ND ND 2x10 9  0.2 
ND = not determined 
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An increase in the amount of 06-MedG added (to 1 x 10-8) resulted in an overall 
increase in the amount bound. As expected, with lower concentrations of 06-MedG 
less binding occurred. The binding also decreased as the concentration of 06-MedG 
exceeded the theoretical binding capacity of the column (fig. 4.9 and 4.10). It was 
assumed that saturation was occurring at the point where the percentage binding 
began to fall. 
The percentage binding for 2G2B1OF1 gave a characteristic plateau shaped curve, 
showing the point at which the antibody, i) first recognised the antigen and, ii) 
became saturated (fig. 4.10). For 2C8C6H5 the saturation point was shown but the 
point at which the antibody first recognised the antigen was not detected (fig. 4. 9). 
Binding with less than 1 x 10 4mol of H-06-MedG could not be investigated as 
the radioactivity was undetectable below this quantity. 
The results indicate that, i) the columns were capable of binding low levels of 06 
MedG, and ii) the column capacities were similar to theoretical values. However 
reasons for a maximum binding of only 8% of H-06-MedG, irrespective of the 
amount added, were uncertain. The purity of.H-06-MedG was ascertained by 
HPLC to ensure that the radioactivity was an integral part of the derivative. In 
addition the immobilised antibodies were tumbled with H-06-MedG to increase the 
time available for antibody-antigen binding, but a maximum of 8% binding was 
continually observed. It was possible that the incorporation of the radiolabel altered 
the specificity of the antibodies towards 06-MedG. However acomparison of the 
immunoreactivity of 06-MedG and H-06-MeclG by competitive ELISA indicated 
that the antibodies had similar specificity towards both labelled and non-labelled O6 
MedG. The results therefore implied that these columns could not be applied fOr the 
identification of 06-alkyl dO in native DNA samples, as the immobilised antibodies 
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Saturated ammonium sulphate (410m1, 40C) was added slowly to hybridoma culture 
supernatant (500m1, 40C).  As the solution reached 45% ammonium sulphate a white 
precipitate appeared and the mixture was stirred gently for 30mm, allowed to settle 
for 15min then centrifuged at 7000rpm for 15 mm. The supernatant was discarded 
and the pellet redissolved in a minimum volume of coupling buffer (see below). 
Preparation of imrnunocolumns 
Coupling buffers 
0.1M sodium bicarbonate, 0.5M sodium chloride, pH8.3. 
50mM sodium acetate, pH 5 
0.01M phosphate (pH 7.4), 0. 1M sodium carbonate, 0.067M sodium chloride, 
pH 9.5. 
Cyanogen bromide activated sepharose 
ig of sepharose was suspended in aqueous HC1 (1mM, 20mls) to allow swelling of 
the beads, which were then washed extensively on a glass sintered funnel with 
aqueous HC1 (1mM, 500m1), then coupling buffer 1 (50m1). The sepharose was 
transferred to a 20m1 universal container and tumbled with purified antibody (5-
l0mis of a 5-10mg/ml solution) in coupling buffer 1, at RT. After 2hr the sepharose 
was collected by filtration and washed with coupling buffer 1 (20m1) [the filtrate 
and wash solution were kept to allow calculation of the amount of antibody 
immobilised on the sepharose]. The unreacted sites of the sepharose were blocked 
by tumbling with glycine (0.2M, lOml). After 2hr the sepharose was washed with 
acetate buffer (0. 1M, with 0.5M NaCl, pH4, 50m1) and was ready for use. The 
amount of antibody bound to the sepharose was estimated by measuring the A280  of 
the total antibody used and subtracting the A280 value of the filtrate and wash 
solution. 
Triazine activated sepharose 
ig of sepharose was suspended in distilled H20 (dH20)(10ml) for 15min to allow 
swelling of the beads, which were then washed with cIFT20 (500m1), then coupling 
buffer 2 (50m1). After the addition of antibody (5-10mi of a 5-10mg/ml solution) in 
coupling buffer 2, the sepharose was tumbled at RT for 2hr, washed with dH20 
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(20m1) then blocked with ethanolamine (2M, lOmi). After washing with dH20 
(25m1) then ethanol/dI-120 (8:2, 25m1) the sepharose was ready for use. 
Periodate activated sepharose 
CL6B sepharose (35g) was washed with dH20 (250m1) on a glass sintered funnel 
then transferred to a 200m1 plastic bottle. Sodium periodate (70m1,0.07M in cIH20) 
was added and the mixture tumbled end over end at RT. After 45min ethylene 
glycol (35m1, 2M in dH20) was added and tumbling continued for a further 30mm, 
followed by filtering and washing of the sepharose with dH20 (200m1) then 0.01M 
NaCO3 (500m1, pH 9.5). Purified antibody (lOmi of 5-10mg/mi solution in coupling 
buffer 3) was added to lOg of activated sepharose and the mixture tumbled at 4°C. 
After 72 hr the sepharose was collected by filtration and washed with ice cold PBS 
(50m1). The sepharose was placed in a lOOmi plastic bottle and tumbled at RT with 
sodium borohydride (20m1 of 1mg/mi in PBS, made immediately before use). After 
1 hr the sepharose was filtered and washed with ice cold PBS (200ml), then 
acetone/H20 9:1 (lOOml), then ice cold PBS (500m1) and was ready for use. 
Use of immunocolumns 
HPLC conditions for all immunocolumn experiments = [C18, 50DS column, buffer.  
A= 75mM KH2PO4, buffer B= 80:20 MeOH/H20, gradient 0-70% B over 15mm, 
280nm, 0.1AUFS] 
Cyanogen bromide activated sepharose 
ig of sepharose was washed with PBS (50m1), then tumbled at RT with 06-EtdG 
(imi of a 10.tg/ml solution in PBS). After lhr the mixture was poured into a small 
plastic filter column and imi of supernatant was collected (fraction 1). Unbound 
06-EtdG was removed by passing PBSR'w (lOmi) through the column and lOxlml 
fractions were collected (fractions 2-11). 06EtdG bound to the immobilised 
antibody was eluted with 9:1 acetone/1120 (lOmi) and lOximi fractions were 
collected (fractions 12-21). All fractions were evaporated, then used in a competitive 
ELISA where any fractions containing substantial amounts of 06-EtdG inhibit the 
binding of antibody to the plate. 
Triazine and Periodate activated sepharose 
Immunoaffinity columns were constructed by pouring sepharose (0.5-1ml) into 
shortened pasteur pipettes with a glass wool filter. Columns were washed with PBS 
(10 volumes) prior to use. 06-alkyl dG samples (1-1Oj.tg/ml) were passed through 
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the columns in PBS under gravity. After loading a sample columns were washed 
with 10 volumes of PBS to remove unbound material, then any 06-alkyl dG bound 
to the sepharose was eluted with acetone/H20 (5-10 volumes). Wash and elution 
fractions were evaporated then analysed by ELISA or HPLC. 
Synthesis of 3H-06-MedG 
Dephosphorylation of 3H-dG-triphosphate 
Alkaline phosphatase (Sigma Type III p4242, lOj.tl, 2 units) was incubated at RT 
with deoxy(P,2'-3H)guanosine-5'-triphosphate (250p.Ci, 7.5 x 10 9mo1) in dH20 
(250p.l). After 2hr an analytical HPLC analysis of the mixture combined with 
scintillation counting showed that 90% of the radioactive material was 3H-dG. This 
was purified using a C18 Bond elute column (J. T. Baker) (3H-dG-triphosphate 
eluted immediately with lml dH20, 3H-dG eluted later with 1 m MeOH). The 
product was dried by blowing with N2. 
Preparation of 3H-06-MedG 
N-methyl-N-nitroso-p-toluenesulphonamide (2g) was dissolved in Et20 (30m1) in a 
specially adapted reaction tube with clear glass joints and a side arm to collect the 
product. 5m1 of an ethanolic potassium hydroxide solution (4g KOH in lOOmi 
EtOH) was added slowly and the mixture heated to 600C in a water bath. An 
ethereal solution of diazomethane (3ml) distilled off and was kept cool on ice. 311-
dG was dissolved in MeOH (lOOp.!) and ethereal diazomethane (200p.l) was added. 
The mixture was stirred at 0C for 2hr then dried under N2 and redissolved in dH20 
(lOOj.tl). Analytical HPLC and scintillation counting confirmed the presence of 3H-
06-MedG, which was purified by prep HPLC. The fractions containing the product 
were combined to give 16.5p.Ci, 3.66 x 107dpm, 5 x 10 10mol, yield 6.6%. 
Using 3H-06-MedG on immunoaffinity columns 
Antibody (ling) immobilised on sepharose (0.25m1) was poured into a shortened 
pasteur pipette containing a glass wool filter, and the resulting column washed with 
10 volumes of PBS. 3H-06-MedG (35000 DBMS I x 10 12mo1) was diluted with 
cold 06-MedG increasing the total amount present to give four samples containing 1 
x 1011, lx  1010,  lx 10 9 and lx 10 8 molof06-MedG. Each sample was added 
to the top of an immunoaffinity column in PBS (200p.l). The column was then 
washed with 10 volumes of PBS and the wash solution collected. Any bound 
material was eluted with acetone/H20 and the elution solution collected. Both the 
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wash and elution samples were evaporated to dryness, redissolved in dH20 (200t1) 
and mixed with scintillation counting fluid (4m1). The radioactivity in each sample 
was measured to determine the amount of capture of 06-MedG on the column. 
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5. Conclusions and future perspectives 
5.1. Conclusions 
06-alkyl dG protein conjugates and 06-alkyl dG oligonucleotides were capable of 
eliciting a specific immune response in mice, to produce antibodies towards 06-alkyl 
dG 
Immunisation with a specific 06-alkyl dG produced an antibody which cross 
reacted with other 06-alkyl dGs. Often the affinity towards the immunising 06-alkyl 
dG was less than the affinity for related derivatives. 
The antibody raised to 06-MedG did not cross react with 06-hydroxyEtdG, but 
the antibody raised to 06-hydroxyEt dG cross reacted with 06-MedG. 
The immobilised antibody specific for 06-alkyl dG bound high amounts of 06 
alkyl dGs on the addition of an excess, but bound only up to 8% of the sample when 
non saturating amounts were added. 
The monoclonal antibodies. generated in this study could not be applied in an 
immunoaffinity mode to extract small quantities of 06-alkyl dG from native DNA 
samples. 
5.2. Future perspectives 
There are many alternatives for future work, but they broadly fall into 3 categories: 
employ 2C8C6H5 and 2G213 1OF1 for the extraction of 06-alkyl dG by altering or 
eliminating the immunoaffinity procedure, 




carry out more immunisations and fusions altering the screening protocol to 
favour the selection of an IgG with highest affinity for 06-MedG. 
i) The immobilisation of 2C8C6H5 and 2G2B1OF1 resulted in low affinity 
immobilised products. This problem may be overcome by the immobilisation of 
antibody fragments. The Fab fragments of antibodies (fig. 4.11) are produced by 
enzymatic digestion creating active fragments with molecular weight approximately 
50 000. Most reported antibody digestion protocols refer to IgGs (Lamoyi, 1986; 
Prisyazhnoy et a!, 1988; Yarmush et a!, 1992). However IgMs have also been 
successfully fragmented, to produce immunoreagents with superior properties (Gorini 
et al, 1972; Matthew and Reichardt, 1982). Generally, more Fab fragments can be 
immobilised per volume of sepharose than intact antibody. In addition, there are 
techniques for determining the orientation of the fragment, to allow the maximum 
number of binding sites to become available (Yarmush et a!, 1992). A single 
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monovalent interaction between the antibody and antigen is believed to be the key 
parameter in IAC (Mason and Williams, 1980), making Fab fragments ideal reagents 








Figure 4.11. Antibody fragmentation 
Assuming that 2C8C6H5 and 2G2B 1OF1 can be easily digested to produce Fab 
fragments, these antibodies may be useful in the identification of 06-alkyl dG in an 
immunoaffinity mode. 
Identification of 06-alkyl dG with 2C8C6H5 and 2G2B 1OF1 may also be possible if 
immobilisation of the antibodies was eliminated. One possible technique involves the 
use of biotinylated antibodies and a streptavadin-agarose column (Hôfmann et al, 
1978; Updyke and Nicholson, 1984; 1986). The biotinylated antibodies are bound to 
the antigen in solution, and the antibody-antigen complexes are extracted on an 
agarose-streptavidin column, followed by elution of the antigen. This technique takes 
advantage of the high affinity of streptavidin for biotin. In addition antibodies are 
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easily biotinylated in aqueous conditions and streptavidin can be attached to agarose 
following antibody immobilisation methods. Generally this method increases the 
level and speed of antibody-antigen binding, as both are in free solution. 
The employment of size exclusion membrane filters ('Microconcentrators', Amicon) 
may provide another possible method for the identification of 06-alkyl dG by 
2C8C6H5 and 2G2B 1OF1 without the requirement for immobilised antibodies. The 
antibody and antigen could be mixed in solution, allowing maximum binding activity 
of the antibody. Subsequent purification on a size exclusion filter would remove any 
small molecules not bound to the antibody. It would then be possible to remove the 
bound antigen from the antibody, using conditions similar to !AC elution. Further 
purification on a size exclusion filter would yield the pure antigen for quantification. 
It is therefore possible to manipulate the immunoaffinity column procedure and 
perhaps increase the binding efficiency of the available class specific antibodies. 
However the affinity of these antibodies may be too low to extract 06-alkyl dG from 
a pool of normal DNA, irrespective of the technique employed. 
During antibody production many immunisations were carried out and antibody 
producing cell lines were cryopreserved at each stage of cloning. It is therefore 
possible to return to these immunised mice or cell lines and select alternative 
antibodies. From these reserves it may be possible to obtain antibodies which are not 
class specific but recognise only one or two of the 06-alkyl dGs. A mixture of these 
antibodies in appropriate amounts may produce a combination which recognises the 
06-alkyl dGs. 
The screening protocols employed in this study favoured the selection of an O6 
alkyl dG antibody with higher affinity towards the higher alkyl derivatives. More 
immunisations and fusions concentrating on the production and selection of 
antibodies which primarily recognise 06-MedG should be carried out. The 
implementation of screening procedures which identify high affinity IgG molecules 
with specificity towards 06-MedG may provide a more appropriate starting ground. 
These antibodies can then be tested for cross reactivity with other 06-alkyl dO 
derivative in the search for a class specific antibody. 
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Appendix 
Ammonia deprotection of an 06-alkyl dGoligonucleotide, over 24 hours 
50 minutes at room temperature 
4 hours at 55°C 
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Ammonia Deprotection of Oligonucleotid&s (continued) 
12.  hours at55°C 
24 hours at 550C 
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